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ROLE OF CELLULAR SENESCENCE IN AGE-RELATED INTERVERTEBRAL DISC 
DEGENERATION 
Prashanti Patil, PhD 
University of Pittsburgh, 2018 
Aging is one of the major risk factors for intervertebral disc degeneration (IDD). IDD is 
characterized by loss of disc matrix homeostasis due to decreased matrix synthesis and increased 
matrix breakdown. Elevated oxidative burden is closely associated with age-related IDD, and 
cellular senescence has been suggested as the mechanism by which oxidative stress perturbs the 
balance between disc anabolic and catabolic matrix homeostasis. Cellular senescence is 
characterized by a state of irreversible growth arrest and chronic secretion of increased 
inflammatory cytokines and matrix proteases. Increased number of senescent cells have been 
recorded with advancing age in discs of rodents and humans. In vitro studies have confirmed 
the catabolic nature of stress-induced senescent disc cells in promoting matrix 
homeostatic imbalance. However, the underlying molecular mechanism of senescent disc cells 
which enable their secretory phenotype and whether cellular senescence is causal in driving age-
related IDD is yet to be ascertained. Herein, we examined the metabolic changes in oxidative 
stress-induced senescent (SIS) disc cells. Compared to non-senescent disc cells, SIS disc cells, in 
addition to acquiring a catabolic phenotype characterized by elevated fragmentation of aggrecan 
and collagen II and expression of IL-6 and IL-8, had upregulated mitochondrial content and ATP-
linked respiration. 
v 
This increase in mitochondrial ATP-linked respiration was driven by increased protein 
secretion in SIS disc cells because abrogation of protein synthesis using cycloheximide 
suppressed the mitochondrial ATP-linked respiration. As disc cells are known to rely on 
glycolysis, this result revealed heretofore unknown metabolic flexibility in disc cells to adapt 
to meet the underlying energy demand of their secretory phenotype. Next, we elucidated if a 
causal relationship existed between senescence and age-related IDD by examining the discs of 
p16-3MR transgenic mice following selective clearance of p16INK4a* senescent cells by the drug 
ganciclovir (GCV). In aged p16-3MR mice, treatment with GCV lowered the levels of 
disc MMP13, a major matrix protease, and reduced disc fragmentation of aggrecan. 
GCV-treated old mice also exhibited increased disc aggrecan and improved histological disc 
features. Altogether, these results suggest that cellular senescence adversely impacts the disc 
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1.0 INTRODUCTION 
1.1 BIOLOGY OF INTERVERTEBRAL DISC 
Intervertebral discs are situated between adjacent vertebrae and consists of an outer fibrosus 
annulus fibrosus (AF) that enclose a gelatinous nucleus pulposus (NP). The discs are present 
between vertebrae and connected to them by cartilaginous endplates (CEP)[1]. The AF possesses 
highly organized lamellae of collagen type I fibrils that run parallel to one another. The AF 
functions primarily to resist the tensile forces generated during bending or twisting and to bear 
the circumferential stresses required to restrain NP swelling. Unlike the AF, the NP is composed 
of proteoglycan aggregates encased in randomly organized loosely organized networks of 
collagen type II and elastin. The NP functions mainly to counteract the axial compression with 







Figure 1. Anatomy of intervertebral disc (IVD) and surrounding structures [3] 
This sketch represents a functional spinal unit consisting of vertebrae, IVD, and endplates. The IVD consists of the 
inner gelatinous nucleus pulposus (NP) and the outer fibrous annulus fibrosus (AF). While the NP serves to 
counteract the compressive forces and distribute them evenly throughout the disc, the AF functions to resist the 
tensile forces generated during bending and stretching (adapted from [3]). 
 
 
The swelling pressure of the discs emanates from the residing proteoglycans. Although 
both NP and AF possess proteoglycans, NP has the highest proteoglycan content [4], [5]. NP 
possesses a variety of proteoglycans in its extracellular matrix, with aggrecan being by far the 
most abundant proteoglycan. Aggrecan possess a large core protein with over 2000 amino acids. 
It contains three globular domains – G1, G2, and G3. The G1 domain binds to the hyaluronan 
chain. The link protein stabilizes the interaction between G1 and hyaluronan. The interglobular 
domain (IGD) separates G1 and G2 and contains sites for proteolytic cleavage. There are several 
chondroitin and keratan sulphate glycosaminoglycan (GAG) chains between G2 and G3. These 




Anulus Fibrosus (AF) 
-Fibrous, tensile force 
Nucleus Pulposus (NP) 
-Gelatinous, compressive load 
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provide the high osmotic pressure needed in resisting compressive loads [6] [7]. Several 
aggrecan monomers are found to bind to the hyluronan chain and form aggregates. 
 
 
Figure 2. Aggrecan components and organization in the IVD 
The aggrecan core protein contains three globular domains- G1, G2, and G3- to which glycosaminoglycans such as 
chondroitin sulphate (CS) and keratin sulphate (KS) are covalently attached. The aggrecan is present in aggregates 
that forms via binding of G1 to hyluronic acid (HA). This interaction is mediated by the link protein (LP). Known 
cleavage sites of proteases MMPs and ADMATSs on aggrecan are indicated (adapted from [3]). 
 
 
In addition to proteoglycans, the disc contains multiple collagen types. The annulus 
fibrosus possessing mostly type I collagen and the nucleus pulposus possesses mostly type II 
collagen [8]. Perturbation in either synthesis or proteolytic cleavage of matrix aggrecan and 
collagen results in weakened functional ability of disc tissue. Indeed, increased fragmentation of 
aggrecan and collagen is seen in disc degeneration [9]. Two class of proteases have been shown 
to play a major role in degradation of matrix proteins in disc: matrix matelloproteinases (MMPs) 
and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) [10], [11]. 
Specifically, MMP -1,-3,-13 and ADAMTS -4, -5 account for much of the degradation of matrix 
proteins in the disc tissue. 
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The cells that populate and synthesize the distinct extracellular matrices in disc include 
chondrocyte-like cells in NP and fibroblast-like cells in AF [12]. This difference is due to the  
fact that the AF develops from the mesenchyme and the NP develops from the notochord [13], 
[14]. In the embryonic disc tissue, there is a clear demarcation in the cellular phenotype of NP, 
which is rich in notochordal cells, and the AF, rich in fibroblasts like cells. However, this 
difference in phenotype is abolished as the notochordal cells in NP are replaced with cells that 
are of mesenchymal origin [15]. Consequently, the cells that populate the AF are more fibroblast 
-like, whereas the NP contain cells that are more spheroidal and chondrocyte-like. The disc tissue 
does  not  contain  a  high  cell  density  and  the  NP   and  AF  of  a  mature  disc  contain   
4x106 cells/cm3 and 9x106 cells/cm3 cells, respectively [1]. 
The disc cells require adequate nutrients to stay alive and function. Nutrients travel into 
disc tissue via two distinct routes- a) diffusion from capillaries that terminate adjacent to the 
cartilaginous endplate and b) diffusion from capillaries that innervate the outer parts of AF [16]. 
Consequently, the concentrations of glucose, oxygen, and other nutrients are lowest at center and 
highest at the periphery of the disc; the cells in the center of a human disc can be 6-8 mm from 
the nearest blood supply [17]. Disc cells adapt to this hypoxic environment by utilizing the 
hypoxia signaling governed by the activities of the transcription factor hypoxia-inducible factor- 
1α (HIF-1α). The disc NP cells are also unique in that they constitutively express HIF-1α [18]. 
This stabilization of HIF-1α is found to be crucial to the survival and expression of genes that are 
characteristic of NP cells. These  genes  include  aggrecan,  the  major  proteoglycan  in  the  
disc, galectin-3, β-1,3-glucuronyltransferase 1, and VEGF-A [19]. In addition, one of the logical 
outcomes of HIF-1α stabilization is that the disc cells are completely reliant on glycolysis to 
generate ATP and rely very little on aerobic respiration even when oxygen is abundant [18], 
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[20]. Treatment of NP cells with 2-deoxy glucose (2DG), a glycolysis inhibitor, results in 
significant depression in ATP synthesis, whereas treatment with mitochondrial inhibitor 
antimycin a does not impact ATP production [18]. Nevertheless, disc NP cells do contain 
mitochondria with normal architecture which retain the capacity to metabolize fatty acids and 




1.2 INTERVERTEBRAL DISC DEGENERATION AND BACK PAIN 
 
 
Intervertebral disc degeneration (IDD) contributes to many pathological conditions of spine. One 
of the major hallmark of disc degeneration is loss of aggrecan content. The reduced aggrecan 
content leads to reduced hydration, and consequently to reduced disc height and increased 
fissures. Degradation of aggrecan, the major proteoglycan of the disc, occurs primarily via action 
of MMPs and ADAMTSs [10], [11], [22], [23]. In the degenerated discs, 55 kDa and 70 kDa 
aggrecan fragments due to cleavage by the MMPs and ADAMTSs, respectively, within the IGD 
region are predominantly found [24]. Consequence of this proteolytic cleavage by either of the 
proteases is that two fragments are generated - one fragment will possess the G1 region and 
remain bound to the HA, whereas the other G2-G3 fragment containing GAG that is essential for 
attracting water is no longer able to interact with the HA and is free to diffuse in the extracellular 
matrix (ECM) [7], [10]. The aggrecan fragment that is bound to hyaluronan impedes the proper 
functioning of the disc as it cannot participate in resisting compression due to the loss of its GAG 
chains. The other proteolytic fragment of aggrecan, which is able to diffuse freely within the 
ECM, may still help in resisting compressive loads only if it does not undergo further proteolytic 
processing and loss by diffusing out of the disc via the tissue fissures. Although less obvious 
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than the changes to proteoglcyans, the collagen II in the NP also undergo denaturation due to the 
action of proteases such as MMP -1, -8, -13 [25], [26]. As a result, the damaged collagen 
molecules that persist in the disc tissue cannot contribute fully and appropriately to the 
biomechanical function of the disc. 
The lower proteoglycan content of the NP have major impact on the disc’s ability to bear 
load [27]. The loading of a disc with lower proteoglycan content results in loss of height and 
fluid more rapidly than compared to normal disc [28], [29]. Such loading of a degenerative discs 
results in distribution of stress inappropriately to other adjacent structures. In accordance with 
this, the later stages of IDD include loss AF lamellae structure, disorganization of the AF 
collagen and elastin networks, increased AF fissures, and formation of neo-osteophytes in the 
adjacent cartilaginous endplate and vertebrae [14], [30]. 
It has become imperative to understand the mechanism that contribute to IDD as it is one 
of the predominant contributor to chronic back pain, a debilitating disorder that erodes the 
quality of life for those who suffer from it. Basic science studies have begun exploring 
mechanisms that contribute to IDD and which eventually lead to back pain. From multiple 
studies, a narrative regarding IDD leading to back pain has emerged- following insult or injury 
[31]–[36], disc cells upregulate expression of inflammatory cytokines and chemokines, such as 
TNFα, IL-1β, IL-6, IL-8 as well as IL-17 and CCL [37]–[41], which suppress matrix protein 
production and promote synthesis of matrix proteases (MMPs and ADAMTSs), and 
consequently, the breakdown of predominant matrix proteins such as aggrecan and collagen II 
[40], [42]–[45]. If the cycle of cytokine secretion and protease production continues, the disc 
undergoes severe degenerated changes resulting in compromised functional ability and 
herniation. The chemokines and the cytokines increase disc cells expression of the neurotrophins 
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NGF and BDNF and induce nerve ingrowth, and act directly on dorsal root ganglions (DRG) to 
induce expression of the pain associated cation channels like ASIC3, a pH sensitive Na+ channel 
associated with ischemic and inflammatory pain, and TrpV1, a nociceptive cation channel [46], 




1.3 CAUSES OF INTERVERTEBRAL DISC DEGENERATION 
 
 
The etiology of IDD is complex and multifactorial. IDD is a commonly associated with age, 
genetic predisposition, and occupational hazards. Recent studies have shown association between 
genetic influences and disc degeneration. So far, gene polymorphism of the collagen I, collagen 
IX, collagen XI, VDR, and aggrecan gene have been associated with disc degeneration [49], 
[50]. However, it should be noted that the magnitude of the influence of the polymorphism of the 
aforementioned genes is modest. Furthermore, the genetic studies conducted so far have included 
only certain demographics and included small sample sizes. Therefore, increasing the sample 
size and conducting the studies in various other populations is still warranted to derive at a 
definite genetic and disc degeneration association. Mechanical insults and environmental factors 
resulting from occupation, sporting injuries, cigarette smoking and atherosclerosis have been 
touted to promote disc degeneration as well [12], [51]. Like the genetic studies, no strong causal 
link between heavy work/trauma and disc degeneration has been found. For instance, lowering 
the time spent heavy lifting or ergonomic interventions have not reduced the incidences of disc 
degeneration [52]. Additionally, no greater increase in disc degeneration is found in people with 
extreme smoking history [53]. If not genetic, mechanical injury or environmental factors, what 
factor greatly influences disc degeneration? Several studies have reported that the occurrence 
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rate of disc degeneration significantly increases with age. Increase in disc degeneration from 0% 
at 20 years of age to approximately 90% at age 70 years was found in 600 autopsy specimens 
[54]. Similarly, investigation of 1000 autopsy specimens found the rate of degenerative findings 
to increase to about 72% by the age of 70 years in men; women reached the same grade of 
degeneration as men about 10 years later [53]. Disc degeneration has been shown to initiate as 
early as second decade of life [55]. By the fifth decade, 97% of all discs show some degree of 
degeneration, with 50% demonstrating severe grades of degeneration [54]. The intervertebral 
disc undergoes striking alteration in volume, shape, structure, and composition with age that 
ultimately compromise motion and mechanical properties of spine. Infact, spine related pain that 
limits mobility are the most common causes of impairment in the middle aged and in the elderly. 
Basic scientific studies have begun to shed light on the underlying changes and the mechanisms 
that promote the gross morphological changes in the disc tissue with age. The section below 
discusses the results of such studies conducted so far. 
 
1.3.1 AGING IS A MAJOR DRIVER OF IDD. 
 
 
The age-related morphological changes in disc tissues include reduction in disc height, 
disappearance of vascular channels originating from the CEP, increased number of fissures and 
granular debris, and neovascularization of the peripheral AF lamellae inwards [55]. The clear 
gelatinous NP is transformed into a fibrous tissue with age. The distinction between AF and NP 
becomes progressively blurred with ageing. Ossification and thinning of the CEP are also found 
with increasing age [56]. 
As in case of IDD, the reduction in disc height with ageing is due loss of proteoglycan 
content, and consequently, its water content. The decrease in proteoglycan content in the disc 
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tissue is because of both decrease in synthesis capacity as well as increase in fragmentation and 
loss of the aggrecan with age[9], [31], [57]. Increased presence of denatured collagen II, 
resulting from proteolytic action of collagenases (MMP -1, -8, -13), is also found in aged discs 
[26], [57], [58]. Another major alteration in ECM that occurs with age is increase in collagen I 
synthesis and decrease in collagen II synthesis in the NP of the disc [55], [59]. These changes 
collectively weaken the ability of the disc tissue to function normally with age. 
The remodeling of the ECM with age in disc tissue suggests that the homeostatic balance 
between the anabolic and catabolic activities is altered. The protagonists of this imbalance are 
most likely the MMPs and ADAMTSs. Indeed, expression of certain matrix metalloproteinases, 
including MMP-1,-3 and ADAMTS-5 is elevated in aged discs compared to young discs [60]– 
[62]. The disc cells are capable of producing the proteases upon induction by pro-inflammatory 
cytokines such as TNFα, IL-1β, IL-6, and IL-8. These inflammatory cytokines promote 
expression of ADAMTS-4 and -5, and MMP-1, -2, -3, -4, -13, and -14, and decrease expression 
of anabolic ECM proteins aggrecan and collagen II in disc cells [37], [40], [43]–[45]. In rat and 
bovine organ culture models, treatment with TNFα results in suppression of multiple collagen 
types, aggrecan, fibromodulin, increased expression of MMPs, ADAMTSs, pain-associated 
molecule nerve growth factor (NGF), and compromised disc biomechanics [63]–[65]. IL-1ra-/- 
mice, which lack the functional IL-1ra, an endogenous antagonist of IL-1R, display greater loss 
of proteoglycans and collagens, and exhibit increased expression of MMPs 3 and 7 and 
ADMTS4 in their IVD [66]. The discs of IL-1ra-/- mice also have higher grade of histological 
degeneration compared to wildtype mice. Importantly, expression of TNFα and IL-1β and their 
respective receptors has been shown to increase with severity of aging in human and animal 
models. Together, these studies suggest that the inflammatory cytokines are major drivers of the 
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cascade of matrix protein degradation that occurs with ageing in the disc tissue. Part of the 
inflammatory response in disc observed during aging may be driven by the infiltrating immune 
cells like macrophages. However, the resident disc cells are also capable of producing IL-6, IL- 
1β and TNFα in the context of disc degeneration independent of infiltrating leukocytes [67]. 
Presently, it is still unclear to what extent infiltrating immune cells and resident disc cells 
contribute to the production of the inflammatory cytokines observed in aged discs. 
The increased inflammatory burden in disc tissue with age is postulated to be propagated 
by oxidative stress. There is ample evidence of increased oxidative stress in disc aging and 
degeneration. Malondialdehyde (MDA), a secondary product of peroxidation of polyunsaturated 
fatty acid residues, was found to be significantly higher in the discs of geriatric rats compared to 
those in adult rats [68]. Accumulation of intermolecular cross-links in long lived proteins such as 
collagen, a result of oxidative reactions, with age in disc is also well documented. One of the 
pathways for cross-link formation is via oxidative modification of glycated proteins, resulting in 
the formation of advanced glycation endproducts (AGEs) such as CML and pentosidine. 
Accumulation of both pentosidine and CML was increased in aggrecan and collagen with aging 
in human disc tissue [69]–[72]. CML was found to be accentuated in degenerative region of disc 
tissue. In another study, redox proteomic analysis revealed that the disc of aged mice contained 
higher levels of oxidized amino acids than discs of younger mice. Importantly, oxidized matrix 
proteins were found to be more susceptible to degradation by MMP -1, -2, -9 and -13 proteases 
[73]. Additionally, numerous in vitro studies have shown that treatment of human and rat disc 
cells with oxidants such as hydrogen peroxide induces expression of matrix proteases and 
inflammatory cytokines with concomitant suppression in the expression of aggrecan and 
collagen matrix proteins [74]–[76]. Importantly, abrogation in disc degenerative markers was 
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seen in rat NP cells, rabbit annulus puncture model of disc degeneration, and in progeroid mouse 
model of disc degeneration upon treatment with antioxidants [77]–[79]. It is still unclear what 
endogenous and exogenous factors mediate the increase in oxidative burden and consequently 
inflammatory stress and matrix degradation in disc tissue with age. Regardless of the event(s) 
that start the trend towards impaired anabolic and catabolic balance, the functionality of the disc 




1.4 THERAPEUTICS TO TREAT IDD 
 
 
Since disc degeneration involves the loss of balance between the anabolic and catabolic events, 
therapeutic targets for treating or delaying age-related disc degeneration have focused on either 
promoting the synthesis of matrix proteins that support the function of the disc or minimizing the 
aberrant damage response that exacerbate tissue damage. Protein-, gene-, and cell-based 
strategies have been explored to counter age-related changes to the disc tissue. Growth factors 
such as TGFβ, BMP-2, GDF-5, IGF-1 have been shown to stimulate synthesis of aggrecan, 
collagen II, and enhance glycosaminoglycan content in disc cells in vitro [80]. The rationale for 
using growth factors for treatment and prevention of disc degeneration lies in their capacity to 
enhance matrix synthesis. Modest improvement in aggrecan, collagen II, and restoration of disc 
height has been reported upon injection of TGFβ and rhGDF-5 into discs of mice and rabbits 
induced to undergo degeneration via static compression or via annular puncture, respectively 
[80]. One of the major limitations of growth factor therapy for disc degeneration is that the half- 
life for these therapeutic proteins is on the order of few minutes, and this limits its clinical utility 
for a chronic disorder like disc degeneration. Additionally, several of the growth factor therapy 
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studies utilize younger aged animals. It therefore is still unclear if growth factor therapy benefits 
only early stages of degeneration or the improvement in disc will occur if the growth factors are 
injected into an older aged animal as well. Unlike the growth factor therapy, the goal with gene 
therapy approaches is to provide long term expression of matrix proteins. The gene therapy 
studies done so far have involved introduction of MMP and ADAMTS inhibitors or growth 
factors that promote matrix protein synthesis via direct application of viral vector constructs or 
via injection of disc cells that have been transduced with these factors in vitro [81]. Though these 
studies have been promising, several complications including long term assessment of the 
expression of the transgenes, feasibility in humans, and cost associated with such therapies are 
yet to be explored. Much like the gene therapy approach, the goal of cell-based therapy is to 
restore the loss of anabolic synthesis capacity of disc cells and regenerate a biologically active 
environment. The majority of the investigations carried to date have utilized bone marrow 
derived mesenchymal stem cells (BM-MSCs) either alone or in combination with carrier agents 
and have shown modest improvement in proteoglycan content, annulus fibrosus structure, and 
disc height upon implantation of the BM-MSCs [82], [83]. Despite these encouraging results, it 
is still unclear whether the injected cells only provide a transient response or whether they exert a 
sustained response, the mechanism by which they act on disc, the ability to survive in disc which 
faces loss of capillaries, and hence nutrients, with age, and the risk of ectopic ossification or 
calcification. 
In addition to aforementioned therapeutic strategies, multiple studies have assessed the 
impact of anti-oxidative and anti-inflammatory strategies to ameliorate the cascade of age-related 
degradative changes in the disc. Systemic administration of a mitochondria-targeted ROS 
scavenger, XJB-5-131, to the Ercc1−/Δ mice, which are deficient in the DNA repair enzyme 
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Ercc1 and recapitulate several features of age-associated disc degenerative changes, resulted in 
significant improvement in the glycosaminoglycan content as well the proteoglycan synthesis 
capacity [77]. Similarly, intradiscal injection of anti-oxidant fullerol increased water and 
proteoglycan content and inhibited ectopic bone formation in discs of rabbits induced to undergo 
disc degeneration by stab puncture of the annulus fibrosus [78]. It was shown via in vitro studies 
that fullerol was able to reverse the suppression of aggrecan and glycosaminoglycan in human 
nucleus pulposus cells treated with hydrogen peroxide or IL-1β. A number of other anti-oxidants 
such as curcumin, resveratrol, pyrroloquinoline have been shown to rescue loss of proteoglycan 
synthesis and reduce catabolism of aggrecan via inhibition of catabolic factors including IL-6, 
IL-1β, IL-8, MMP-1,-3, and -13 [79], [84]–[86]. These studies demonstrate yet again that 
oxidative stress is one of the key drivers of age-associated disc degeneration and oxidant 
scavengers may play a promising role in slowing disc aging. In addition to anti-oxidants, several 
anti-inflammatory agents have been reported to be therapeutic for treating IDD as well. 
Application of IL-1Ra, an endogenous antagonist of IL-1 receptor, and etanercept, TNFα 
inhibitor, to tissue explants or rat discs resulted in reduced biochemical markers of disc 
degeneration, such as IL-1 and IL-6 [87]. Another strategy to lower the inflammatory burden and 
the ensuing degenerative changes has focused on targeting pathways or molecules that induce 
expression of the inflammatory factors. One such candidate is the NF-κB pathway whose chronic 
activation has been implicated in several age-related pathologies. The NF-κB activity has been 
found to accompany the increase in oxidative stress with ageing in disc and several of the 
cytokines involved in disc degeneration, including TNF-α, IL-1β, IL-6 and IL-8, are considered 
typical NF-κB target genes  [88].  Indeed,  previous  studies  from  our  lab  have  shown  that  
the Ercc1−/Δ mouse with genetic and pharmacological block of NF-κB activity, have higher 
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proteoglycan content and GAG content compared to untreated controls. [89]. Furthermore, 
injection of “NF-κB decoy oligonucleotides” resulted in amelioration of degenerative changes in 
animal model of degeneration [90]. Together these reports suggest a promising alternative to the 
invasive cell and gene therapy approaches. However, the precise mechanism by which the anti- 
oxidant and anti-inflammatory agents elicit the anabolic activity while suppressing the catabolic 
events in disc has yet to be investigated. Moreover, disc aging probably does not occur in 
isolation and is likely influenced by systemic changes. Therefore, it is essential to investigate 
whether improvement in disc structure and function is plausible with strategies that aim to delay 
or prevent disorders prevalent during ageing. Equally important is to conduct studies to identify 
certain common age-related changes in different organ systems as this will enable development 




1.5 CELLULAR SENESCENCE AND AGING 
 
 
1.5.1 HISTORY OF CELLULAR SENESCENCE 
 
 
Cellular senescence is a state of irreversible growth arrest that can be induced by a wide variety 
of stressors [91]. Cellular senescence was first reported by Hayflick and colleagues after they 
observed that human fibroblasts replication ceased after a finite number of divisions [92]. They 
termed this phenomenon as replicative senescence. Despite supply of nutrients and appropriate 
growth conditions, the replicative senescent cells did not proliferate further. The study included 
two contradictory speculations. First, it speculated that the dysfunctional telomeres, that result 
because of successive replications and contribute to malignant transformation of cells, can be 
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prevented if the cells senesce. In this context, cellular senescence protected organisms from 
cancer, and hence, was beneficial. The second speculation proposed cellular senescence to 
promote ageing as it could limit the proliferative capacity of the resident cells and thus could 
contribute to decline in tissue regenerative ability. 
The answer to the paradox of cellular senescence as both a beneficial and detrimental 
phenomenon is explained by the antagonistic pleiotropy theory [91]. This posits that processes 
that are beneficial in the younger organisms (example, tumor suppression) can be deleterious in 
older organisms (example, senescent cells that escape clearance or accumulate). There is now 
substantial evidence that cellular senescence can promote both tumor suppression and age- 
related pathologies. 
In the ensuing decades since replicative senescence was described by Hayflick et. al, it 
has become apparent that a plethora of stressors can induce cellular senescence. Overexpression 
of oncogenes in normal cells can induce senescence, a phenomenon termed as oncogene-induced 
senescence (OIS). Cellular senescence induction also occurs upon epigenetic modifications as 
well. Lastly, DNA-damaging stresses have been shown to induce senescence as well. Such 
stresses include UV and IR radiation, drugs generating DNA breaks such as bleomycin and 
ciplastain, and agents capable of generating oxidative stress such as hyperoxia, hydrogen 
peroxide, tert-butyl hydroperoxide etc. [91]. These different stressors all engage the DNA 
damage response (DDR) pathway [93]. In fact, cellular senescence is viewed as the outcome of a 
protracted DDR. The DDR in stress induced senescent human fibroblasts is found to persist for 
days, months in some cases, and is essential for sustenance of the growth suppressive 
mechanisms [94]. 
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The diverse stimuli that induce senescence response seem to converge on two pathways 
to mediate the DDR and establish and maintain growth arrest. p53-p21Cip1-Rb and p16INK4a-Rb 
pathways are central to induction of senescence [95]. p53-p21Cip1-Rb and p16INK4a-Rb are the 
two well-known and extensively studied pathways in context of cell cycle control, tumor 
suppression, and cellular senescence. p53 guards genomic integrity by regulating several cellular 
processes, including cell cycle arrest, DNA repair, apoptosis and senescence, resulting from 
various stress signals. Upon genomic damage induced by endogenous and exogenous stressors, 
the ATM protein undergoes autophosphorylation and activation. The active ATM protein 
phosphorylates p53 directly to activate it or indirectly via phosphorylating Chk1 and Chk2 
proteins [91]. H2A.X, a variant of the H2A histone protein family and a component of the 
histone octomer in nucleosomes, is another downstream target of ATM and is activated by 
phosphorylation by ATM. The phosphorylated protein, γH2A.X, serves to recruit and repair 
proteins to the DNA damage site. Persistent DNA damage response (DDR) is needed to maintain 
the cellular senescence phenotype [94], [96], [97]. p53 also stimulates expression of the cyclin- 
dependent kinase inhibitor (CDK1) p21Cip1, which prevents cyclin-dependent kinase-2 (CDK2) 
mediated phosphorylation of retinoblastoma protein (pRb). Consequently, the cell cycle 
progression from G1 to S is inhibited as the hypo-phosphorylated pRb blocks the transcriptional 
activity of the E2F factor to promote the expression of the genes necessary for G1 to S 
progression [91]. Similarly, expression of the cyclin-dependent kinase inhibitor p16INK4a is 
increased by numerous cell stressors including oxidative stress, inappropriate activation of 
signaling pathways, oncogene activation, and telomere shortening. p16INK4a binds CDK4/CDK6 
and suppresses the association of CDK4/6 and cyclin D. This leads to disruption of D-type 
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cyclins. This consequently leads to hypophosphorylation of pRB and suppression of G1 to S 
phase progression [95]. 
It is not clear whether both the p53-p21Cip1-Rb and p16INK4a-Rb pathways are needed to 
 
establish senescence in response to diverse stimuli. The consensus is that p53 mediates 
senescence primarily due to telomere dysfunction and DNA damage and p16 INK4a mediates 
senescence primarily due to oncogenes, chromatin disruption, and other stressors [98]. However, 
currently, there are no studies which unambiguously provide evidence to support this consensus. 
Upregulation of both the pathways is found in different human cell strains induced to undergo 
replicative senescence, OIS, and senescence induced by stressors such as hydrogen peroxide, 
hyperoxia, U.V, and IR [99] [100][98]. It may be that cells within a tissue may contain a mosaic 
of cells that senesce either due to expression of p53 or p16 or both. The reports published on the 
roles of these pathways in regulating cellular senescence thus far are still fragmented and 
incomplete. 
 
1.5.2 CHARACTERISTICS OF SENESCENT CELL 
 
 
Senescent cells in culture and in vivo are identified by several different markers. However, no 
single specific marker is exclusively present in all senescent cell types; aggregate of markers is 
typically used in confirming senescent cells. Senescent cells adopt a “fried egg morphology” and 
increase in cell size [92]. The senescent cells have increased lysosomal content, and this results 
in suboptimal functioning of the β-galactosidase enzyme. This phenomenon is termed as 
senescence associated β-galactosidase (SA-βgal)[101]. Many cell types also acquire resistance 
to apoptotic signals upon becoming senescent [91]. This resistance has been found to be due 
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to suppression of apoptotic mediating proteins such as caspase-3 or death-associated protein 3 
(DAP3) and persistent upregulation of pro-survival factor Bcl-2 [102]–[104]. 
 
 
Figure 3. Characteristics of senescent cells 
A myriad number of stressors can induce cellular senescence in mitotically competent cells. These stressors include 
telomere damage generated by replicative exhaustion, non-telomeric genomic damage induced by I.R, U.V, 
oxidative stress etc., and excessive mitogenic signals produced by oncogenes (which also cause DNA damage). The 
different stressors all engage DNA damage response (DDR) signaling cascade and ultimately induce cell cycle arrest 
by activating p53, p16INK4a, or both. If the damage induced by the stressors is irreparable and is of sufficient 
magnitude, the cells undergo permanent growth arrest and chronically secrete elevated levels of inflammatory 
cytokines and proteases, a phenotype termed as senescent associated secretory phenotype (SASP). The other 
hallmarks of senescence include senescence associated beta galactosidase (SA-βGal) and apoptotic resistance. 
 
 
Another characteristic feature of senescent cells is chronic and elevated expression of 
pro-inflammatory cytokines and chemokines, tissue-damaging proteases, growth factors, and 
factors that can impact stem and progenitor cell function. This phenomenon is termed as 
senescence associated secretory phenotype (SASP) [105]. Though a core of the SASP factors are 
feature of all senescent cell types, there does exists variation in terms of quality and quantity that 
depends on the cell type and senescence inducer [96], [105], [106]. Furthermore, in cell culture a 
full SASP develops 5-7 days after cell cycle arrest. Importantly DDR proteins ATM and Chk2, 
but not p53 and pRb, are found to be needed to initiate and maintain SASP [96]. Functional 
inactivation of p53 or gain of oncogenic Ras following senescence establishment allows cells to 
resume proliferation but does not suppress SASP [96]. 
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The SASP factors are reported to be mediated by multiple mechanisms. The most well 
studied of them is the canonical NF-κB pathway. p65 subunit of NF-κB is found to act as a 
master regulator of the SASP and its suppression is found to down-regulate expression of 
several inflammatory factors and matrix proteinases in  oncogene-induced,  replication- 
induced, and X-irradiated senescence [107]. Depending on the cell type, the stress-inducible 
kinase p38MAPK and the transcription factor GATA binding protein 4  (GATA4)  are  
activated by multiple different stressors capable of inducing senescence and are found to  act  
as an upstream activator of NF-κB to initiate SASP [108], [109]. The CCAAT/enhancer- 
binding protein β (C/EBPβ) is another transcription factor that is found to be tightly associated 
with senescent chromatin and control secretion of IL-6 and IL-8 SASP factors [110]. 
Furthermore, inhibition of mTORC1 complex of the mTOR kinase by rapamycin is found to 
dampen expression of SASP factors in X-irradiation induced senescent human fibroblast cell 
lines by suppressing the positive feedback loop between IL-1A- NF-κB [111]. Strikingly, the 
protein synthesis mechanism controlled by the mTOR and protein degradation mediated by 
autophagy are found to occur in unison in senescence. It is found that suppression in synthesis 
of certain SASP factor occurs if the mTOR and autophagy are inhibited [112]. The protein 
degradation controlled by autophagy is speculated to provide the raw materials for facilitating 
protein translation and consequent protein turnover to establish SASP. 
In addition to aforementioned specific proteins and pathways, recent reports have 
revealed that the senescence induction and SASP are intimately linked to the metabolic state.  
In replication-induced senescent human fibroblasts, increased glucose consumption as well as 
increased lactate production were found [113]. However, the increase in glycolysis was not 
accompanied by increased intracellular ATP levels in the senescent cells. Subsequently it was 
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found that the replication induced senescent fibroblast cells fail to upregulate certain other 
glycolytic enzymes such as GAPDH and enolase and it is this failure to co-ordinately regulate 
all the glycolytic enzymes that contributes to the reduced ATP  levels [114]. Other  studies  
have found the mtDNA copy number, mitochondrial protein expression, and respiration are 
found to increase 2- to 3- fold in human fibroblasts induced to senesce using diverse stimuli; 
elimination of mitochondria using the uncoupler CCCP, which induces mitophagy by allowing 
the protein Parkin to localize to mitochondria, resulted in suppression of cell cycle arrest proteins 
(p21 and p16) and several SASP factors [115]. Increased mitochondrial biogenesis results in 
increased reactive oxygen species (ROS) and DNA damage. Indeed, reduction in mitochondrial 
mass lowered mitochondrial derived ROS, 53BP1 foci (marker of DNA double-strand breaks) 
and DDR signaling, which is required for the initiation and maintenance of SASP [115]. 
Therefore, the expansion of mitochondria served to maintain the DDR signaling, and thus, the 
SASP phenotype in this context. Unlike this study, in chemotherapy-induced senescent 
lymphoma cells, metabolic alteration consisting of increased oxygen consumption, ATP 
concentration, and fatty acid oxidation were needed to maintain the production of senescent 
associated proteins, including SASP factors [116]. In addition to protein production, the 
increased energy generation was found to support increased expression of proteins involved in 
unfolded protein response (UPR) and autophagy. It was hypothesized that the elevated synthesis 
of proteins overwhelms the capacity for accurate post-translation processing and vesicular 
transport and secretion. Indeed, inactivation of NF-κB, which regulates synthesis of numerous 
SASP factors, was shown to suppress expression of UPR transcripts- ATF4, CHOP- and 
autophagy markers-p62, LC3 I/II. Thus, in this context, the high and presumably not always 
proper production and processing of senescence-associated secretory peptides was found to elicit 
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the demand for high energy generation. Similarly, in Ras-induced senescent fibroblasts, the 
metabolic alteration consisting of increased fatty acid catabolism and oxygen consumption due to 
oxidation of fatty acids were found to support the increased secretion of SASP factors [117]. 
From the studies discussed above, it is evident that the mechanism driving senescence 
establishment, SASP secretion, and the ensuing metabolic alteration are dependent on the cell 
type, senescent stimuli, and the magnitude of the stimuli. However, our understanding of the 
changes that occur in senescent cells is still evolving. Nevertheless, the differences between 
senescent and non-senescent cells highlighted by the different studies can be utilized in preparing 
therapeutics targets. 
 
1.5.3 CELLULAR SENESCENCE IS A MAJOR DRIVER OF AGE-RELATED 
PATHOLOGIES 
 
Cellular senescence can contribute to loss of regenerative potential of the tissue due to the 
proliferate arrest. Markers of cellular senescence such as SA-βGal, telomere attrition, and 
p16INK4a have been found to accumulate in multiple tissues with age in humans and rodents 
[118]. Additionally, senescent cells have been identified at the sites of age-associated 
pathologies. For instance, increased SA-βGal and chondrocytes with shorter telomere length 
are found in articular cartilage in patients with osteoarthritis (OA) [119]. Similarly, in the 
pancreas, p16INK4a positive β-cells levels increase with age in humans and in mice [120]. This 
restricts the regenerative potential of β-cells and limits the adaptive response to insulin 
resistance. It is hypothesized that the increase in β-cell senescence with age could contribute to 
the age-related increase in prevalence of type 2 diabetes mellitus (T2DM). Much like OA and 
T2DM, loss of proliferation competent cells due to senescence have been attributed to the 
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development of other age-related pathologies such as glaucoma, cataracts, atherosclerosis, and 
cardiovascular disease [121]–[124]. 
In addition to loss of proliferative potential, cellular senescence can alter the tissue 
microenvironment by virtue of the SASP. Induction of secondary senescence in neighboring 
cells is one scenario by which SASP can impact tissue health [125]. SASP factors, especially 
IL-1β and TGFβ, produced by fibroblasts cells undergoing replicative- or oncogene- induced 
senescence were capable of inducing DDR, senescence arrest, SASP in non-senescent 
fibroblasts [126]. Additionally, senescent cells can disrupt the architecture of the tissue and 
synergize with cells with mutations to promote malignancies [127]. For instance, senescent 
fibroblasts transform non-tumorigenic, immortal mammary epithelial cells into cells  capable  
of producing tumors in mice. In vitro experiments suggested that the transformation was 
brought by the soluble factors secreted by the senescent cells [128]. Similarly, another study 
revealed that human fibroblasts induced to senesce using DNA damaging agent  bleomycin 
when injected with cancer cells (MDA-MB-231) in mice, causes enhanced growth of cancer  
cells and the growth is abolished if an MMP inhibitor is incorporated into the transplants [129]. 
Taken together, these studies suggest that senescent cells can stimulate hyperproliferation and 
malignant progression of preneoplastic and neoplastic cells. SASP factors are also implicated in 
progression of other age-related disorders as well. Senescent bronchial cells are present in lungs 
of humans with idiopathic pulmonary fibrosis (IPF) and are known to  secrete  elevated  levels 
of IL-1β and other extracellular matrix proteins [130]. In brain tissue from patients with 
Alzheimer’s disease (AD), elevated levels of astrocytes co-expressing p16 and MMP1 was 
found, suggesting a link between senescence and age-related pathology such as AD [131]. 
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Other age-related pathologies associated with SASP include cystic fibrosis, intestinal bowel 
disease, and cataracts [132]–[134]. 
The association between age-related dysfunction and cellular senescence is more than 
correlative. Evidence for the causal role of senescence and age-associated disorders was 
established by a study which showed improvement in skeletal, eye, and adipose tissue upon 
selective and life-long clearance of p16INK4a positive senescent cells [134]. Additionally, late  
life clearance of p16INK4a expressing cells, when age-related pathologies are apparent,  
attenuated the decline in physical activity and subdermal adipose layer thickness. This study 
achieved selective clearance of p16INK4a expressing cells by using a transgenic mouse that 
contained GFP and caspase-8-FKP fusion protein under the control of 2.6 kbp p16INK4a mini 
promoter; upon administration of AP20187 drug, the caspase-8-FKP undergo dimerization and 
activation and induce apoptosis only in  p16INK4a positive cells. Though this study provided  
solid evidence for targeting senescence for delaying or treating age-related diseases, the 
transgenic mice carried a progeroid genetic background (BubR1 hypomorphism), and therefore, 
the stress for senescence development could be non-physiological compared to natural aging 
mice. Nevertheless, the results of subsequent studies which selectively cleared senescent cells in 
a natural aging mouse strongly support the causal role of senescence in age-related dysfunction. 
The investigators of these later studies made use of a transgenic mouse called p16-3MR. 
These mice contain three proteins - synthetic Renilla luciferase (LUC), monomeric red 
fluorescent protein (mRFP), and truncated herpes simplex virus 1 (HSV-1) thymidine kinase 
(HSV-TK), under the control of p16INK4a promoter [135]. To generate the p16-3MR mice, the 
3MR cDNA was inserted into bacterial artificial chromosome (BAC) containing approximately 
50 kbp of the murine INK4a/ARF locus, which encodes two proteins- p16INK4a and p19ARF by 
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alternative splicing mechanism. The 3MR cDNA was inserted in frame with p16 into exon 2, 
creating a fusion protein containing first 62 amino acids of p16, but no full-length WT p16. 
Insertion of the 3MR cDNA also resulted in a stop codon in p19 reading frame in exon 2, thereby 
preventing full length p19 expression from BAC. The transgenic mouse line that was created 
contained a single integrated copy of the engineered p16-3MR BAC and contained  diploid 
copies of p16INK4a and p19ARF. In these p16-3MR mice, the cells that express HSV-TK are killed 
by ganciclovir (GCV), a nucleoside analog which has high affinity for HSV-TK but not cellular 
TK. When normal dividing cells expressing 3MR are administered GCV, the HSV-TK 
phosphorylates GCV which then competes with endogenous nucleotides for incorporation into 
nuclear DNA, causing replication dependent double strand breaks, and apoptosis subsequently 
[136]. However, when GCV is administered to senescent 3MR expressing cells, S-phase 
independent incorporation of GCV into mtDNA, mtDNA fragmentation, and caspase-dependent 
cell death ensues [136]. Elimination of chemotherapeutic agent (doxorubicin)-induced p16INK4a 
senescent cells in p16-3MR using GCV resulted in reduced serum and tissue inflammatory 
cytokines, cardiac dysfunction, bone marrow suppression, cancer recurrence, and improved 
physical activity and strength [137]. Similarly, clearance of total body irradiation-induced 
p16INK4a senescent cells using GCV, suppressed expression of several inflammatory SASP 
factors, attenuated the disruption of hematopoietic stem cell (HSC) quiescence, which can lead to 
premature HSC exhaustion, and age prominent phenotype of HSC myeloid skewing [138]. 
Together, these studies provide convincing evidence for the healthspan benefits that can be 
achieved by elimination of senescent cells. 
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1.5.4 THERAPEUTIC STRATEGIES TO ELIMINATE CELLULAR SENESCENCE 
 
 
Targeting senescent cells is an attractive strategy to prevent or delay age-related disorders and 
thereby achieve healthy aging. In this regard, approaches including selectively ablating senescent 
cells and blocking the secretion of SASP factors can be utilized. In particular, senolytic 
compounds, that specifically kill senescent cells, hold much promise. These drugs are dependent 
on senescent-specific vulnerabilities compared with normal dividing or differentiated cells. For 
example, ABT263 (navitoclax) and ABT737, specifically inhibit the anti‐apoptotic proteins 
B‐cell lymphoma 2 and B‐cell lymphoma–extra-large, which are upregulated in certain types of 
senescence, and can induce rapid apoptosis in senescent cells [138]–[141]. Indeed, clearance of 
senescent cells using ABT737 in natural aging mice ameliorated the cartilage degradation and 
development of post-traumatic osteoarthritis [142]. Two other pharmacological agents that also 
target the pro-survival pathways upregulated in senescent and which can be employed for 
targeted killing of senescent cells include dasatinib, a kinase inhibitor that targets a myriad 
number of kinases, and quercetin, a flavonoid that is derived from plants and which possesses 
anti-inflammatory properties. Improvement in cardiac and vascular function and later-life 
physical endurance was seen in mice provided with these compounds [140]. These findings are a 
significant step towards translating these strategies for clinical applications. However, the 
senolytic drugs identified to date might have limitations for clinical applications. For example, in 
a phase II study of ABT263 applied to advanced and recurrent small-cell lung carcinoma 
patients, transient thrombocytopenia and neutropenia have been reported as side-effects [143]. 
Thus, identification of additional senolytic drugs is warranted. 
Controlling the induction of SASP is also a promising strategy to prevent the negative 
effects of senescence. This could be achieved by targeting its transcriptional regulatory systems, 
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such as NF‐κB or mTOR signaling, or by blocking the function of several key inflammatory 
mediators such as IL-1, IL‐6 or TNFα [107], [111], [144], [145]. Rapamycin, an inhibitor of 
mTOR , reduces the secretion of inflammatory cytokines in senescent cells, and has been shown 
to extend the lifespan of mice [146], [147]. These findings, together with the fact that mTOR 
inhibitors are already used in clinical settings, suggest that mTOR inhibitors are highly 
promising drugs for the prevention of deleterious effects of cellular senescence. Likewise, some 
agents that target SASP factors are already in clinical use and could be candidates for drug 
repositioning. An IL-1 receptor anatagonist, anakinra, an IL-6 receptor antibody, tocilizumab, 
and TNFα inhibitors, such as etanercept and infliximab, are currently used to treat rheumatoid 
arthritis [148], [149]. As IL-6, IL-1, TNFα are core components of SASP of multiple different 
senescent cell types and appear to reinforce senescence autonomously and non-autonomously, 
the inhibitors of these factors may be useful for selectively blocking SASP [107], [110], [150]. 
 
1.5.5 CELLULAR SENESCENCE IN INTERVERTEBRAL DISC 
 
 
As discussed earlier, damage due to numerous factors are implicated in driving disc aging [151]. 
However, of these factors, the cumulative oxidative and inflammatory burden are considered key 
in disrupting the balance between disc ECM anabolism and catabolism that occurs with age [48], 
[73]. Oxidative and inflammatory stress are also inducers of cellular senescence phenotype in a 
myriad number of cell types [99], and thus, could contribute to disc degeneration by inducing 
senescence in disc cells. Indeed, human NP (hNP) cells exposed to oxidative stress, e.g., 
hydrogen peroxide, become senescent and display PG homeostatic imbalance [74], [76]. These 
cells upregulate expression of p53 and p21 proteins and cease to proliferate. Additionally, H2O2- 
treated hNP cells show suppressed expression of aggrecan and collagen II and enhanced 
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expression of multiple proinflammatory cytokines (IL-6, IL-8, IL1β, TNFα), and matrix 
proteases (MMP-1, 2, 3, 9, 13 and ADAMTS-4, 5). Consequently, increased fragmentation of 
aggrecan and collagen is also evident in H2O2-treated hNP cells. Similarly, culturing rat NP cells 
in 20% oxygen upregulated ROS expression, induced DNA damage and cell cycle arrest, and 
elevated expression of catabolic factors- ADAMTS 4,5 and MMP 2,3, 14 [152]. Treatment of rat 
disc cells with exceptionally high glucose concentration was also reported to induce senescence 
via oxidative stress mechanism [153]. 
There is convincing evidence for the role of inflammatory stress in propagating cellular 
senescence phenotype in disc cells as well. Exposure of bovine caudal IVDs to TNFα for 21 days 
resulted in increased aggrecan breakdown, upregulation of IL-6, MMP-3, and SA-βgal [64]. 
Interestingly, the degradative changes were persistent in IVDs even after a recovery period of 14 
days following a 7-day exposure to TNFα, suggesting a non-recoverable catabolic shift mediated 
by the transition to a cellular senescence phenotype. In addition, loss of proliferative capacity 
and greater susceptibility to degradative changes is seen in disc of IL-1ra-/- mice which lack 
functional endogenous antagonist of IL-1R [66]. This could be due to senescence induction as 
IL-1β has been shown to induce senescence in articular chondrocytes and fibroblasts [105], 
[154]. Additionally, the collagen proteolytic fragments generated as a consequence of cytokine- 
mediated stimulation of MMPs and ADAMTS expression induced premature senescence in rat 
NP cells [155]. Importantly, loss of disc height was observed in rat spine upon injection of rat  
NP cells induced to senesce with collagen MMP fragments. Together, these studies suggest that 
disc cells may undergo a phenotypic shift to a cellular senescence phenotype and promote the 
matrix homeostatic imbalance seen with aging in disc tissue in response to accumulative 
oxidative and inflammatory stress. 
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Chronic unrepaired DNA damage, a well-known inducer of senescence, emanating from 
factors other than oxidative or inflammatory stress has been implicated in driving senescence in 
disc cells as well. In old mice, chronic exposure to different types of genotoxic stress, including 
ionizing radiation and tobacco smoke, resulted in dramatic up regulation of disc p16INK4a and 
accelerated disc PG loss [156]. Furthermore, reduced nutrient supply, which is an important 
contributor to the pathophysiology of disc degeneration, has been shown to promote senescence 
phenotype in disc cells [157]. 
Evidence for the role of cellular senescence has been explored in human disc tissue as 
well. Expression of p16INK4a protein was found to increase with age in human disc tissue and was 
positively correlated with expression of ADAMTS-5 and MMP-13, suggesting senescent disc 
cells as the source of the matrix degrading proteases [158]. In another study, increase in the 
fraction of disc cells stained with SA-βGal positively correlated to the degeneration grades of 
disc tissue and, more importantly, negatively correlated with Ki67 positive proliferating cells 
[159], [160]. Collectively, both the animal and human studies suggest that age-induced 
senescence can greatly reduce the percent of proliferative and functional cells in the disc and can 













Intervertebral disc degeneration is one of the major contributors to back pain, a largest chronic 
disorder that impacts the functional ability in the elderly. Individuals over 60 years old have a 
significantly higher risk of developing pain stemming from intervertebral disc degeneration 
(IDD) [161]. As such, there is now great impetus to understand how aging drives IDD in order to 
preserve mobility and fitness in the elderly population. Previous reports have examined the 
changes that accompany, and likely contribute, to the degeneration of the disc tissue with aging. 
Among these changes, the accumulative oxidative stress has been shown to be the predominant 
driver of the ensuing increase in inflammatory burden and matrix proteases with age in the disc 
tissue [55], [73], [151]. Oxidative stress is a well-known inducer of cellular senescence [99], a 
cell phenotype that has been reported to be causal in other age-associated pathologies, including 
atherosclerosis and osteoarthritis [124], [142]. Indeed, earlier studies have shown increased 
cellular senescence with age in disc of humans and mice [156], [158], [160], and in vitro studies 
have established that senescent disc cells have a catabolic phenotype characterized by increased 
secretion of proinflammatory factors, matrix proteases, and elevated matrix protein degradation 
ability [74], [76]. However, these studies are correlative and do not assess the changes that 
sustains the elevated secretion of proteins in senescent disc cells. To address these gaps, this 
dissertation work proposed the following Specific Aims (SAs): 
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SA1. To test the hypothesis that elevated protein secretion in senescent disc cells 
upregulates the energy generation pathway(s). Rationale: Previous studies have shown that 
metabolic changes characterized by increased energy generation are critical in sustaining the 
secretion of senescent related peptides in chemotherapy- and oncogene-induced senescent cells. 
Approach: We will use an in vitro cell culture model of oxidative stress-induced senescent disc 
cells to assess a) glycolysis and oxidative phosphorylation, b) changes that accompany these two 
energy generation pathways, and c) whether senescent associated protein synthesis requires 
upregulation of the energy generation pathways. Significance: Completion of these proposed 
experiments will elucidate the metabolic changes that enable disc senescent cells to secrete 
proteins, a large part of which are the catabolic SASP factors. 
SA2. To test the hypothesis that senescence disc cells play a causal role in driving 
age-related  disc  degeneration.  Rationale:  Previous  studies  reported  an  association,  not 
causation, of increased cellular senescent levels in disc tissue of mice, humans, and sand rats 
with age. Approach: We will make use of the p16-3MR mice model which enables selective 
clearance of p16INK4a positive senescent cells upon treatment with the drug ganciclovir (GCV). 
Using three p16-3MR mice groups- young, old treated with vehicle, and old treated with GCV- 
we will assess changes in histological features, expression of matrix proteases, and aggrecan 
content and proteolytic fragmentation in their intervertebral discs.  Significance: Completion of 
this study will determine whether the senescent disc cells cause age-associated disc degeneration. 
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3.0 OXIDATIVE STRESS-INDUCED SENESCENCE MARKEDLY INCREASES 
DISC CELL BIOENERGETICS 
This work, essentially as presented here, was submitted for publication in Mechanism of Aging 
and Development: Patil P, Falabella M, Saeed A, et al. Mech Ageing Dev. 2018 Oct 4. Results 
from this work were presented as podium presentation at the 44th International Society for the 
Study of the Lumbar Spine conference (ISSLS, 2017) in Athens, Greece. To provide the proper 
context, the paper is presented here in its entirety. The supplementary materials are included in 
Appendix A. 
3.1 INTRODUCTION 
Intervertebral disc degeneration (IDD) is one of the most common underlying causes of low back 
pain and disability in older adults [162]. The intervertebral disc tissue undergoes several 
structural, biochemical, and biomechanical changes with age which ultimately impede the   
normal   disc   function   and   patient   mobility.   With increasing    age,    the    disc tissue 
experiences loss and fragmentation of matrix proteins, specifically aggrecan, the major 
proteoglycan (PG), with concomitant decrease in water content, leading to fissures and decreased 
disc height [1]. Multiple reports suggest that the elevated inflammatory cytokines, such as  IL-  6, 
IL-8, TNFα, and IL-1β, are closely associated with the development of IDD. These cytokines 
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suppress synthesis      of      matrix      proteins       and       upregulate       secretion       of 
matrix proteases that includes ADAMTS (A Disintegrin and Metalloproteinase with 
Thrombospondin motifs) -4/5 and MMP (matrix metalloproteinases)-1, -2, -3, -13, -14 [48]. The 
age-related imbalance in matrix homeostasis of disc tissue suggests that the disc cells undergo 
phenotypic  alteration. Indeed, the tissue milieu of the aged disc contains elevated quantities 
of inflammatory proteins and oxidants, two well-known inducers of cellular senescence. Thus, 
the age-related degeneration of disc tissue could be speculated to be driven by transformation of 
the disc cells into senescence phenotype. 
Cellular senescence is functionally defined as the irreversible loss of cellular proliferative 
potential and can be induced by a wide array of stressors, which commonly involve DNA 
damage [163]. Historically, senescence was first characterized as the finite proliferative capacity 
of primary human cells in culture, triggered by erosion in telomere length [92]. Telomere 
attrition is found to generate persistent DNA damage response (DDR), which is needed to 
enforce the permanent growth arrest attained by serial cell passaging [164]. In addition to the 
passage-dependent telomere shortening, other stressors are known to induce senescence as well. 
The best studied examples come from conditions in which cells are exposed to subtoxic stress 
that directly damage the DNA (hydrogen peroxide, UV), termed as stress-induced senescence 
(SIS) [165]. Senescence can also occur when cells experience strong and continuous mitogenic 
signals, termed as oncogene-induced senescence (OIS) [166]. Both the SIS and OIS share several 
features with replicative senescence, including characteristic morphological changes, persistent 
DDR, irreversible growth arrest, and enhanced senescence-associated beta-galactosidase (SA- 
βGal) expression. 
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Growing evidence supports cellular senescence as one of the major drivers of aging and 
age-associated pathologies [167]. Indeed, senescent cells have been documented to increase with 
age in many rodent, non-human primate and human tissues [168]–[170]. Moreover, elevated 
number of senescent cells have been identified at the sites of several degenerative age-associated 
pathologies including osteoarthritis, glomerulosclerosis, and atherosclerosis [118]. Removal of 
senescent cells, in natural and accelerated aging mice, ameliorates age-related degenerative 
changes in several tissues and attenuates functional decline of skeletal and cardiac tissue [134], 
[140]. The increase in cellular senescence levels has also been documented in degenerative and 
aging human discs [158], [160]. Recently, we reported a dramatic upregulation of p16Ink4a and 
accelerated loss of disc PG in mice chronically exposed to genotoxic stress, including tobacco 
smoke and ionizing radiation [156]. All together these studies suggest a correlative relationship 
between DNA damage-induced senescent cells and IDD. 
While senescent cells growth are arrested, they are far from being inert. One of the most 
defining features of SIS and OIS cells is the elevated and chronic secretion of myriad 
inflammatory cytokines and matrix proteases. This robust secretory phenotype of senescent cells 
is termed as senescent associated secretory phenotype (SASP) [105]. It is postulated that the 
senescent cells drive tissue aging through the action of SASP factors. In vitro and mouse 
xenograft studies have shown that the SASP factors can promote profound degenerative changes 
that ultimately compromise the tissue structure and function [106]. Furthermore, it was reported 
that the level of SASP factors provide predictive power regarding onset of disability and 
mortality in the elderly [171], [172]. The bioenergetic demands of such robust SASP production 
is becoming an important area of aging research. 
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Relatively little is known regarding the metabolic alterations that occur with entry into 
senescence. In Ras-induced and replication-induced senescent human fibroblast cells, impaired 
mitochondrial function and increased oxidant formation have been documented [173], [174]. 
However, in oncogenic BRAFV600E-induced senescence, metabolic rewiring to increase 
mitochondrial respiration was necessary to maintain growth arrest and  elevated secretion of IL-
6 and IL-8 SASP factors [175]. Similarly, in chemotherapy-induced senescence, metabolic shift 
to elevated mitochondrial energy generation was needed to sustain the synthesis of NF-  κB 
mediated SASP factors [116]. These findings suggest that the elevated and chronic production 
of the proteins, including SASP factors, caused by multiple stressors drives increased energy 
production in senescent cells. However, none of the studies to date have elucidated whether such 
metabolic changes occur in the context of oxidative stress-induced senescent disc cells. 
Herein,     we     performed      bioenergetic      analysis      of hydrogen peroxide-  
induced senescent human disc cells. In these SIS cells, we observed increased mitochondrial 
number, protein expression, and mitochondrial-ATP linked respiration, together with elevated 
fragmentation of matrix proteins and pro-inflammatory cytokines. Furthermore, protein synthesis 
in senescent disc cells was found to be supported by the increased mitochondrial respiration. Our 
findings demonstrated that SIS disc cells acquire enhanced bioenergetics to support secretion of 
senescent associated proteins. 
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3.2 METHODS 
3.2.1 SAMPLE COLLECTION AND ISOLATION 
Human nucleus pulposus disc samples were obtained from patients undergoing surgery (mean 
age ± SD = 50 ± 11.4 years, mean degeneration grade = 2.41 ± 0.5) (IRB #: PRO12100603). 
Cells were isolated from digested tissues as described before [176]. Cells were cultured in 
monolayer in F-12 media (Cat. No. 11765-062, Life Technologies) under hypoxic conditions   
(37 °C, 5% CO2, and 5% O2 with a bicarbonate buffer to maintain pH 7.2). 
3.2.2 SENESCENCE INDUCTION 
Hydrogen peroxide was used to induce cellular senescence as previously described [76]. Briefly, 
primary human nucleus pulposus (hNP) cells were treated with 500 μM hydrogen peroxide in F- 
12 (Cat. No. 11765-062, Life Technologies), supplemented with 10% Fetal Bovine Serum (FBS; 
Cat. No. S12450, Atlanta Biologicals;) and 1% Penicillin/Streptomycin solution (PS; Cat. No. 
15140-16, Life Technologies), for 2 h. Culture media was then replaced with fresh F-12 with 
10% FBS and 1% PS media without hydrogen peroxide. Cells were then maintained in culture 
for 10 days to establish senescence. 
3.2.3 SENESCENCE ASSOCIATED β-GALACTOSIDASE STAINING 
Senescence-associated β-galactosidase (SA β-gal) staining was performed as previously 





Conditioned media was collected at the end of culture (day 10) and concentrated 40x with 3kDa 
cutoff centrifugal concentrators (Cat. No. UFC 900324, Millipore Sigma). IL-6, IL-8, and CTX- 
II protein levels  were  determined  using  R&D  Total  Human  IL6  and  IL8  DuoSets  (Cat.  
No. DY206 and DY208) and Biomatik Cross Linked C-Telopeptide of Type II Collagen kit (Cat. 
No. EKU03505), respectively, as per manufacturer’s instruction. Protein concentration was 





To assess aggrecan fragmentation, conditioned media was collected at day 10 of culture and 
concentrated as described above. To assess p53 protein expression levels, protein extracts from 
cell cultures were obtained using T-PER Tissue Protein Extraction Reagent supplemented with 
proteinase inhibitor cocktail as per the manufacturer’s instructions (Cat. No. 78510, Thermo 
Fisher). Concentrated conditioned supernatant and cell lysates from cell cultures were separated 
using Tris-HEPES 4–20% gradient polyacrylamide denaturing gel (Cat. No. 25204, Thermo 
Scientific). The amount of conditioned media and cell lysates loaded on the gel corresponded to 
equal cell number. After electrophoresis, the proteins were transferred to a PVDF membrane by 
electroblotting and processed as described before [76]. Immunoreactive proteins were detected 
using  chemiluminescent detection  system  (Cat.  No.  34096,   Thermo   Scientific and Bio-   
Rad ChemiDoc MP). The following primary and secondary antibodies were used: Aggrecan 
(Cat.No. ab36861 (anti-G1), Abcam), p53 (Cat.No. 2524,  CST)  and  β-actin  (Cat.No.  PA1- 
183, Thermo Fisher), anti-rabbit goat secondary antibody with HRP (Cat. No. PI-31460, Thermo 
37  
Scientific). Quantification was performed with densitometry analysis using Bio-Rad ChemiDoc 
MP. 
 
3.2.6 BIOENERGETIC FLUX MEASURMENTS BY SEAHORSE XFe96 
 
 
Bioenergetic measurements were performed using Seahorse Extracellular Flux Analyzer. The 
protocol for adherent cells was adapted to disc cells [177]. Briefly, hydrogen peroxide treated 
and untreated disc cells were plated at a density of 80,000 cells per well on a XFe96 plate and 
cultured overnight in F-12 media (10% FBS and 1% P/S). On the day of the experiment, cell 
culture media was replaced with unbuffered DMEM (Cat. No. D5030, Sigma Aldrich) 
supplemented with 2 mM Glutamax-1 (Cat. No. A1286001, Gibco), 1 mM sodium pyruvate 
(Cat. No. P5280, Sigma), 25 mM glucose (Cat. No. G7021, Sigma), 32 mM sodium chloride 
(Cat. No. S3014, Sigma Aldrich), and 15 mg phenol red (Cat. No. P3532, Sigma Aldrich) and 
incubated in non-CO2 incubator at 37 °C. Extracellular flux measurements were performed two- 
three times at six-minute intervals over five different treatment conditions: basal, oligomycin 
(2.5 µM) (Cat. No. 75351, Sigma), carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP) (2.5 µM) (Cat. No. C2920, Sigma Aldrich), 2-deoxglucose (2DG) (100 mM) (Cat. No. 
D6134, Sigma Aldrich), and rotenone (Cat. No R-8875, Sigma Aldrich) and antimycin A (Cat. 
No. A8674, Sigma) (2 µM each). Oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) were calculated at each measurement. OCR and ECAR calculations were 
normalized by cell number per well using the tryphan blue exclusion assay. Mitochondrial ATP- 
linked respiration was calculated by subtracting the OCR values after oligomycin addition from 
the Basal OCR values. The proton leak was calculated by subtracting the OCR values after 
rotenone and antimycin A addition from basal OCR values. 
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To assess the relationship between protein production and upregulation of bioenergetic 
parameters, 2.5 μg/ml cycloheximide (CHX), an inhibitor of protein synthesis, was added to 
hydrogen peroxide treated and untreated cells for 24 hours before measuring extracellular flux 
parameters. 
 
3.2.7 IMMUNOFLUORESCENT STAINING 
 
 
Cells were washed twice with cold PBS and fixed in 2% paraformaldehyde in PBS for 15 min at 
room temperature. Cells were then permeabilized with 0.25% Triton X-100, and blocked with 
20% serum (using the species in which the secondary antibodies were made) and 1% BSA in 
PBS (PBB) for 45 min at room temperature. Cells were incubated with the specific primary 
antibodies for γH2A.X (Cat. No. 05-636, Millipore), mtDNA (Cat. No. 03-61014, American 
Research Products, Inc.), TOM20 (Cat. No.PA5-52843, ThermoFisher Scientific) or ATP 
synthase beta (Cat. No. A-21351, ThermoFisher Scientific) overnight at 4°C. Cells were then 
washed three times with PBB and incubated with secondary antibody. The following secondary 
antibodies were used: 488 anti-rabbit (Cat. No. A21206, Life Technologies), Cy3 AffiniPure 
Goat anti-mouse (Cat. No. 115-165-003, Jackson Immuno Research) or Alexa Fluor 647 
AffiniPure Goat anti-rabbit (Cat. No. 111-605-003, Jackson Immuno Research) for 1 hour at 
room temperature. To assess mtDNA colocalization with mitochondria, Cy3 (mtDNA) and 
Hoechst (BIsbenzimide; Cat. No. B-2883, Sigma-Aldrich) were collected simultaneously and 
Cy5 (TOM20) was collected by sequential scanning frames using a Leica TCS SP8 system. The 
images were then deconvolved through Huygens Professional software (SVI). Images of cells 
stained with anti γH2A.X antibodies were acquired with an Eclipse TE2000-U (Nikon, Minato, 
Tokyo, JP). 
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3.2.8 MITOCHONDRIAL QUANTIFICATION 
 
 
To assess mitochondrial morphology, we performed immunofluorescent analysis of fixed cells 
using TOM20 (Cat. No.PA5-52843, ThermoFisher Scientific) to label mitochondria. Cells were 
co-stained with Hoechst (nuclei). Confocal Z-stacks were collected using a 60X (1.43NA) optic 
on a Nikon A1 equipped with GASP detectors and NIS Elements software (Nikon Inc., Melville 
NY). The confocal datasets were imported into Imaris (Bitplane Zurich, Switzerland) for surface 
rendering and calculation of mitochondrial number, volume, and sphericity. 
 
3.2.9 mtDNA MEASUREMENTS 
 
 
Total DNA from primary human nucleus pulposus (hNP) cells was isolated by sodium dodecyl 
sulfate lysis and proteinase K digestion as previously described [178]. DNA was then 
resuspended at 37°C in Tris-EDTA buffer containing RNAse A and the total DNA concentration 
determined by fluorescence using AccuBlue Broad range kit (Biotium, Fremont, CA). mtDNA 
and nDNA abundance was measured by duplex qPCR using three different TAQMAN 
primer/probes sets (ND1 and B2M; CytB and GUSB; Cox1 and ACTB) and averaged. Serial 
dilutions of combined samples were also performed to confirm assay linearity and dilution 
independence of results. qPCR was conducted on a StepOnePlus thermo cycler (ThermoFisher 
Scientific) using TaqMan Fast Advanced Master Mix (ThermoFisher Scientific), 4.6 ng/reaction 
DNA, and 5 μM of primer/probes in 10 μl final reaction volume. Relative mtDNA abundance 
was calculated by the ΔΔCq method [179]. The qPCR amplification profile was: one cycle (95°C 
for 20 sec) and 40 cycles (95°C for 1 sec and 60°C for 20 sec). Assays for mtDNA (mtND1, 
mtCYTB, and mtCOXI) were primer limited (1 primer: 1 probe), whereas assays for nuclear 
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DNA (B2M, GUSB, ACTB) were not primer limited (3 primer: 1 probe). The primers and 
probes used for the mtDNA quatification were purchased from Integrated DNA Technologies 
(IDT) and are listed below: 
Table 1. Primers used for qPCR for mtDNA measurements 
 
mtND1 probe 5’-/5HEX/CCATCACCC/ZEN/TCTACATCACCGCCC-3’ 
mtND1 primer 1 5’-GAGCGATGGTGAGAGCTAAGGT-3’ 
mtND1 primer 2 5’-CCCTAAAACCCGCCACATCT-3’ 
B2M probe 5’-/6FAM/ ATGTGTCTG/ZEN/GGTTTCATCCATCCGACA - 
3’ 
B2M primer 1 5’- TCTCTCTCCATTCTTCAGTAAGTCAACT-3’ 
B2M primer 2 5’- CCAGCAGAGAATGGAAAGTCAA-3’ 
mtCYTB probe 5’-/5HEX/ATCATCCGC/ZEN/TACCTTCACGCCAAT-3’ 
mtCYTB primer 1 5’-CCACATCACTCGAGACGTAAAT -3’ 
mtCYTB primer 2 5’-GATGTGTAGGAAGAGGCAGATAAA -3’ 
GUSB probe 5’-/6FAM/AAGAGTGGT/ZEN/GCTGAGGATTGGCA-3’ 
GUSB primer 1 5’-TGGTACGAACGGGAGGT -3’ 
GUSB primer 2 5’-ACGATGGCATAGGAATGGG -3’ 
mtCOXI probe 5’-/5HEX/TGCCATAAC/ZEN/CCAATACCAAACGCC-3’ 
mtCOXI primer 1 5’-CTAGCAGGTGTCTCCTCTATCT -3’ 
mtCOXI primer 2 5’-GAGAAGTAGGACTGCTGTGATTAG-3’ 
ACTB probe 5’-/6FAM/CTGCCTCCA/ZEN/CCCACTCCCA-3’ 
ACTB primer 1 5’-GTCCCCCAACTTGAGATGTATG-3’ 
ACTB primer 2 5’-AAGTCAGTGTACAGGTAAGCC -3’ 
 
 
3.2.10 GENERAL STATISTICAL ANALYSIS 
 
 
Shapiro-Wilk test was used to test for normality.  Student independent T-test was used to analyze 
data found to be normal.  For two variable non-parametric data, the Mann-Whitney test was 
used.  Analysis of variance (ANOVA) with Bonferroni correction for multiple comparison was 
used in cases of data with multi-variables.  Statistics were derived using GraphPad Prism 
from GraphPad Software (San Diego, CA). All graphs show mean values with error bars (SD or 






3.3.1 ESTABLISHMENT OF OXIDATIVE STRESS INDUCED SENESCENT DISC 
CULTURE SYSTEM 
 
To better understand the phenotype of cellular senescence and its role in driving disc tissue 
aging, it would be most ideal to isolate and characterize the native senescent cells from disc 
tissue. However, this is technically challenging as no single specific biomarker of senescent 
cells, and disc senescent cells in particular, has been identified to allow for selection and 
isolation. Therefore, we made use of a previously engineered in vitro model to induce senescence 
in human disc cells derived from surgical specimens using hydrogen peroxide (H2O2) [76]. The 
rationale for this experimental approach was twofold: 1) H2O2 induces oxidative damage, an 
established feature in aged disc tissue; 2) H2O2 provokes DNA damage, a well-known hallmark 
of cellular senescence [96]. hNP cells were treated with hydrogen peroxide to induce DNA 
damage and incubated in culture media sans hydrogen peroxide for 10 days to allow cells to 
establish stress-induced senescence (SIS). This treatment regime ensured that the observed 
changes were in fact due to senescent phenotype and not to H2O2-induced transient oxidative 
stress experienced by cells. To confirm establishment of the senescent phenotype, we assessed 
the expression of well-known senescent markers, including SA-βgal, γH2A.X, marker of a DNA 
damage response, and p53 protein, a regulator of cell cycle arrest (Fig 4A-C). At 10 days post- 
H2O2 treatment, 90% of the hNP cells expressed p53 protein and contained nuclear foci of 
γH2A.X. In addition, a majority of the cells stained positive for SA-βgal and displayed a 
flattened and enlarged cell morphology that is commonly associated with senescent phenotype in 
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these cells. Detection of these markers confirmed successful induction and establishment of SIS 
disc cells. 
 
Figure 4. Establishment of stress-induced senescence (SIS) in disc cells 
Senescence phenotype establishment in human disc cells treated with hydrogen peroxide (500 µM, 2 hr and 
examined 10 days later) was verified by SA-βGal staining (A), punctated expression of the DNA damage response 
marker γH2A.X in nuclei (B), and p53 protein expression (C). The individual points in (A) indicate the percent SA- 
βGal positive cells in one field of imaging and in (B) indicate the number of γH2A.X foci divided by the number of 
cells (DAPI) in one field of imaging. Data in (A) and (B) are means ± SEM of 4 independent experiments. The 
graphs in (C) indicate volume of p53 band divided by volume of β-actin band from 3 independent  experiments. 
Data in (C) is means ± SD; *** p < 0.0001; *p < 0.05. Scale bar = 10µM. 
 
 
3.3.2 SENESCENT DISC CELLS ACQUIRE A CATABOLIC PHENOTYPE THAT IS 
REMINISCENT OF AN OLDER DISC TISSUE PHENOTYPE 
 
To test for markers of age-related IDD, we assessed matrix catabolism in SIS disc cells. The 
aggrecan fragmentation mediated by ADAMTS and MMP class of proteases was 30x and 5x 
higher in SIS compared to non-SIS disc cells, respectively (Fig 5A). The collagen II 
fragmentation in hNP SIS cells was modestly, but not significantly, higher as well (Fig 5B). We 
next tested levels of proinflammatory cytokines, including IL-6 and IL-8, which are known to 
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promote the increased collagen and aggrecan fragmentation with age by inducing synthesis of 
MMP and ADAMTS class of proteases in disc cells. Indeed, we observed greater than 10x 
increase in lL-6 and IL-8 protein levels in media from hNP SIS cultures compared to that of non- 
SIS cells (Fig 5C). This suggested that SIS disc cells, by virtue of their elevated secretion of 
proinflammatory cytokines (IL-6 and IL-8), can promote MMP and ADAMTS catalyzed matrix 
protein fragmentation seen with aging in disc tissue. 
 
 
Figure 5. SIS disc cells mirror markers of age-related disc degeneration 
SIS disc cells display elevated levels of aggrecan fragments mediated by action of ADAMTS and MMP proteases as 
assessed  by  Western  blot  (A),  collagen  II  fragments  (B),  and   IL-6   and   IL-8   proteins  by  ELISA   (C). 
Data are means ± SD of 3 independent experiments; *** p < 0.0001; *p < 0.05. 
 
 
3.3.3 MITOCHONDRIAL RESPIRATION IS INCREASED IN STRESS-INDUCED 
SENESCENT DISC CELLS 
 
One key feature of senescent cells is their elevated and chronic secretion of numerous proteins, 
including pro-inflammatory cytokines and matrix proteases. We hypothesized that increased 
chronic protein secretion is an energetically demanding process, and we therefore examined the 
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bioenergetic profile of SIS disc cells using Seahorse Flux Analyzer, which measures cellular 
glycolytic and oxidative phosphorylation (OXPHOS) rates simultaneously. The glycolysis 
activity is measured via changes in the extracellular acidification rate (ECAR) and OXPHOS 
activity is assessed via oxygen consumption rate (Fig 16). The SIS disc cells had a significantly 
higher (182%) basal OCR compared to non-SIS disc cells (Fig 6). The SIS disc cells also had 
higher ECAR, though not statistically significant, than that of the non-SIS disc cells. Since the 
increase in basal OCR could be driven by either increase in mitochondrial ATP-linked 
respiration or proton leak, we examined the sensitivity of the cells to oligomycin, an inhibitor of 
ATP synthase (complex V) and to rotenone and antimycin A compounds, which inhibit complex 
I and III, respectively (Mito ATP and Proton leak OCR, described in Fig 16). The mitochondrial 
respiration associated with ATP production was significantly higher (165%) in SIS cells 
compared to non-SIS disc cells. However, the mitochondrial respiration associated with proton 
leak did not change appreciably, suggesting the increase in basal OCR is driven by increased 






Figure 6. SIS disc cells exhibit alteration in energy metabolism 
80x 103 SIS and non-SIS disc cells were plated in Seahorse XF96 Extracellular Flux Analyzer plate. The Seahorse 
Analyzer records rates of OXPHOS and glycolysis via the oxygen consumption rate (OCR) and the extracellular 
acidification rate (ECAR). Basal OCR and ECAR were recorded at the start of the assay. ATP-linked OCR (Mito 
ATP) is the difference between the basal OCR and OCR after the addition of oligomycin to sample cultures. Proton 
leak is the difference between oligomycin sensitive OCR and OCR after the addition of rotenone and antimycin A 
(Fig Sup 1). The data is representative of 5 independent experiments and expressed as means ± SEM; *p < 0.05. 
 
 
3.3.4 INCREASED MITOCHONDRIAL CONTENT ACCOMPANIES THE 
INCREASED MITOCHONDRIAL RESPIRATION IN SENESCENT DISC CELLS 
 
Increase in mitochondrial ATP-linked respiration is driven typically by increased mitochondrial 
biogenesis. First, we assessed mitochondrial protein expression by 2-D imaging SIS and non-SIS 
disc cells labeled with antibodies against ATP synthase beta and TOM20. ATP synthase beta is a 
mitochondria specific protein which is integral to the electron transport chain complex V. 
TOM20 is a mitochondrial membrane protein which helps in translocating cytosolically 
synthesized proteins destined for mitochondria. The expression of both these mitochondrial 
proteins was higher in SIS compared to non-SIS disc cells (Fig 7A, B). Next, we assessed 
mitochondrial number and morphology by 3-D imaging SIS and non-SIS disc cells labeled    
with TOM20. 
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The data sets from the imaging were imported into Imaris software for surface volume rendering 
using intensity based segmentation to identify discrete objects (mitochondria). The SIS disc cells 
had significantly more objects compared to non-SIS disc cells, suggesting a greater number of 
discrete mitochondrial units (Fig 7C). As the volume per mitochondrial unit was similar, the 
difference is most likely explained by increased mitochondrial abundance rather than increased 
fission which would be expected to be associated with increased fragmentation and decreased 
volume per fragment (Fig 7E). There were no differences in the shape/morphology of the 
individual mitochondria as reflected by sphericity (roundness) measurements (Fig 7D). The 
sphericity parameter is defined as the ratio of the surface area of the given object to the 
surfacearea of a sphere with the same volume as the given object; the closer the sphericity value 
is to 1, the more spherical the object. Consistently, morphological assessment done using EM 
imaging of SIS and non-SIS disc cells revealed similarity in terms of mitochondrial cristae and 
membrane structure between SIS and non-SIS disc cells (Fig 17). 
Next, we examined the levels of mtDNA by quantitative PCR in SIS and non-SIS disc 
cells (Fig 8). To ensure against sequence variation, we used three mtDNA/nDNA multiplex 
TAQMAN primer/probe sets.  Unexpectedly,  the  qPCR  results  revealed  the  SIS  disc  cells  
to contain ~37%  of  the  mtDNA  levels  of  non-SIS  disc  cells  (Fig  8).  Thus,  the  increase  
in mitochondria respiration in SIS  disc  cells  occurs  without  the  expected  increase  in  
mtDNA content. Additionally, we performed immunohistochemistry for mtDNA levels in both 
cell types (Fig 9) and found altered in situ levels and distribution of mtDNA in SIS disc cells. 
Specifically, while most mtDNA localized with TOM20 in non-SIS disc cells,  much  of  
mtDNA did not localize with TOM20 in SIS disc cells. Hence, SIS disc cells not only contain 





Figure 7. SIS disc cells have increased mitochondrial content compared to non-SIS disc cells 
Expression of Tom20 (A) and ATP synthase beta (B) in SIS and non-SIS disc cells as assessed by 
immunofluorescence imaging. To assess mitochondrial number and morphology, 3-D imaging of SIS and non-SIS 
disc cells labelled with anti-TOM20 antibody was carried out. The data sets from imaging were imported into Imaris 
software for surface rendering. The 3-D surface rendering revealed higher number of mitochondria in SIS disc cells 
(C) but similar sphericity (D) and volume (E). The individual data points in C and E represent the number of surface 
unit or volume divided by the number of cells (DAPI) in one field of imaging. Data are means ± SEM of 3 




Figure 8. SIS disc cells have lower mtDNA compared to non-SIS disc cells 
The relative mtDNA levels in the population was determined by averaging the results of three quantitative PCR 
assays after normalization to nuclear DNA. SIS disc cells contained significantly lower amounts of mtDNA relative 











Figure 9. The SIS disc cells mtDNA do not localize with mitochondria 
mtDNA (green) and mitochondria (red) were detected in situ by immunohistochemistry in SIS and non-SIS disc 
cells by fluorescent microscopy (see methods). To quantify mtDNA resident in mitochondria, images were 
deconvolved and fluorescence volume of mtDNA that co-localized with mitochondria was divided by the total 
fluorescence volume of mtDNA for each sample. The average of three samples were calculated for each group and 
normalized to control values (100%). The graph is the quantification of results from three independent experiments. 
Data is expressed as means ± SD; *p < 0.05. Scale = 10 µM 
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3.3.5 THE ELEVATED MITOCHONDRIAL RESPIRATION IN SENESCENT DISC 
CELLS IS DRIVEN BY INCREASED PROTEIN SYNTHESIS 
To determine whether the increased mitochondrial ATP-linked respiration was in fact needed for 
the elevated production of the proteins, we assessed the mitochondrial bioenergetics profile of 
SIS and non-SIS disc cells in presence of the protein synthesis inhibitor cycloheximide (CHX). 
Consistent with our earlier observation, SIS disc cells had significantly increased basal OCR rate 
compared to non-SIS disc cells (Fig 10A). However, upon treatment with CHX, the SIS disc 
cells had 7x lower basal OCR rate compared to untreated SIS disc cells. The basal OCR 
difference between CHX treated and untreated non-SIS disc cells was very minimal. The 
reduction in basal OCR rate in SIS disc cells treated with CHX was found to be primarily driven 
by lower mitochondrial respiration needed for ATP production as the oligomycin sensitive 
respiration in SIS disc cells treated with CHX was significantly lower compared to untreated SIS 
disc cells (Fig 10B); no such appreciable difference in proton leak between SIS cells treated with 
CHX compared to untreated SIS cells was found (Fig 10C). The ATP-linked respiration and 
proton leak difference in CHX treated and untreated non-SIS disc cells was very modest. These 
results collectively suggested that the high mitochondrial ATP-linked respiration in SIS disc cells 
is needed in synthesis of proteins, presumably to maintain SASP where an abundance of 





Figure 10. Suppression of protein synthesis dampens mitochondrial-ATP linked OCR in SIS disc cells 
80x 103 SIS and non-SIS disc cells were plated in a well of Seahorse XF96 Extracellular Flux Analyzer and 
incubated with or without 2.5 μg/ml of cycloheximide (CHX) for 24 hr before commencing Seahorse recording of 
the basal OCR and ECAR and OCR after addition of sequential addition of metabolic inhibitors. A) The high basal 
OCR in SIS disc cells is abrogated after inhibition of protein synthesis using CHX. Assessment of mitochondrial- 
ATP linked OCR (Mito ATP) (B) and proton leak OCR (C) in presence of CHX suggests that the reduction in basal 
OCR in SIS cells in A is due to dampening of mitochondrial ATP-linked respiration and not due to proton leak.  








Senescent cells accumulate in multiple tissues with age in vertebrate organisms and contribute to 
the decline in tissue homeostasis via secretion of myriad catabolic factors that can 
51  
have potent impact on neighboring cells and surrounding tissues. Multiple reports have shown an 
increase in cellular senescence with age and degeneration in human and rodent discs [156], 
[158], [160]. The relationship between cellular senescence and age-related disc degeneration 
maybe more than correlative, as work done by Ngo et al has shown that human senescent disc 
cells express elevated amounts of matrix proteases as well as proinflammatory cytokines, factors 
that are known to promote loss of disc tissue health with aging. However, no study to date has 
explored the underlying metabolic changes of senescent disc cells. 
In the present study, we demonstrated elevated production of the key SASP factors IL-6 
and IL-8 which mirror the increased aggrecan fragmentation in SIS disc cells. We also 
discovered that SIS disc cells harbor a substantially greater number of mitochondria and exhibit 
increased mitochondrial ATP-linked respiration. We speculate that this metabolic alteration, i.e., 
increased mitochondria ATP-linked respiration in disc cells is necessary to meet the energy 
demand elicited by the elevated production of proteins in senescent cells. This idea is supported 
by our experiment showing that inhibition of protein synthesis significantly lowered 
mitochondrial ATP-linked respiration in SIS but not control disc cells. Our finding is consistent 
with other reports which show that in chemotherapy and oncogene induced senescent cells, lower 
macromolecule synthesis (fatty acids) and high mitochondrial ATP production are metabolic 
adaptations necessary to maintain the persistent and high protein production, including SASP 
factors [116], [117]. 
Mitochondria’s role in cellular senescence has been widely associated with generation of 
ROS, which acts as a driver of signaling networks necessary to maintain the senescent phenotype 
[180]. However, recent work has shed light on the true necessity of mitochondria for senescence 
in addition to ROS generation. Report by Correia-Melo et al. demonstrated that in irradiation- 
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induced senescent fibroblasts, suppression of a vast number of genes involved in senescence was 
seen upon depletion of mitochondria by treatment with CCCP, an uncoupler that targets the 
ubiquitin ligase Parkin to mitochondria and promotes their degradation [115]. In accordance with 
this, the protein synthesis in SIS disc cells was seen to drive the elevated mitochondrial ATP- 
linked respiration. This result was unexpected as disc cells are known to rely on glycolysis for 
generation of ATP. Therefore, it can be derived that the disc cells upon becoming senescent 
become adapted to generate energy via OXPHOS to support synthesis of senescent related 
peptides. 
Increased mitochondrial number and protein expression were found to be the changes 
accompanying the upregulation in mitochondrial ATP-linked respiration in SIS disc cells. 
However, surprisingly, no concurrent increase in mtDNA levels was seen in SIS disc cells. The 
conundrum of increased mitochondrial function with lower mtDNA is not unprecedented, 
however. Heddi et al. observed coordinated increase in nuclear and mitochondrial OXPHOS 
transcripts in muscle of MERRF (myoclonic epilepsy associated with red ragged fibers) and 
MELAS (myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) patients with 
diagnosed mutation in mitochondrial genome [181]. Work by Piechota et al. showed that in 
HeLa cells, despite a reduction in mtDNA by 90%, the COX2 protein and COX activity were 6- 
fold higher relative to mtDNA content. Taken together, these results suggest that the depletion in 
mtDNA can be compensated by increased transcription per genome and efficient protein 
synthesis [182]. Interestingly, the mtDNA in SIS disc cells did not co-localize with mitochondria 
and was mostly cytoplasmic. Cytoplasmic DNA is a known trigger for the cytosolic DNA sensor 
cGAS to produce second messenger cyclic GMP-AMP (cGAMP), which binds and activates the 
adaptor protein STING, thereby leading to the production of inflammatory cytokines [183]. The 
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cGAS-STING pathway plays a key role in activation of immune system during microbial 
infection. Recently, it was shown that cGAS-STING also helps in initiation and maintenance of 
SASP factors in cells induced to senescence by various means [184], [185]. It therefore could be 
speculated that the cytoplasmic mtDNA of SIS disc cells plays a role in regulating the SASP 
factor synthesis. However, this remains to be verified. 
Alteration in metabolic state of cells is accompanied by changes in mitochondrial 
morphology. Specifically, mitochondrial fusion is favored under energetically demanding 
conditions as it allows for complementation of genes and efficient dissipation of membrane 
potential [186]. Mitochondrial fission, on the other hand, helps maintain bioenergetic state of the 
cell by promoting degradation of damaged organelle by autophagy [186]. The mitochondria in 
SIS disc cells had similar cristae structure, outer membrane definition, sphericity, and volume 
compared to non-SIS disc cells. In contrast, previous reports show that in human cell lines 
induced to undergo senescence there is an overall shift to more fusion events, resulting in 
abnormally elongated mitochondria [187], [188]. However, it is unclear if elongated 
mitochondria are truly needed to maintain permanent growth arrest in all cell types or whether 
such morphological changes are only seen in transformed cell lines. 
Despite the morphological similarity between SIS and non-SIS disc cell mitochondria, 
mitochondrial ATP-linked respiration in senescent disc cells is elevated. It cannot be discounted 
that this upregulation in SIS disc cells, which would consequently lead to higher mitochondrial 
ATP concentration, could be utilized towards processes other than protein synthesis. In 
chemotherapy-induced senescent cells, part of the mitochondrial ATP-linked respiration was 
shown to be devoted to autophagic degradation of the improperly synthesized and processed 
senescent-associated secretory peptides [116]. It was speculated that the increased secretion of 
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the catabolic factors by senescent cells overwhelms the cells capacity for proper protein 
synthesis, post-translation modification, vesicular transport, and secretion. Hence, it is plausible 
that in SIS disc cells the mitochondrial ATP-linked respiration could be utilized by mechanisms 
which alleviate the proteotoxic stress. Nevertheless, protein synthesis is positioned at the top of 
the hierarchy of ATP-consuming processes in cells [189]. Therefore, in senescent disc cells most 
of the mitochondrial ATP-linked respiration is probably utilized by protein synthesis. In 
summary, the results of this study collectively suggest that the SIS disc cells attain a catabolic 








4.0 SYSTEMIC CLEARANCE OF P16INK4A-POSITIVE SENESCENT CELLS 
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Low back pain (LBP) is a major chronic disorder that significantly reduces the quality of life of 
the elderly. In the United States, direct and indirect costs associated with LBP, including, lost 
wages and productivity and legal and insurance costs, amount to $100 billion annually [190], 
[191]. Though the exact cause of LBP is not known, the degenerative changes that accompany 
the intervertebral disc with age are most frequently associated with LBP [192]. The debilitating 
back pain stemming from intervertebral disc degeneration (IDD) causes loss of mobility and 
increases the risk of mortality in the elderly [193]. Furthermore, disc degeneration is associated 
with clinical conditions such as herniated discs, spinal stenosis and spondylolisthesis, which are 
major diagnoses which often require surgical treatment. Therefore, there is great need to 
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understand how aging affects the disc in order to maintain mobility and fitness in the fast- 
growing population of elderly. 
During aging, the intervertebral disc undergoes structural, biochemical and 
biomechanical changes that ultimately compromise its function. The loss of aggrecan, a major 
disc matrix proteoglycan (PG), results in reduced capacity to resist compressive forces, a well- 
established  hallmark  of  IDD.  The  disc  transforms  into  a  fibrous  tissue with  age because  
of increased fragmentation and loss of disc PG, with a concomitant decrease in water content, 
leading to fissures and decreased disc height [8], [24], [151]. Evidence also exists for elevated 
levels of matrix fragments generated by the proteolytic action of matrix metalloproteinases 
(MMPs), as well as a disintegrin and metalloproteinase with thrombospondin  motifs 
(ADAMTs), in aged discs [60]. Expressions of major pro-inflammatory cytokines such as IL-1ß, 
IL-6, IL-8, and TNF-α, all known to induce gene expression of ADAMTs and MMPs in IVD 
cells, are also increased in older adult discs when compared to younger or adolescent discs. 
Additionally, IL-6 levels are found to be higher in patients with low back pain prompted by disc 
degeneration [48]. At the cellular level, cellular senescence has been reported to increase with 
age   in   discs [194].  Cellular senescence   may   play   a   major   role in   age-related    IDD    
as the senescent phenotype occurs at the right time and has the right characteristics to drive age- 
related disc degeneration. 
Cellular senescence is a response to stress and certain physiological signals by which 
cells cease to divide and adopt a distinct phenotype [195]. This phenotype includes marked 
chromatin and secretome changes, and increased expression of tumor suppressor genes such as 
the p16INK4a cell cycle inhibitor [105]. The senescence response is a potent tumor suppressive 
mechanism, and has also been implicated in organismal aging [196]. Senescent 
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cells accumulate with age in most, if not all, tissues of humans, primates and rodents [163], 
[169], [170]. Furthermore, senescent cells are found at higher levels in diseased tissue compare 
to unaffected tissue in patients with age-related disorders such as osteoarthritis and type 2 
diabetes [197]. Senescent cells are postulated to promote aging via their senescence-associated 
secretory phenotype (SASP): the increased and chronic secretion of a number of inflammatory 
cytokines and proteases [105], which can disrupt tissue function and structure. Recent reports 
showing amelioration of several age-associated pathologies upon senescent cell clearance in 
naturally aged and transgenic mice strongly support the idea that senescent cells can drive tissue 
aging [134]. The role of cellular senescence in disc aging and degeneration is less firmly 
established. Published reports showed an increased number of senescent cells with age and 
degeneration  in  human  discs  [158],  [160].  However,  these correlative studies  do  not   
clarify whether senescent cells play a causal role in age-related disc degeneration. 
To test the hypothesis that senescent cells play a causal role in age-associated disc 
degeneration,  we   used   a transgenic mouse   model   in   which p16Ink4a-positive senescent  
cells express the herpes simplex virus thymidine kinase, and thus can be selectively eliminated 
upon treatment with ganciclovir (GCV) [135], [138]. Here we show that year-long clearance of 
senescent cells mitigates age-associated increases in disc protease and blunts age-dependent disc 
PG matrix fragmentation and PG loss. These results provide compelling evidence that senescent 
cells are responsible for generating inflammatory cytokines and catabolic proteases that are 
known to increase with aging in disc, and thus support a causal relationship between cellular 









Naturally aged 6 month (Young) and 20 month (Old) old C57BL/6 wild‐type mice were obtained 
from the National Institute of Aging and maintained under specific pathogen‐free conditions at 
University of Pittsburgh’s animal facility. All animal work was approved and done in  
accordance with University of Pittsburgh’s IACUC. Tissues from the p16-3MR mice were 
obtained from Dr. Daohong Zhou's group at University of Arkansas for Medical Sciences. 
Briefly, the p16-3MR mice were either sacrificed at 12 months (Young) or were treated with 
either PBS (Old-Veh) or GCV (Old-GCV) for additional 12 months (25 mg/kg/day for 5 
days/cycle, every other two weeks) before sacrifice [138]. Spines and tails isolated from the p16- 
3MR mice were immediately frozen using liquid nitrogen and stored at -800 C until shipment. 
 
4.2.2 QUANTIFICATION OF MATRIX PROTEOGLYCAN SYNTHESIS 
 
 
Ex vivo culture of functional spine units (FSUs), consisting of vertebrae-disc-vertebrae, was 
established as described [77]. FSUs were cultured in F-12/D-MEM containing 10% fetal bovine 
serum, 1% PS (10000 units/ml penicillin, 10 mg/ml streptomycin), and 25 μg/ml L-ascorbic acid 
for two days followed by a 12-hour incubation with 35S-sulfate (20 μCi/ml). Proteoglycan 
synthesis   was   calculated   as fmoles of   sulfate   incorporated   per μg DNA   by    as 
described [77]. Average values from three mice, each analyzed in duplicate, were calculated and 
reported ± one standard error. 
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4.2.3 HISTOLOGICAL STAIN 
 
 
Isolated   spines   were   decalcified   and   embedded   in    paraffin    (Tissue Tek processor    
and Leica embedder). Seven-micrometer sections were stained with hematoxylin and eosin 
(H&E) by standard procedures and  photographed  under  40-200×  magnification  (Nikon 





Ten tail discs from each mouse was used to assess aggrecan fragmentation utilizing a previously 
established method using anti-aggrecan primary antibody (Cat.No. ab36861, Abcam) and anti- 
rabbit-HRP secondary antibody (Cat.No. 31460, ThermoFisher) [31]. Expression of p53 protein 
was examined by extracting protein from spine discs using T-PER Tissue Protein Extraction 
Reagent with proteinase inhibitor cocktail as per the manufacturer’s instructions (Cat.  No  
78510, ThermoFisher) and running a western blot using the p53 (Cat.No. 2524, CST) and β-actin 
(Cat.No. PA1-183, ThermoFisher) primary antibody and anti-rabbit-HRP secondary antibody 





Mouse lumbar intervertebral disc tissue were isolated from spines and fixed overnight at 4° C in 
2% paraformaldehyde. For immunofluorescent staining, the tissues were cryoprotected  with 
30% sucrose in PBS overnight at 4° C, then embedded  in  OCT  (Tissue-Tek).  Serial  axial 
plane cryosections were cut at thicknesses of 5 µm. The tissue sections were rehydrated in PBS, 
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permeabilized and blocked with 0.25% Triton X-100, 10% goat serum and 1% BSA in PBS for 
 
30 min at room temperature. Incubation with primary antibodies (anti-Aggrecan, Cat.No. 
abB1031,   Abcam;   anti-MMP13, Cat.No.   ab39012, Abcam;   anti-IL-6, Cat.No.   PAI-   
26811, ThermoFisher) were carried out overnight at 4° C following blocking. The sections were 
then incubated with secondary antibodies (Cy3-conjugate Goat anti-rabbit IgG, Jackson 
laboratory)   for   60   min    at room    temperature, according    to the manufacturer’s   
protocols. Immunostained sections were imaged and analyzed using a Nikon instrument A1 
confocal laser microscope and NIS-elements microscopy imaging software. 
 
4.2.6 mRNA ANALYSIS 
 
 
Total RNA was isolated using TRIzol™ Reagent as per the manufacturer’s instructions (Cat. No. 
15596026, ThermoFisher). Real-time quantitative RT-PCR was run using iTaq™ Universal 
SYBR® Green One-Step Kit (Cat. No. 1725151, BIORAD) and Bio-Rad iCyclyer IQ5 detection 
system. Target gene expression was calculated by the comparative CT method (ΔΔ CT) and 
normalized to the GAPDH mRNA level. PCR primers used in the study are as follows: Cdkn2a 
(p16) forward: AATCTCCGCGAGGAAAGC; Cdkn2a (p16) reverse: 
GTCTGCAGCGGACTCCAT; MMP13 forward: TCCCTGCCCCTTCCCTATGGT; MMP13 
reverse: CTCGGAGCCTGTCAACTGTGGA; GAPDH forward: GAGGCCGGTGCTGAGTAT; 
GAPDH reverse: GCGGAGATGATGACCCTTTTGG; Aggrecan forward: 
GCGAAGCAGTACACATCATAGG; Aggrecan reverse: ATACCCCATCCACACGCCCCG. 
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4.2.7 STATISTICAL ANALYSIS 
 
 
Shapiro-Wilk test was used to test for normality. Student independent T-test was used to analyze 
data found to be normal. For two variable non-parametric data, the Mann-Whitney test  was 
used. Analysis of variance (ANOVA) with Bonferroni correction for multiple comparison was 
used in cases of data with  multi-variables.  Statistics  were  derived  using GraphPad Prism  
from GraphPad Software (San Diego, CA). All graphs show mean values with error bars (SD or 








4.3.1 INCREASED CELLULAR SENESCENCE IN DISCS OF NATURALLY AGING 
MICE 
 
Evidence of increased disc cellular senescence with age in humans, rats and in an accelerated 
aging mouse model was previously reported. However, it was not known whether cellular 
senescence       also       occurs       in the       discs        of naturally aged        mice.        Hence, 
we assessed senescence markers in the discs of naturally aging mice. We determined the 
expression levels of p53, p21 and p16Ink4a, which are known to regulate cell cycle and senescence 
in response to stress, in discs of young (6 months) and old (22 months) C57BL/6 mice by 
Western blotting and real time quantitative RT-PCR. Discs from older mice expressed 
significantly higher levels of p53 (3x) and p21 (1.5x) protein and p16Ink4a mRNA (1.5x) 
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compared to discs from younger mice (Fig. 11 A.1-.3). As expected, ADAMTS- and MMP- 
mediated fragmentation of aggrecan in older mouse disc were 10x higher in discs from older, 
compared to younger, mice (Fig 11B). In contrast, PG synthesis capacity, assessed by 35S-sulfate 
incorporation, was lower in discs from older, compared to younger, mice (Fig. 11C). These in 
vivo correlations between disc cellular senescence and perturbed matrix homeostasis are 
consistent with our recent cell culture study demonstrating a matrix imbalance phenotype of 
senescent disc cells. 
 
Figure 11. Degenerative changes in intervertebral discs of naturally aging mice 
Expression   of   selected    senescent    markers,    p53    (A.1),    p21    (A.2)    and    p16IINK4a (A.3)    in disc    
tissue from young (6 mo) and old (22 mo) mice determined by Western blotting and qRT-PCR. Graphs on the right 
are quantification of results. Graphs of A.1 and A.2 indicate volume of respective protein band divided by volume of 
β-actin band. B) A schematic of the mouse aggrecan core protein covalently linked to the sulfate-rich 
glycosaminoglycan (GAG) and non-covalently bound to a hyaluronic acid (HA) chain via the link protein. The 
cleavage sites of ADAMTS (G1-NVTEGE392) and MMP (G1VDIPEN360) proteases between G1 and G2 
interglobular domains are indicated. C) Western blot analysis of aggrecan fragments generated by ADAMTS and 
MMP proteases. Graphs below are quantification of the results. D) Proteoglycan synthesis as measured by 35S- 
sulfate incorporation using whole disc organ cultures. Data are means ± SD of 4 independent experiments; * p < 
0.05. Y=young and O= Old. 
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4.3.2 CLEARANCE OF DISC SENESCENT CELLS USING P16- 3MR TRANSGENIC 
MICE 
 
To test the concept of a causative role for cellular senescence in driving age-related IDD, we 
used p16-3MR transgenic  mice (Fig.  12A).  These mice  contain a  transgene  in  which a  
fusion protein consisting of renilla luciferase (LUC), monomeric red fluorescent protein (mRFP) 
and herpes simplex virus 1 thymidine kinase (HSV-TK) is driven by the senescent sensitive 
p16INK4a promoter. p16 INK4a-positive senescent cells in p16-3MR mice can be selectively killed 
by ganciclovir (GCV), a nucleoside analog with a high affinity for HSV-TK that is converted 
into    a     toxic     DNA     chain     terminator, causing fragmentation     of     mitochondrial 
DNA and apoptosis selectively in HSV-TK expressing senescent cells [135], [136], [138]. In our 
study, expression of RFP in old mice treated with GCV was three times lower compared to old 
mice treated with PBS, suggesting that GCV reduced p16INK4a-positive senescent disc cells in  
the old GCV-treated group. Notably, disc RFP expression was higher in old mice treated with 
PBS than young mice, confirming the increased disc senescence observed in aged WT mice (Fig. 
12B). It is important to note that ganciclovir treatment eliminates p16INK4a-positive cells in all 






Figure 12. Clearance of senescent cells in p16-3MR mice 
A) Schematic of the p16-3MR transgene and strategy used to selectively kill senescent cells. The  transgene  
contains functional domains of renilla luciferase (renLuc), monomeric red fluorescent protein (mRFP), and herpes 
simplex  virus  (HSV-1)   thymidine   kinase   (HSV-TK)   under   control of   the senescence sensitive   promoter   
of the p16Ink4a gene. p16INK4a- positive cells are selectively killed  by  ganciclovir  (GCV),  a  nucleoside  analog,  
that upon phosphorylation by HSV-TK, can terminate DNA chain elongation and kill cells. p16-3MR mice were 
sacrificed at 12 months of age (Young) or were administered PBS (Old-Veh) or GCV (Old-GCV) for an additional 
12 months before sacrifice. B) Confirmation of elimination of p16INK4a-positive cells in Old-GCV mice  was 
assessed by examining levels of disc RFP protein. Graph on  the  right  is  quantification  of  the  results.  Data 
shown are means ± SEM of 4 independent experiments, * p < 0.05. 
 
 
4.3.3 ELIMINATION OF SENESCENT CELLS BY GCV TREATMENT 
SUPPRESSES DEGRADATIVE HISTOLOGICAL CHANGES AND AGE-RELATED 
DISC MATRIX PG LOSS 
 
Histologic evaluation revealed fissures in nucleus pulposus, loss of AF-NP boundary, and 
disorganization of AF lamellae with age, but these declines were blunted in older p16-3MR mice 
treated with GCV (Fig. 13). These histological changes were supported by the increase in 
aggrecan content as demonstrated in Fig 15. The GCV treated old mice had 37% of the aggrecan 
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content of younger mice, whereas vehicle treated mice only had 10% of the aggrecan content of 
young (Fig. 15B). Aggrecan gene expression upon GCV treatment was significantly improved  
as well (Fig. 15A). 
 
 
Figure 13. Impact of GCV treatment on gross morphology 
H&E staining to assess the gross morphological changes revealed the discs of old p16-3MR mice treated with PBS 
to contain fissures (orange arrow) in NP, loss of NP and AF boundary (black arrow), and transition to non- 
concentric serpentine lamellae with each lamella spaced farther apart (black arrow heads) compared to young AF 
lamellae. These degradative changes seem blunted in the old p16-3MR mice treated with GCV. Discs sections from 
5 individual p16-3MR Young, Old-Veh, and Old-GCV were compared. 
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4.3.4 CLEARANCE OF CELLULAR SENESCENCE BLUNTED DISC MATRIX PG 
PROTEOLYTIC DESTRUCTION 
 
Disc matrix  PG  loss  is  largely due  to  destruction  of  aggrecan,  the  major  PG  constituent  
of the disc matrix. Disc aggrecan fragmentation catalyzed by MMP and ADAMTS classes of 
proteases was suppressed in old GCV-treated mice compared to old vehicle-treated mice. In  
fact, MMP mediated fragmentation in Old-GCV mice was comparable to that of young and was 
six times lower than in Old-Veh mice. In contrast, the decrease in ADAMTS mediated 
fragmentation of aggrecan in Old-GCV mice is less dramatic compared to Old-Veh mice (Fig. 
14). Indeed, one of the  major  MMPs implicated  in  IDD  is  MMP13 [48].  MMP13  
expression, at both the protein and mRNA level, were blocked by GCV treatment  (Fig.  
15C&D). Surprisingly, a major disc aggrecanase, ADAMTS4, was not altered by GCV  
treatment (data not shown). Reduced aggrecan  fragmentation  was  also  seen  in  p16-3MR  
mice treated with GCV for 6 months to clear senescent cells late in life (Fig 20). However, the 
effects were not as pronounced, suggesting that prolong senescence clearance is needed to 
produce beneficial effects. 
 
 
Figure 14. Effects of GCV treatment on disc aggrecanolysis of p16-3MR mice 
A) Immunoblot of MMP and ADAMTS mediated cleavage of aggrecan. Graphs on right are quantification of 




Figure 15. Effects of GCV treatment on aggrecan and MMP13 mRNA and protein levels in intervertebral 
discs of p16-3MR mice 
Aggrecan mRNA levels   were   quantified by qRT-PCR   (A)   and   protein was   quantified by 
immunofluorescence signals (B) in nucleus pulposus and annulus fibrosus section of disc tissue. MMP-13 
expression of whole disc mRNA by qRT-PCR (C) and protein by immunofluorescence (D) in inner nucleus 
pulposus and outer annulus fibrosus section of disc tissue. Graphs on the right are quantification of the 
immunofluorescence results. Data shown is mean ± SEM of 4 independent experiments, * p < 0.05, *** p < 








Cellular senescence and the SASP negatively impact tissue health and contribute to a myriad of 
age-associated disorders. Previous studies documented elevated cellular senescence in 
degenerative discs and a positive correlation between disc cellular senescence level and 
chronological age in humans [158], [160]. It was not clear, however, whether cellular  
senescence was a driver or bystander in disc aging and degeneration in these reports. 
Since aging is the major contributor to disc degeneration, we hypothesized that cellular 
senescence is causal in age-related disc degeneration. We found elevated levels of senescence 
markers, together with repressed PG synthesis and increased aggrecan fragmentation, in 
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intervertebral discs of aged mice. Notably, the selective removal of senescent cells ameliorated 
these degenerative changes in conjunction with suppression of matrix protease expression. These 
findings suggest that the removal of senescent cells attenuated the age-associated disc 
degenerative changes. This is the first study to evaluate and report a direct adverse impact of 
cellular senescence on intervertebral disc with age. 
The increased fragmentation and loss of proteoglycan, specifically aggrecan, are 
hallmarks of disc degeneration. Matrix degradative changes invariably lead to altered 
biomechanics and pathologic outcomes such as disabling chronic back pain and stenosis. 
Multiple reports show that inflammatory cytokines such as IL-1β, IL-6, and TNFα initiate the 
cascade that culminates in disc degeneration. These cytokines suppress the synthesis of matrix 
proteins and upregulate production of matrix proteases that include ADAMTS-4/5, MMP-1, -2, - 
3,-13, -14 [151]. Indeed, in this study, we saw a concomitant reduction in levels of the major  
disc  protease,  MMP13,  and  aggrecan   fragmentation   in   Old-GCV compared   to   Old-   
Veh mice, suggesting cellular senescence phenotype as the source of the inflammatory proteins 
that trigger the degeneration cascade. This claim is substantiated by the report published by Ngo 
et. al., which showed decreased PG synthesis capacity, enhanced aggrecan fragmentation, as well 
as increased production of several cytokines and matrix proteases in oxidative stress-induced 
senescent human NP cells [76]. Together, these studies support the causal role for senescent  
cells in driving matrix homeostatic imbalance in aging discs. 
Compared to young p16-3MR mice, both MMP- and ADAMTS- mediated proteolysis of 
aggrecan was elevated in aged p16-3MR mice. However, only MMP-, not  ADAMTS-,  
mediated aggrecanolysis was reduced in discs of GCV-treated old p16-3MR mice. This result is 
consistent with the effects of GCV on expression of the two predominant matrix proteases in disc 
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tissue, MMP13 and ADAMTS4. MMP13 expression was reduced, while ADAMTS4 remained 
unaffected. This failure could  be due  to  the   fact   that ADAMTS4   is  not   a   SASP   factor 
of p16INK4a-positive disc cells and hence are not reduced by GCV administration. Overall, the 
reduced aggrecan fragmentation seen in GCV treated old p16-3MR mice could be due to 
elimination of p16INK4a positive disc cells that express MMPs, and increased PG synthesis. 
To reduce the levels of other  catabolic factors that are not  decreased  upon elimination 
of p16INK4a-positive senescent    cells, it will    be important    to     identify p16INK4a-  
independent stressor(s) that induce senescence in the disc. Studies published to date suggest that 
oxidative stress, genotoxic stress and chronic activation of NF-κB signaling play an important 
role in propagating age-related disc degenerative changes [77], [156], [198]. For example, 
lowering oxidative stress can increase PG content [77]. Likewise, inhibition of classical NF-kB 
signaling ameliorated several disc aging  features, including  PG   content   and   cellularity 
[198]. However, much like this study,  these studies  relied on  models  wherein  the  stressor  
had systemic effects, so it is unclear whether these effects occur if the stress is induced only 
locally in the intervertebral disc tissue. Further investigation is needed to resolve the ambiguity 
about the relative contributions of systemic versus local factors to age-associated disc 
degeneration. 
The observed improvement in disc pathology in p16-3MR mice treated with GCV are 
consistent with previous results using treatment of aged mice intermittently with senolytic 
agents. For example, the senolytic combination of dasatinib and quercetin was shown to not only 
reduce senescence and improve multiple age-related pathologies, but also to improve PG content 
in the disc of progerioid Ercc1-/∆ mice [140]. Similarly, treatment of Ercc1-/∆ mice with the 
senolytic HSP90 inhibitor 17-DMAG resulted in not only an extension of healthspan, but also 
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improved PG content [199]. Furthermore, intra-articular injection of the senolytic drug 
Navitoclax, a Bcl-2 family inhibitor, was recently shown to slow the progression of age- 
associated and post-traumatic osteoarthritis in aged mice [142]. However, the effect of these 
senolytics on disc pathology in natural aged mice is unknown. 
The results of this study unambiguously demonstrate the deleterious impact of senescent 
cells on intervertebral disc degeneration with natural aging. Notably, we found that p16INK4a- 
positive senescent cells promote the production of catabolic factors that are known to contribute 
to age-associated disc degeneration. As such our findings indicate that therapeutic approaches 
involving repopulation with functional IVD cells, growth factor supplementation or gene therapy 
may face challenges unless the inflammatory milieu created by senescent cells is eliminated from 
the degenerative disc [81], [200], [201]. In addition, these results suggest that a therapeutic 
strategy utilizing senotherapeutic agents such as D+Q, 17-DMAG or Navitoclax could be 















Age-related changes in the intervertebral disc tissue predominantly contribute to low back pain, a 
pathology that imposes substantial societal and economic burden [8], [192]. The persistent 
oxidative burden and the ensuing inflammatory stress and matrix degradation are characteristic 
features of aged discs [55], [73]. Evidence in recent years implicate chronic oxidative and 
inflammatory burden as the stressors in the disc tissue that induce senescent phenotype in disc 
cells with age [64], [74], [76]. Growing evidence also implicate that the senescent disc cells are 
key players in propagating the progressive deterioration of disc health with age by robbing the 
disc of functional cells and exacerbating the degradation of disc tissue via secretion of SASP 
factors [158], [160]. However, it is not known whether senescent cells play a causal role in 
driving age-associated IDD despite their presence in aged disc tissue. Likewise, though in vitro 
reports have documented increased secretion of catabolic factors and enhanced fragmentation of 
matrix aggrecan, none have assessed the underlying metabolic changes that energetically support 
the enhanced secretion of proteins in the senescent disc cells. Therefore, for this dissertation 
work, we assessed the metabolic changes in senescent disc cells and determined whether they are 
causal in driving age-related degradative changes in disc tissue. 
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In Chapter 3, we described the extent of utilization of the two major energy generating 
pathways- glycolysis and OXPHOS- and the accompanying changes in oxidative stress-induced 
senescent (SIS) and non-senescent disc cells. In addition to displaying increased fragmentation  
of aggrecan and collagen II and secretion of inflammatory factors IL-6 & 8, the SIS disc cells 
had enhanced mitochondrial content and mitochondrial ATP-linked respiration. This metabolic 
alteration, i.e., increased mitochondrial respiration associated with ATP production was found to 
be needed for increased protein synthesis as abrogation of protein synthesis dampened the 
mitochondrial ATP-linked respiration in SIS disc cells but not in non-senescent disc cell control. 
This is consistent with other reports which show that in senescence induced by various stressors, 
lower synthesis of fatty acids and higher mitochondrial ATP production are metabolic 
adaptations these cells need to sustain their persistent and elevated production of proteins, 
including SASP factors [116], [117], [175]. The reliance on mitochondrial ATP was unexpected 
as the disc cells are known to rely on glycolysis for generation of ATP [18]. Therefore, these 
results suggest that the disc cells can be metabolically flexible and adapt to support the demands 
elicited by change in phenotype. Interestingly, the increased mitochondrial ATP related 
respiration in SIS disc cells was accompanied by increased mitochondrial number and protein 
expression (TOM20 and ATP synthase beta) but not mtDNA copy number. Equally interesting 
was the fact that the mtDNA did not colocalize with the mitochondria and was mostly 
cytoplasmic. The presence of cytoplasmic DNA activates the cGas-STING pathway, which was 
shown to mediate secretion of SASP factors in cells induced to senesce by various means [183]– 
[185]. Therefore, it is reasonable to conjecture that the cytoplasmic mtDNA in SIS disc cells play 
a role in regulating SASP factor synthesis as well. However, this remains to be verified. 
Furthermore, it cannot be discounted that the increased mitochondrial ATP -linked respiration is 
73  
to generate ATP for processes other than protein synthesis. Indeed, in chemotherapy-induced 
senescent cells, part of the increased mitochondrial ATP-associated respiration was needed for 
autophagic degradation of improperly synthesized proteins [116]. It was reasoned that the 
elevated secretion of proteins by senescent cells overwhelms their capacity for proper protein 
synthesis, and thus, autophagy is upregulated to cope with this proteotoxic stress. However, 
because protein synthesis is the most ATP-consuming process in cells [189], it is likely that most 
of the respiration associated with mitochondrial ATP production is utilized to produce proteins in 
SIS disc cells. In summary, these results suggest that the SIS disc cells acquire a catabolic 
phenotype and metabolic adaptation to support protein synthesis. 
We reasoned that removal of senescent disc cells should attenuate the deterioration of 
disc associated with ageing. This is based on the observations that in vitro generated oxidative 
stress-induced senescent disc cells display the catabolic phenotype similar to that found in vivo 
which is a driver of age-related IDD. In Chapter 4, we described the age-related disc 
degenerative markers in the natural ageing p16-3MR mice and the changes in these markers 
upon selective clearance of p16INK4a positive senescent cells. We found elevated levels of 
p16INK4a positive senescent cells in the discs of old p16-3MR treated with vehicle compared to 
the young p16-3MR mice. The old p16-3MR mice administered with vehicle had all the 
histological markers associated with disc ageing, including clefts and fissures in the NP and AF 
and loss of AF lamellae structure (non-concentric). These histological changes appeared 
attenuated in the old p16-3MR mice treated with GCV to selectively remove p16INK4a positive 
senescent cells. In addition, substantial loss in aggrecan content, a major hallmark of disc 
degeneration, associated with ageing in disc was attenuated upon treatment with GCV. Since 
aggrecan loss could be due to increased fragmentation and diffusion through clefts/fissures, we 
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assessed the proteolytic degradation of aggrecan. Whereas the aggrecan fragmentation in p16- 
3MR old mice treated with vehicle was significantly elevated compared to young mice, the 
proteolytic cleavage of aggrecan in p16-3MR old-mice treated with GCV was significantly 
reduced and was comparable to that of the young mice. However, only MMP-, and not 
ADAMTS- mediated proteolytic cleavage was reduced in discs of GCV-treated old p16-3MR 
mice. This result was consistent with the impact of GCV on the expression of the two major 
protease in disc tissue, MMP13 and ADAMTS4. While the expression of MMP13 was reduced, 
the ADAMTS4 levels remain unaltered. This result was unexpected and could be due to the 
ability of GCV to eliminate p16INK4a senescent cells that secrete MMP13, and not, senescent cells 
that secrete ADAMTS4 as part of their SASP. However, this remains to be verified. As 
mentioned earlier, the disc tissue likely contains a mosaic of distinct senescent cell types. 
Therefore, as this study highlights, it is important in future studies to identify disc senescent cell 
types that contain other proteases such as ADAMTS4 and other pro-inflammatory cytokines as 
part of their SASP repertoire. Overall, the reduced fragmentation and increased content of disc 
aggrecan and the improvement in histological features could  be  due  to  elimination  of  
p16INK4a positive disc cells that express MMPs, and probably other SASP factors, and increased 
PG synthesis. In summary, this study demonstrates the causal role of senescent cells in age- 
related disc degeneration. 
Collectively, the studies described in Chapter 3 and 4, provide solid evidence for 
considering senescent disc cells as therapeutic targets to ameliorate age-related disc 
degeneration. The studies described herein are the first to evaluate the underlying metabolic 
changes in senescent disc cells and demonstrate their causative role in promoting age-related 
IDD. As such, the current senolytics which have been investigated in context of osteoarthritis, 
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atherosclerosis, and stem cell rejuvenation, should be evaluated in context of age-related disc 
degeneration as well. Senolytics provide a promising alternative to current disc degeneration 
treatments such as gene-, protein-, and stem cell- based therapies, which are invasive, expensive, 







The experimentation performed in this work has a number of noteworthy limitations. First, in the 
in vitro model, the disc cells were cultured in Ham’s F-12 media supplemented with 10% FBS, 
which is a standard practice in the field. However, this is does not completely mimic 
physiological condition as the glucose concentration (10 mM) [202] is much higher and 
osmolarity (~300 mOsm/ kg H2O) [203] much lower in the Ham’s F-12 media/10% FBS culture 
media compared to what disc cells experience in vivo (<<5mM glucose and 500 mOsm/ kg H2O) 
[204], [205]. Additionally, the mechanical stress that the disc cells experience in vivo was also 
absent, possibly resulting in cellular responses that would not be present in vivo. This limitation 
could be overcome by applying the appropriate mechanical load, e.g. using the Flexcell system, 
and culture media that approximates the physiologic osmolarity and nutrient concentration. 
While this dissertation work was well under way, media ideal for culture of disc cells, called 
PrimeGrowthTM, was made commercially available [206]. Therefore, incorporation of 
mechanical load and culture in PrimeGrowthTM media in the engineered in vitro culture model 
would be optimal. Second, the oxidative stress-induced senescent disc cells with the described 
phenotype may not recapitulate the features of the senescent disc cells that exists in vivo. This 
limitation could certainly be resolved by isolating the native p16INK4a positive cells from the 
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discs of p16-3MR mice and comparing their phenotypes to senescent disc cells generated in 
vitro. Lastly, the ability of proteins to upregulate mitochondrial respiration in senescent disc cells 
in vitro was assessed by performing Seahorse assay in presence of cycloheximide, which is a 
non-specific protein synthesis inhibitor. It would be interesting to assess whether the SASP  
factor synthesis in senescent disc cells is dependent on the upregulated mitochondrial respiration. 
This limitation could be addressed by blocking the mitochondrial respiration by antimycin 
A/rotenone and then assessing the expression of SASP factors. 
The in vivo study involving the p16-3MR mice has several limitations as well. As in the 
case of every biological study, the outcomes in the in vivo study represent only a small portion of 
the broad gamut of potential biological markers. Proof of absence of cellular senescence by 
assessment of additional senescence markers which are known to be expressed in p16INK4a 
senescent cells, such as loss of HMGB1 [105], DNA damage markers, and cytoplasmic 
localization of lamin B1 [207], in discs of p16-3MR mice would further strengthen the claim of 
amelioration of disc degenerative changes with elimination of senescent cells. Additionally, 
evaluation of other SASP factors such as IL-1β, TNFα, IL-8 was also warranted as these factors 
are known to play key role in propagating disc degeneration and back pain. Additionally, scoring 
of the degenerative changes in the NP, AF, and EP in the H&E images would have been useful in 
understanding the impact of senescence on the whole disc, and not just aggrecan. Other 
limitations are more difficult to overcome without significant development. The clearance of 
p16INK4a positive cells in the old p16-3MR mice is systemic, and therefore, the ensuing effects 
cannot just be attributed to elimination of p16INK4a positive cells in the disc. Overcoming this 
limitation would require creation of mice model that would enable clearance of disc-specific 
p16INK4a positive cells. To target genes specifically in the disc, transgenic mice which contain 
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expression of candidate genes under the control of the promoter aggrecan or type II collagen 
have been created [208]. However, though the aggrecan and collagen II are abundantly expressed 
in disc, they are also expressed in other cartilage tissue. Therefore, limitations exist with the 




5.3 FUTURE DIRECTIONS 
 
 
Immediate extensions of this work include investigation of the mechanism that regulates the 
secretion of SASP factors. The classical NF-κB signaling pathway is upregulated with ageing in 
disc tissue and is known to control expression of multiple different catabolic factors that are 
involved in promoting matrix degradation of disc tissue [209]. Importantly, genetic and 
pharmacological inhibition of canonical NF-κB signaling is found to ameliorate age-related disc 
degenerative changes [198]. Equally important is the fact that the oxidative stress-induced 
senescent disc cells contain cytoplasmic mtDNA which could activate cGAS-STING pathway, 
which in turn could activate the classical NF-κB signaling pathway [183]. Therefore, it would be 
logical to assess whether p65 subunit of NF-κB controls the expression of senescent disc cell 
SASP. It also would be interesting to assess the capability of the in vitro generated oxidative 
stress-induced senescent disc cells to impact the disc tissue in vivo. This could be achieved by 
injecting the senescent disc cells into the discs of rat and evaluating the outcomes such as disc 
height, proteoglycan content and fragmentation, and biomechanical function few weeks post the 
administration of the senescent cells. Rats injected with vehicle (PBS) and proliferating disc cells 
would be used as control. Another potential path from the in vitro work would be to evaluate the 
capability of these in vitro engineered senescent disc cells to induce senescence in proliferating 
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disc cells. One of the ways cellular senescence promotes loss of tissue health and function with 
age is by induction of senescence in neighboring cells. Hence, it would be instructive in 
determining if the SASP secreted by senescent disc cells is capable of inducing senescence in 
proliferating disc cells. 
Over the past few years research has uncovered multiple different compounds which 
specifically target and kill senescent cells and show improvement in healthspan when 
administered to mice in vivo. Treatment with a combination of dasatinib and quercitin resulted in 
improvement in healthspan and reduction in PG loss in the  disc  of progeroid Ercc1-/∆ mice 
[140]. Likewise, treatment with another senolytic HSP90 inhibitor 17-DMAG also resulted in 
improved PG content along with improvement in healthspan [199]. However, few of these agents 
have been tested to improve disc pathology in natural aging mice. Therefore, future work should 
focus on evaluating the senolytic compounds with proven efficacy to attenuate age-related 
changes in disc tissue. Furthermore, compounds which have shown to extend lifespan in mice by 
the National Institute on Aging Interventions Testing Program (NIA-ITP), such as rapamycin, 
acarbose, 17α-estradiol and nordihydroguaiaretic acid (NDGA) [146], [210], should be evaluated 
for their ability to improve disc pathology by eliminating or suppressing senescent cells and their 
SASP. The in vitro studies done so far do suggest that compounds such as rapamycin might  
serve to suppress SASP in disc senescent cells [211]. Metformin is another drug which will be 
tested in a clinical trial for its ability to delay onset of multiple age-related pathologies by the 
NIA-ITP (National Clinical Trial number: NCT02432287) [212]. Metformin is a FDA approved 
drug for the treatment of diabetes. It inhibits complex I of ETC and can therefore suppress 
production of mitochondrially derived reactive oxygen species (ROS), a major contributor to  
disc degeneration [213]. Tert-butyl hydroxide-induced senescence in NP cells was suppressed 
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when treated with metformin [75]. More importantly, metformin treatment was able to 
ameliorate IDD in a puncture-induced rat model [75]. Examining the impact of metformin in  
vivo on the age-related inflammatory and catabolic events promoted by senescence and other 
factors holds much promise. The other compounds to consider as well include curcumin [84], 
[214], an active ingredient of turmeric, and resveratrol [215], a sirtuin agonist, neither of which 
extend the lifespan of mice but do show amelioration of disc degenerative changes in mice. The 
in vitro oxidative stress-induced senescence model developed in this dissertation work can be 
used as a screen to test the efficacy of the potential senolytic agents before commencing in vivo 
work. 
Considering the fact that the population in Unites States and elsewhere is ageing rapidly, 
research work that develop therapeutics to compress the functional decline in old age is 
imperative as a greater percent of people over the age of 65 years have more than one chronic 
disease pathology [216]. Cellular senescence has been implicated in driving multiple age- 
associated pathologies, and therefore therapeutic approaches that specifically kill senescent cells 
hold potential to extend the healthspan and lifespan. Since IDD is an age-related pathology, it is 
important to address whether cellular senescence adversely impact disc tissue health with ageing. 

























A.1.1 TRANSMISSION ELECTRON MICROSCOPY (TEM) IMAGING 
 
 
SIS and non-SIS disc cells were fixed in cold 2.5% glutaraldehyde in 0.01 M PBS for 1 hour at 
room temperature. The specimens were rinsed in PBS, treated with 1% osmium tetroxide/1% 
potassium ferricyanide, rinsed in PBS, dehydrated through a graded series of ethanol and 
propylene oxide and then embedded in Poly/Bed® 812 (Luft formulations). Semi-thin (300 nm) 
sections were cut on a Leica Reichart Ultracut, stained with 0.5% Toluidine Blue in 1% sodium 
borate and examined under the light microscope. Ultrathin sections (65 nm) were stained with 
uranyl acetate and Reynold’s lead citrate and examined on JEOL 1011 transmission electron 
microscope with a side mount AMT 2k digital camera (Advanced Microscopy Techniques, 
Danvers, MA). 
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A.1.2 PROTEIN SYNTHESIS 
 
 
Disc cells were cultured for 24 hours in F-12 media containing 10% FBS and 1% PS in a 6-well 
plate in the presence of 10 µCi/ml 3H-L-proline at 37°C. The cells were either supplemented with 
2.5, 5, 10 μg/ml cycloheximide (CHX) or left untreated (0 μg/ml CHX) at the start of the assay. 
The conditioned media (CM) was collected and the cell samples suspended in homogenizing 
buffer (20 mM Tris-HCl, 200 mM NaCl, 100 mM glycine, 0.1% Triton×100, 50 µM DTT, 0.1 
mg/ml soybean trypsin inhibitor) and subjected to three freeze/thaw cycles at the end of the 24hr 
incubation period. The samples were then stirred at 4°C for overnight, the CM and cell layer 
combined, and protein synthesis determined by 3H-proline incorporation using a previously 
established method [217]. 
 
A.1.3 CELL VIABILITY 
 
 
The quantity of disc cells in presence of 0, 2.5, 5, 10 μg/ml cycloheximide (CHX) was 
determined using Picogreen assay kit (Cat. No. P7589, ThermoFisher Scientific) as before [217]. 
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Figure 16. (in support of Fig 6). Representative profiles of SIS and non-SIS glycolytic and oxidative activity 
by Seahorse assay 
80x 103 SIS and non-SIS disc cells were plated in Seahorse XF96 Extracellular Flux Analyzer plate. A) The 
Seahorse Analyzer records rates of oxidative phosphorylation via the oxygen consumption rate (OCR) in each well. 
Basal OCR is calculated from the mean time points of 1-3. ATP-linked OCR is calculated by taking the basal OCR 
and subtracting the mean of time points 4 and 5. Proton leak is calculated from taking the taking the mean of 
oligomycin sensitive OCR and subtracting it from the mean time points of 10 and 11. B) Glycolytic activity is 
assessed by recording the extracellular acidification rate (ECAR). Basal ECAR is calculated from the mean of time 
points 1-3. Metabolic inhibitors, oligomycin, carbonyl cyanide 4- (trifluoromethoxy) phenylhydrazone (FCCP), 2- 
deoxyglucose (2DG), and rotenone and antimycin A were added sequentially to distinguish cellular reliance upon 
glycolysis and oxidative phosphorylation. The plots are illustrative of seahorse trace of a single experiment. Each 




Figure 17. Electron microscopic imaging of mitochondria in SIS and non-SIS cells 
The mitochondria in SIS and non-SIS disc cells as assessed by TEM imaging revealed similarity in terms of 









Figure 18. Determination of cytotoxicity and protein synthesis in disc cells treated with CHX 
A) Viability of disc cells treated with either 0, 2.5, 5, 10 μg/ml CHX for 24h was assessed by picogreen fluorescence 
assay. B) Protein synthesis as measured by incorporation of [3H] Proline in disc cells after 24h incubation with 




Figure 19. (in support of Fig 10). Representative Seahorse profiles of oxidative activity of SIS and non-SIS 
disc cells treated with and without protein synthesis inhibitor 
Seahorse trace illustrating basal OCR and OCR after addition of sequential metabolic inhibitors (indicated) of SIS 
and non-SIS disc cells treated with cycloheximide or left untreated. Graph is illustrative of a single seahorse 




























Figure 20. Late life clearance of p16-positive senescent cells in p16-3MR mice 
p16-3MR mice were sacrificed at 12 months of age or treated with either PBS or 25mg/kg of GCV for 5 days every 
two weeks beginning 20 months of age for 6 months. The PBS and GCV treated p16-3MR mice were then  
sacrificed at the end of treatment and the spines and tails isolated for further analysis. A) Immunoblot of MMP and 
ADAMTS mediated aggrecan fragments. Graphs on right are quantification of results in left panel. Data shown is 












[1] P. J. Roughley, “Biology of intervertebral disc aging and degeneration: involvement of 
the extracellular matrix.,” Spine (Phila. Pa. 1976)., vol. 29, no. 23, pp. 2691–9, Dec. 
2004. 
 
[2] M. A. Adams and P. J. Roughley, “What is intervertebral disc degeneration, and what 
causes it?,” Spine (Phila. Pa. 1976)., vol. 31, no. 18, pp. 2151–61, Aug. 2006. 
 
[3] Kevin Ngo, “CHARACTERIZATION OF SENESCENT INTERVERTEBRAL DISC 
CELLS AND THEIR ROLE IN PERTURBATION OF MATRIX HOMEOSTASIS 
Master’s Thesis, University of Pittsburgh.,” 2015. 
 
[4] A. J. Roughley P. J,Alini M, “The role of proteoglycans in aging, degeneration and repair 
of the intervertebral disc,” Biochem. Soc. Trans., vol. 30, no. Pt 6, pp. 869–74, Apr. 2002. 
 
[5] N. V Vo, R. A. Hartman, P. R. Patil, M. V Risbud, D. Kletsas, J. C. Iatridis, J. A. 
Hoyland, C. L. Le Maitre, G. A. Sowa, and J. D. Kang, “Molecular mechanisms of 
biological aging in intervertebral discs.,” J. Orthop. Res., Feb. 2016. 
 
[6] P. J. Roughley and J. S. Mort, “The role of aggrecan in normal and osteoarthritic 
cartilage,” J. Exp. Orthop., vol. 1, no. 1, p. 8, Dec. 2014. 
 
[7] S. S. Sivan, E. Wachtel, and P. Roughley, “Structure, function, aging and turnover of 
aggrecan in the intervertebral disc,” Biochim. Biophys. Acta - Gen. Subj., vol. 1840, no. 
10, pp. 3181–3189, Oct. 2014. 
 
[8] J. Buckwalter, “Aging and degeneration of the human intervertebral disc,” Spine (Phila 
Pa 1976), vol. 20, pp. 1307–1314, 1995. 
 
[9] J. Antoniou, T. Steffen, F. Nelson, N. Winterbottom, A. P. Hollander, R. A. Poole, M. 
Aebi, and M. Alini, “The human lumbar intervertebral disc: evidence for changes in the 
biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, 
and degeneration.,” J. Clin. Invest., vol. 98, no. 4, pp. 996–1003, Aug. 1996. 
 
[10] S. Roberts, B. Caterson, J. Menage, E. H. Evans, D. C. Jaffray, and S. M. Eisenstein, 
“Matrix metalloproteinases and aggrecanase: their role in disorders of the human 
intervertebral disc.,” Spine (Phila. Pa. 1976)., vol. 25, no. 23, pp. 3005–13, Dec. 2000. 
87  
[11] P. Goupille, M. I. Jayson, J. P. Valat, and A. J. Freemont, “Matrix metalloproteinases: the 
clue to intervertebral disc degeneration?,” Spine (Phila. Pa. 1976)., vol. 23, no. 14, pp. 
1612–26, Jul. 1998. 
 
[12] N. V Vo, R. A. Hartman, P. R. Patil, M. V Risbud, D. Kletsas, J. C. Iatridis, J. A. 
Hoyland, C. Le Maitre, G. A. Sowa, and J. D. Kang, “Molecular mechanisms of 
biological aging in intervertebral discs,” J. Orthop. Res., vol. 34, no. 8, pp. 1289–1306, 
2016. 
 
[13] J. P. G. Urban, S. Roberts, and J. R. Ralphs, “The Nucleus of the Intervertebral Disc from 
Development to Degeneration,” Integr. Comp. Biol., vol. 40, no. 1, pp. 53-061, Feb. 
2000. 
 
[14] F. Postacchini, M. Bellocci, and M. Massobrio, “Morphologic changes in annulus 
fibrosus during aging. An ultrastructural study in rats.,” Spine (Phila. Pa. 1976)., vol. 9, 
no. 6, pp. 596–603, Sep. 1984. 
 
[15] M. V Risbud and I. M. Shapiro, “Notochordal cells in the adult intervertebral disc: new 
perspective on an old question.,” Crit. Rev. Eukaryot. Gene Expr., vol. 21, no. 1, pp. 29– 
41, Jan. 2011. 
 
[16] J. P. G. Urban, S. Smith, and J. C. T. Fairbank, “Nutrition of the intervertebral disc.,” 
Spine (Phila. Pa. 1976)., vol. 29, no. 23, pp. 2700–9, Dec. 2004. 
 
[17] Y.-C. Huang, J. P. G. Urban, and K. D. K. Luk, “Intervertebral disc regeneration: do 
nutrients lead the way?,” Nat. Rev. Rheumatol., vol. 10, no. 9, pp. 561–566, Sep. 2014. 
 
[18] A. Agrawal, A. Guttapalli, S. Narayan, T. J. Albert, I. M. Shapiro, and M. V Risbud, 
“Normoxic stabilization of HIF-1alpha drives glycolytic metabolism and regulates 
aggrecan gene expression in nucleus pulposus cells of the rat intervertebral disk.,” Am. J. 
Physiol. Cell Physiol., vol. 293, no. 2, pp. C621-31, Aug. 2007. 
 
[19] A. A. Thorpe, A. L. A. Binch, L. B. Creemers, C. Sammon, and C. L. Le Maitre, 
“Nucleus pulposus phenotypic markers to determine stem cell differentiation: fact or 
fiction?,” Oncotarget, vol. 7, no. 3, pp. 2189–200, Jan. 2016. 
 
[20] M. V Risbud, E. Schipani, and I. M. Shapiro, “Hypoxic regulation of nucleus pulposus 
cell survival: from niche to notch.,” Am. J. Pathol., vol. 176, no. 4, pp. 1577–83, Apr. 
2010. 
 
[21] J. C. Gan, P. Ducheyne, E. J. Vresilovic, W. Swaim, and I. M. Shapiro, “Intervertebral 
disc tissue engineering I: characterization of the nucleus pulposus.,” Clin. Orthop. Relat. 
Res., no. 411, pp. 305–14, Jun. 2003. 
 
[22] M. Kanemoto, S. Hukuda, Y. Komiya, A. Katsuura, and J. Nishioka, 
“Immunohistochemical study of matrix metalloproteinase-3 and tissue inhibitor of 
metalloproteinase-1 human intervertebral discs.,” Spine (Phila. Pa. 1976)., vol. 21, no. 1, 
pp. 1–8, Jan. 1996. 
88  
[23] J. K. Crean, S. Roberts, D. C. Jaffray, S. M. Eisenstein, and V. C. Duance, “Matrix 
metalloproteinases in the human intervertebral disc: role in disc degeneration and 
scoliosis.,” Spine (Phila. Pa. 1976)., vol. 22, no. 24, pp. 2877–84, Dec. 1997. 
 
[24] R. Sztrolovics, M. Alini, P. J. Roughley, and J. S. Mort, “Aggrecan degradation in human 
intervertebral disc and articular cartilage.,” Biochem. J., vol. 326 ( Pt 1, pp. 235–41, Aug. 
1997. 
 
[25] A. Hollander, “Enhanced denaturation of the a1(II) chains of type-II collagen in normal 
adult human intervertebral discs compared with femoral articular cartilage,” Journal of 
Orthopaedic Research. 22-Oct-1996. 
 
[26] H. Birkedal-Hansen, “Proteolytic remodeling of extracellular matrix.,” Curr. Opin. Cell 
Biol., vol. 7, no. 5, pp. 728–35, Oct. 1995. 
 
[27] J. C. Iatridis, L. A. Setton, M. Weidenbaum, and V. C. Mow, “Alterations in the 
mechanical behavior of the human lumbar nucleus pulposus with degeneration and 
aging,” J. Orthop. Res., vol. 15, no. 2, pp. 318–322, Mar. 1997. 
 
[28] G. Lyons, S. M. Eisenstein, and M. B. Sweet, “Biochemical changes in intervertebral disc 
degeneration.,” Biochim. Biophys. Acta, vol. 673, no. 4, pp. 443–53, Apr. 1981. 
 
[29] W. Frobin, P. Brinckmann, M. Kramer, and E. Hartwig, “Height of lumbar discs 
measured from radiographs compared with degeneration and height classified from MR 
images,” Eur. Radiol., vol. 11, no. 2, pp. 263–269, Jan. 2001. 
 
[30] C. HIRSCH and F. SCHAJOWICZ, “Studies on structural changes in the lumbar annulus 
fibrosus.,” Acta Orthop. Scand., vol. 22, no. 1–4, pp. 184–231, 1952. 
 
[31] S. Roberts, H. Evans, J. Trivedi, and J. Menage, “Histology and Pathology of the Human 
Intervertebral Disc,” J. Bone Jt. Surg., vol. 88, no. suppl_2, p. 10, Apr. 2006. 
 
[32] M. Kanayama, D. Togawa, C. Takahashi, T. Terai, and T. Hashimoto, “Cross-sectional 
magnetic resonance imaging study of lumbar disc degeneration in 200 healthy 
individuals,” J. Neurosurg. Spine, vol. 11, no. 4, pp. 501–507, Oct. 2009. 
 
[33] M. C. Battié, T. Videman, J. Kaprio, L. E. Gibbons, K. Gill, H. Manninen, J. Saarela, and 
L. Peltonen, “The Twin Spine Study: contributions to a changing view of disc 
degeneration.,” Spine J., vol. 9, no. 1, pp. 47–59, Jan. . 
 
[34] M. A. Adams, B. J. Freeman, H. P. Morrison, I. W. Nelson, and P. Dolan, “Mechanical 
initiation of intervertebral disc degeneration.,” Spine (Phila. Pa. 1976)., vol. 25, no. 13, 
pp. 1625–36, Jul. 2000. 
 
[35] D. Wang, L. A. Nasto, P. Roughley, A. S. Leme, A. M. Houghton, A. Usas, G. Sowa, J. 
Lee, L. Niedernhofer, S. Shapiro, J. Kang, and N. Vo, “Spine degeneration in a murine 
model of chronic human tobacco smokers.,” Osteoarthritis Cartilage, vol. 20, no. 8, pp. 
896–905, Aug. 2012. 
89  
[36] A. Stirling, T. Worthington, M. Rafiq, P. A. Lambert, and T. S. Elliott, “Association 
between sciatica and Propionibacterium acnes,” Lancet, vol. 357, no. 9273, pp. 2024– 
2025, Jun. 2001. 
 
[37] C. L. Le Maitre, A. J. Freemont, and J. A. Hoyland, “The role of interleukin-1 in the 
pathogenesis of human intervertebral disc degeneration.,” Arthritis Res. Ther., vol. 7, no. 
4, pp. R732-45, Jan. 2005. 
 
[38] C. Le Maitre, J. Hoyland, and A. J. Freemont, “Catabolic cytokine expression in 
degenerate and herniated human intervertebral discs: IL-1β and TNFα expression 
profile,” Arthritis Res. Ther., vol. 9, no. 4, p. R77, Jan. 2007. 
 
[39] M. F. Shamji, L. A. Setton, W. Jarvis, S. So, J. Chen, L. Jing, R. Bullock, R. E. Isaacs, C. 
Brown, and W. J. Richardson, “Pro-inflammatory cytokine expression profile in 
degenerative and herniated human intervertebral disc tissues,” Arthritis Rheum., vol. 62, 
no. 7, p. NA-NA, Jul. 2010. 
 
[40] C. A. Séguin, R. M. Pilliar, P. J. Roughley, and R. A. Kandel, “Tumor necrosis factor- 
alpha modulates matrix production and catabolism in nucleus pulposus tissue.,” Spine 
(Phila. Pa. 1976)., vol. 30, no. 17, pp. 1940–8, Sep. 2005. 
 
[41] J. M. Cuéllar, P. M. Borges, V. G. Cuéllar, A. Yoo, G. J. Scuderi, and D. C. Yeomans, 
“Cytokine Expression in the Epidural Space,” Spine (Phila. Pa. 1976)., vol. 38, no. 1, pp. 
17–23, Jan. 2013. 
 
[42] C. Le Maitre, A. J. Freemont, and J. Hoyland, “The role of interleukin-1 in the 
pathogenesis of human intervertebral disc degeneration.,” Arthritis Res. Ther., vol. 7, no. 
4, p. R732, 2005. 
 
[43] J. Wang, D. Markova, D. G. Anderson, Z. Zheng, I. M. Shapiro, and M. V. Risbud, 
“TNF-α and IL-1β Promote a Disintegrin-like and Metalloprotease with Thrombospondin 
Type I Motif-5-mediated Aggrecan Degradation through Syndecan-4 in Intervertebral 
Disc,” J. Biol. Chem., vol. 286, no. 46, pp. 39738–39749, Nov. 2011. 
 
[44] Y. Tian, W. Yuan, N. Fujita, J. Wang, H. Wang, I. M. Shapiro, and M. V Risbud, 
“Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 
(ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB.,” Am. J. 
Pathol., vol. 182, no. 6, pp. 2310–21, Jun. 2013. 
 
[45] R. Studer, N. Vo, G. Sowa, C. Ondeck, and J. Kang, “Human nucleus pulposus cells react 
to IL-6: independent actions and amplification of response to IL-1 and TNF-α,” Spine 
(Phila Pa 1976), vol. 36, no. 8, pp. 593–599, 2011. 
 
[46] S. Ohtori, G. Inoue, T. Koshi, T. Ito, H. Doya, T. Saito, H. Moriya, and K. Takahashi, 
“Up-Regulation of Acid-Sensing Ion Channel 3 in Dorsal Root Ganglion Neurons 
Following Application of Nucleus Pulposus on Nerve Root in Rats,” Spine (Phila. Pa. 
1976)., vol. 31, no. 18, pp. 2048–2052, Aug. 2006. 
90  
[47] Y. Uchiyama, C.-C. Cheng, K. G. Danielson, J. Mochida, T. J. Albert, I. M. Shapiro, and 
M. V Risbud, “Expression of Acid-Sensing Ion Channel 3 (ASIC3) in Nucleus Pulposus 
Cells of the Intervertebral Disc Is Regulated by p75NTR and ERK Signaling,” J. Bone 
Miner. Res., vol. 22, no. 12, pp. 1996–2006, Aug. 2007. 
 
[48] M. V Risbud and I. M. Shapiro, “Role of cytokines in intervertebral disc degeneration: 
pain and disc content.,” Nat. Rev. Rheumatol., vol. 10, no. 1, pp. 44–56, Jan. 2014. 
 
[49] D. Chan, Y. Song, P. Sham, and K. M. C. Cheung, “Genetics of disc degeneration.,” Eur. 
Spine J., vol. 15 Suppl 3, pp. S317-25, Aug. 2006. 
 
[50] Y. Feng, B. Egan, and J. Wang, “Genetic Factors in Intervertebral Disc Degeneration.,” 
Genes Dis., vol. 3, no. 3, pp. 178–185, Sep. 2016. 
 
[51] L. I. Kauppila, “Atherosclerosis and Disc Degeneration/Low-Back Pain – A Systematic 
Review,” Eur. J. Vasc. Endovasc. Surg., vol. 37, no. 6, pp. 661–670, Jun. 2009. 
 
[52] T. Videman and M. C. Battié, “The influence of occupation on lumbar degeneration.,” 
Spine (Phila. Pa. 1976)., vol. 24, no. 11, pp. 1164–8, Jun. 1999. 
 
[53] M. C. Battié, T. Videman, K. Gill, G. B. Moneta, R. Nyman, J. Kaprio, and M. 
Koskenvuo, “1991 Volvo Award in clinical sciences. Smoking and lumbar intervertebral 
disc degeneration: an MRI study of identical twins.,” Spine (Phila. Pa. 1976)., vol. 16, 
no. 9, pp. 1015–21, Sep. 1991. 
 
[54] J. A. Miller, C. Schmatz, and A. B. Schultz, “Lumbar disc degeneration: correlation with 
age, sex, and spine level in 600 autopsy specimens.,” Spine (Phila. Pa. 1976)., vol. 13, 
no. 2, pp. 173–8, Feb. 1988. 
 
[55] N. Boos, S. Weissbach, H. Rohrbach, C. Weiler, K. F. Spratt, and A. G. Nerlich, 
“Classification of age-related changes in lumbar intervertebral discs: 2002 Volvo Award 
in basic science.,” Spine (Phila. Pa. 1976)., vol. 27, no. 23, pp. 2631–44, Dec. 2002. 
 
[56] J. G. Edelson and H. Nathan, “Stages in the natural history of the vertebral end-plates.,” 
Spine (Phila. Pa. 1976)., vol. 13, no. 1, pp. 21–6, Jan. 1988. 
 
[57] C. L. Le Maitre, A. J. Freemont, and J. A. Hoyland, “Localization of degradative 
enzymes and their inhibitors in the degenerate human intervertebral disc.,” J. Pathol., vol. 
204, no. 1, pp. 47–54, Sep. 2004. 
 
[58] A. P. Hollander, T. F. Heathfield, J. J. Liu, I. Pidoux, P. J. Roughley, J. S. Mort, and A. 
R. Poole, “Enhanced denaturation of the ?1(II) chains of type-II collagen in normal adult 
human intervertebral discs compared with femoral articular cartilage,” J. Orthop. Res., 
vol. 14, no. 1, pp. 61–66, Jan. 1996. 
 
[59] A. G. Nerlich, E. D. Schleicher, and N. Boos, “1997 Volvo Award winner in basic 
science studies. Immunohistologic markers for age-related changes of human lumbar 
intervertebral discs.,” Spine (Phila. Pa. 1976)., vol. 22, no. 24, pp. 2781–95, Dec. 1997. 
91  
[60] X. Haidong, Q. Mei, B. Xu, and L. J. Gang, “Expression of matrix metalloproteinases is 
positively related to the severity of disc degeneration and growing age in the East Asian 
lumbar disc herniation patients,” Cell Biochem. Biophys., vol. 70, pp. 1219–1225, 2014. 
 
[61] C. Q. Zhao, Y. H. Zhang, S. D. Jiang, H. Li, L. S. Jiang, and L. Y. Dai, “ADAMTS-5 and 
intervertebral disc degeneration: The results of tissue immunohistochemistry and in vitro 
cell culture,” J. Orthop. Res., vol. 29, no. 5, pp. 718–725, 2011. 
 
[62] K. Fujita, T. Ando, T. Ohba, M. Wako, N. Sato, Y. Nakamura, Y. Ohnuma, Y. Hara, R. 
Kato, A. Nakao, and H. Haro, “Age-related expression of MCP-1 and MMP-3 in mouse 
intervertebral disc in relation to TWEAK and TNF-α stimulation,” J. Orthop. Res., vol. 
30, no. 4, pp. 599–605, Apr. 2012. 
 
[63] R. Kang, H. Li, K. Rickers, S. Ringgaard, L. Xie, and C. Bünger, “Intervertebral disc 
degenerative changes after intradiscal injection of TNF-α in a porcine model,” Eur. Spine 
J., vol. 24, no. 9, pp. 2010–2016, Sep. 2015. 
 
[64] D. Purmessur, B. A. Walter, P. J. Roughley, D. M. Laudier, A. C. Hecht, and J. Iatridis, 
“A role for TNFα in intervertebral disc degeneration: a non-recoverable catabolic shift.,” 
Biochem. Biophys. Res. Commun., vol. 433, no. 1, pp. 151–6, Mar. 2013. 
 
[65] D. Z. Markova, C. K. Kepler, S. Addya, H. B. Murray, A. R. Vaccaro, I. M. Shapiro, D. 
Greg Anderson, T. J. Albert, and M. V Risbud, “An organ culture system to model early 
degenerative changes of the intervertebral disc II: profiling global gene expression 
changes,” Arthritis Res. Ther., vol. 15, no. 5, p. R121, 2013. 
 
[66] K. L. E. Phillips, N. Jordan-Mahy, M. J. H. Nicklin, and C. L. Le Maitre, “Interleukin-1 
receptor antagonist deficient mice provide insights into pathogenesis of human 
intervertebral disc degeneration.,” Ann. Rheum. Dis., vol. 72, no. 11, pp. 1860–7, Nov. 
2013. 
 
[67] H. Hamamoto, H. Miyamoto, M. Doita, T. Takada, K. Nishida, and M. Kurosaka, 
“Capability of Nondegenerated and Degenerated Discs in Producing Inflammatory 
Agents With or Without Macrophage Interaction,” Spine (Phila. Pa. 1976)., vol. 37, no. 
3, pp. 161–167, Feb. 2012. 
 
[68] G. Hou, H. Lu, M. Chen, H. Yao, and H. Zhao, “Oxidative stress participates in age- 
related changes in rat lumbar intervertebral discs,” Arch. Gerontol. Geriatr., vol. 59, no. 
3, pp. 665–669, 2014. 
 
[69] S. S. Sivan, E. Tsitron, E. Wachtel, P. Roughley, N. Sakkee, F. van der Ham, J. Degroot, 
and A. Maroudas, “Age-related accumulation of pentosidine in aggrecan and collagen 
from normal and degenerate human intervertebral discs.,” Biochem. J., vol. 399, no. 1, 
pp. 29–35, Oct. 2006. 
 
[70] H. K. Pokharna and F. M. Phillips, “Collagen crosslinks in human lumbar intervertebral 
disc aging.,” Spine (Phila. Pa. 1976)., vol. 23, no. 15, pp. 1645–8, Aug. 1998. 
92  
[71] A. Gautieri, A. Redaelli, M. J. Buehler, and S. Vesentini, “Age- and diabetes-related 
nonenzymatic crosslinks in collagen fibrils: candidate amino acids involved in Advanced 
Glycation End-products.,” Matrix Biol., vol. 34, pp. 89–95, Feb. 2014. 
 
[72] N. Verzijl, J. DeGroot, C. Ben Zaken, O. Braun-Benjamin, A. Maroudas, R. A. Bank, J. 
Mizrahi, C. G. Schalkwijk, S. R. Thorpe, J. W. Baynes, J. W. J. Bijlsma, F. P. J. G. 
Lafeber, and J. M. TeKoppele, “Crosslinking by advanced glycation end products 
increases the stiffness of the collagen network in human articular cartilage: A possible 
mechanism through which age is a risk factor for osteoarthritis,” Arthritis Rheum., vol. 
46, no. 1, pp. 114–123, Jan. 2002. 
 
[73] B. Scharf, C. C. Clement, S. Yodmuang, A. M. Urbanska, S. O. Suadicani, D. 
Aphkhazava, M. M. Thi, G. Perino, J. A. Hardin, N. Cobelli, G. Vunjak-Novakovic, and 
L. Santambrogio, “Age-related carbonylation of fibrocartilage structural proteins drives 
tissue degenerative modification.,” Chem. Biol., vol. 20, no. 7, pp. 922–34, Jul. 2013. 
 
[74] A. Dimozi, E. Mavrogonatou, A. Sklirou, and D. Kletsas, “Oxidative stress inhibits the 
proliferation, induces premature senescence and promotes a catabolic phenotype in 
human nucleus pulposus intervertebral disc cells.,” Eur. Cell. Mater., vol. 30, pp. 89–103, 
Jan. 2015. 
 
[75] D. Chen, D. Xia, Z. Pan, D. Xu, Y. Zhou, Y. Wu, N. Cai, Q. Tang, C. Wang, M. Yan, J. 
J. Zhang, K. Zhou, Q. Wang, Y. Feng, X. Wang, H. Xu, X. Zhang, and N. Tian, 
“Metformin protects against apoptosis and senescence in nucleus pulposus cells and 
ameliorates disc degeneration in vivo,” Cell Death Dis., vol. 7, no. 10, pp. e2441–e2441, 
Oct. 2016. 
 
[76] K. Ngo, P. Patil, S. J. McGowan, L. J. Niedernhofer, P. D. Robbins, J. Kang, G. Sowa, 
and N. Vo, “Senescent intervertebral disc cells exhibit perturbed matrix homeostasis 
phenotype,” Mech. Ageing Dev., vol. 166, pp. 16–23, Sep. 2017. 
 
[77] L. A. Nasto, A. R. Robinson, K. Ngo, C. L. Clauson, Q. Dong, C. St. Croix, G. Sowa, E. 
Pola, P. D. Robbins, J. Kang, L. J. Niedernhofer, P. Wipf, and N. V. Vo, “Mitochondrial- 
derived reactive oxygen species (ROS) play a causal role in aging-related intervertebral 
disc degeneration,” J. Orthop. Res., vol. 31, no. 7, pp. 1150–1157, Jul. 2013. 
 
[78] X. Yang, L. Jin, L. Yao, F. H. Shen, A. L. Shimer, and X. Li, “Antioxidative nanofullerol 
prevents intervertebral disk degeneration.,” Int. J. Nanomedicine, vol. 9, pp. 2419–30, 
May 2014. 
 
[79] L. Yang, Z. Rong, M. Zeng, Y. Cao, X. Gong, L. Lin, Y. Chen, W. Cao, L. Zhu, and W. 
Dong, “Pyrroloquinoline quinone protects nucleus pulposus cells from hydrogen 
peroxide-induced apoptosis by inhibiting the mitochondria-mediated pathway.,” Eur. 
Spine J., vol. 24, no. 8, pp. 1702–10, Aug. 2015. 
 
[80] U. G. Longo, S. Petrillo, E. Franceschetti, N. Maffulli, and V. Denaro, “Growth Factors 
and Anticatabolic Substances for Prevention and Management of Intervertebral Disc 
Degeneration,” Stem Cells Int., vol. 2012, pp. 1–9, 2012. 
93  
[81] K. Nishida, T. Suzuki, K. Kakutani, T. Yurube, K. Maeno, M. Kurosaka, and M. Doita, 
“Gene therapy approach for disc degeneration and associated spinal disorders.,” Eur. 
Spine J., vol. 17 Suppl 4, pp. 459–66, Dec. 2008. 
 
[82] S. K. Leckie, G. A. Sowa, B. P. Bechara, R. A. Hartman, J. P. Coelho, W. T. Witt, Q. D. 
Dong, B. W. Bowman, K. M. Bell, N. V. Vo, B. C. Kramer, and J. D. Kang, “Injection of 
human umbilical tissue–derived cells into the nucleus pulposus alters the course of 
intervertebral disc degeneration in vivo,” Spine J., vol. 13, no. 3, pp. 263–272, Mar.  
2013. 
 
[83] L. E. Clarke, S. M. Richardson, and J. A. Hoyland, “Harnessing the Potential of 
Mesenchymal Stem Cells for IVD Regeneration.,” Curr. Stem Cell Res. Ther., vol. 10, 
no. 4, pp. 296–306, Jan. 2015. 
 
[84] M. Klawitter, L. Quero, J. Klasen, A. N. Gloess, B. Klopprogge, O. Hausmann, N. Boos, 
and K. Wuertz, “Curcuma DMSO extracts and curcumin exhibit an anti-inflammatory 
and anti-catabolic effect on human intervertebral disc cells, possibly by influencing TLR2 
expression and JNK activity,” J. Inflamm., vol. 9, no. 1, p. 29, Jan. 2012. 
 
[85] X. Li, F. M. Phillips, H. S. An, M. Ellman, E. J. Thonar, W. Wu, D. Park, and H.-J. Im, 
“The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc.,” 
Spine (Phila. Pa. 1976)., vol. 33, no. 24, pp. 2586–95, Nov. 2008. 
 
[86] O. Krupkova, M. Sekiguchi, J. Klasen, O. Hausmann, S. Konno, S. J. Ferguson, and K. 
Wuertz-Kozak, “Epigallocatechin 3-gallate suppresses interleukin-1β-induced 
inflammatory responses in intervertebral disc cells in vitro and reduces radiculopathic 
pain in rats.,” Eur. Cell. Mater., vol. 28, pp. 372–86, Jan. 2014. 
 
[87] M. Horii, S. Orita, M. Nagata, M. Takaso, K. Yamauchi, M. Yamashita, G. Inoue, Y. 
Eguchi, N. Ochiai, S. Kishida, Y. Aoki, T. Ishikawa, G. Arai, M. Miyagi, H. Kamoda, K. 
Kuniyoshi, M. Suzuki, J. Nakamura, T. Toyone, K. Takahashi, and S. Ohtori, “Direct 
application of the tumor necrosis factor-α inhibitor, etanercept, into a punctured 
intervertebral disc decreases calcitonin gene-related peptide expression in rat dorsal root 
ganglion neurons.,” Spine (Phila. Pa. 1976)., vol. 36, no. 2, pp. E80-5, Jan. 2011. 
 
[88] A. G. Nerlich, B. E. Bachmeier, E. Schleicher, H. Rohrbach, G. Paesold, and N. Boos, 
“Immunomorphological analysis of RAGE receptor expression and NF-kappaB 
activation in tissue samples from normal and degenerated intervertebral discs of various 
ages.,” Ann. N. Y. Acad. Sci., vol. 1096, pp. 239–48, Jan. 2007. 
 
[89] J. S. Tilstra, A. R. Robinson, J. Wang, S. Q. Gregg, C. L. Clauson, D. P. Reay, L. A. 
Nasto, C. M. St Croix, A. Usas, N. Vo, J. Huard, P. R. Clemens, D. B. Stolz, D. C. 
Guttridge, S. C. Watkins, G. A. Garinis, Y. Wang, L. J. Niedernhofer, and P. D. Robbins, 
“NF-κB inhibition delays DNA damage-induced senescence and aging in mice.,” J. Clin. 





[90] Okuma M; Miyamoto K; Chujo T; Kitahara S; and Masuda, “A NEW GENE THERAPY 
APPROACH: IN VIVO TRANSFECTION OF ‘NAKED’ NF?B 
DECOYOLIGONUCLEOTIDE RESTORED DISC DEGENERATION IN THE RABBIT 
ANNULAR NEEDLE PUNCTURE MODEL,” 2005. 
 
[91] J. Campisi and F. d’Adda di Fagagna, “Cellular senescence: when bad things happen to 
good cells.,” Nat. Rev. Mol. Cell Biol., vol. 8, no. 9, pp. 729–40, Sep. 2007. 
 
[92] L. Hayflick, “The limited in vitro lifetime of human diploid cell strains,” Exp. Cell Res., 
vol. 37, no. 3, pp. 614–636, Mar. 1965. 
 
[93] T. von Zglinicki, G. Saretzki, J. Ladhoff, F. d’Adda di Fagagna, and S. P. Jackson, 
“Human cell senescence as a DNA damage response,” Mech. Ageing Dev., vol. 126, no. 
1, pp. 111–117, Jan. 2005. 
 
[94] F. Rodier, D. P. Muñoz, R. Teachenor, V. Chu, O. Le, D. Bhaumik, J.-P. Coppé, E. 
Campeau, C. M. Beauséjour, S.-H. Kim, A. R. Davalos, and J. Campisi, “DNA-SCARS: 
distinct nuclear structures that sustain damage-induced senescence growth arrest and 
inflammatory cytokine secretion.,” J. Cell Sci., vol. 124, no. Pt 1, pp. 68–81, Jan. 2011. 
 
[95] I. Ben-Porath and R. A. Weinberg, “The signals and pathways activating cellular 
senescence,” Int. J. Biochem. Cell Biol., vol. 37, pp. 961–976, 2005. 
 
[96] F. Rodier, J.-P. Coppé, C. K. Patil, W. A. M. Hoeijmakers, D. P. Muñoz, S. R. Raza, A. 
Freund, E. Campeau, A. R. Davalos, and J. Campisi, “Persistent DNA damage signalling 
triggers senescence-associated inflammatory cytokine secretion.,” Nat. Cell Biol., vol. 11, 
no. 8, pp. 973–9, Aug. 2009. 
 
[97] C. Wang, D. Jurk, M. Maddick, G. Nelson, C. Martin-Ruiz, and T. von Zglinicki, “DNA 
damage response and cellular senescence in tissues of aging mice.,” Aging Cell, vol. 8, 
no. 3, pp. 311–23, Jun. 2009. 
 
[98] I. Ben-Porath and R. A. Weinberg, “When cells get stressed: an integrative view of 
cellular senescence.,” J. Clin. Invest., vol. 113, no. 1, pp. 8–13, Jan. 2004. 
 
[99] J. Campisi, “Senescent cells, tumor suppression, and organismal aging: good citizens, bad 
neighbors,” Cell, vol. 120, no. 5, pp. 513–522, 2005. 
 
[100] S. Brookes, J. Rowe, M. Ruas, S. Llanos, P. A. Clark, M. Lomax, M. C. James, R. 
Vatcheva, S. Bates, K. H. Vousden, D. Parry, N. Gruis, N. Smit, W. Bergman, and G. 
Peters, “INK4a-deficient human diploid fibroblasts are resistant to RAS-induced 
senescence.,” EMBO J., vol. 21, no. 12, pp. 2936–45, Jun. 2002. 
 
[101] G. P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. 
Linskens, I. Rubelj, and O. Pereira-Smith, “A biomarker that identifies senescent human 
cells in culture and in aging skin in vivo.,” Proc. Natl. Acad. Sci., vol. 92, no. 20, pp. 
9363–9367, Sep. 1995. 
95  
[102] Y. Murata, T. Wakoh, N. Uekawa, M. Sugimoto, A. Asai, T. Miyazaki, and M. 
Maruyama, “Death-associated protein 3 regulates cellular senescence through oxidative 
stress response,” FEBS Lett., vol. 580, no. 26, pp. 6093–6099, Nov. 2006. 
 
[103] R. Marcotte, C. Lacelle, and E. Wang, “Senescent fibroblasts resist apoptosis by 
downregulating caspase-3,” Mech. Ageing Dev., vol. 125, no. 10–11, pp. 777–783, Oct. 
2004. 
 
[104] E. Crescenzi, G. Palumbo, and H. J. M. Brady, “Bcl-2 activates a programme of 
premature senescence in human carcinoma cells.,” Biochem. J., vol. 375, no. Pt 2, pp. 
263–74, Oct. 2003. 
 
[105] J.-P. Coppé, P.-Y. Desprez, A. Krtolica, and J. Campisi, “The senescence-associated 
secretory phenotype: the dark side of tumor suppression.,” Annu. Rev. Pathol., vol. 5, pp. 
99–118, Jan. 2010. 
 
[106] J.-P. Coppé, C. K. Patil, F. Rodier, Y. Sun, D. P. Muñoz, J. Goldstein, P. S. Nelson, P.-Y. 
Desprez, and J. Campisi, “Senescence-associated secretory phenotypes reveal cell- 
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.,” PLoS Biol., 
vol. 6, no. 12, pp. 2853–68, Dec. 2008. 
 
[107] Y. Chien, C. Scuoppo, X. Wang, X. Fang, B. Balgley, J. E. Bolden, P. Premsrirut, W. 
Luo, A. Chicas, C. S. Lee, S. C. Kogan, and S. W. Lowe, “Control of the senescence- 
associated secretory phenotype by NF-κB promotes senescence and enhances 
chemosensitivity.,” Genes Dev., vol. 25, no. 20, pp. 2125–36, Oct. 2011. 
 
[108] A. Freund, C. K. Patil, and J. Campisi, “p38MAPK is a novel DNA damage response- 
independent regulator of the senescence-associated secretory phenotype.,” EMBO J., vol. 
30, no. 8, pp. 1536–48, Apr. 2011. 
 
[109] C. Kang, Q. Xu, T. D. Martin, M. Z. Li, M. Demaria, L. Aron, T. Lu, B. A. Yankner, J. 
Campisi, and S. J. Elledge, “The DNA damage response induces inflammation and 
senescence by inhibiting autophagy of GATA4.,” Science, vol. 349, no. 6255, p. aaa5612, 
Sep. 2015. 
 
[110] T. Kuilman, C. Michaloglou, L. C. W. Vredeveld, S. Douma, R. van Doorn, C. J. 
Desmet, L. a Aarden, W. J. Mooi, and D. S. Peeper, “Oncogene-induced senescence 
relayed by an interleukin-dependent inflammatory network.,” Cell, 2008. 
 
[111] R.-M. Laberge, Y. Sun, A. V. Orjalo, C. K. Patil, A. Freund, L. Zhou, S. C. Curran, A. R. 
Davalos, K. A. Wilson-Edell, S. Liu, C. Limbad, M. Demaria, P. Li, G. B. Hubbard, Y. 
Ikeno, M. Javors, P.-Y. Desprez, C. C. Benz, P. Kapahi, P. S. Nelson, and J. Campisi, 
“MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by 






[112] M. Narita, A. R. J. Young, S. Arakawa, S. A. Samarajiwa, T. Nakashima, S. Yoshida, S. 
Hong, L. S. Berry, S. Reichelt, M. Ferreira, S. Tavaré, K. Inoki, S. Shimizu, and 
M.Narita, “Spatial coupling of mTOR and autophagy augments secretory phenotypes.,” 
Science, vol. 332, no. 6032, pp. 966–70, May 2011. 
 
[113] A. H. Bittles and N. Harper, “Increased glycolysis in ageing cultured human diploid 
fibroblasts.,” Biosci. Rep., vol. 4, no. 9, pp. 751–6, Sep. 1984. 
 
[114] W. Zwerschke, S. Mazurek, P. Stöckl, E. Hütter, E. Eigenbrodt, and P. Jansen-Dürr, 
“Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular 
senescence.,” Biochem. J., vol. 376, no. Pt 2, pp. 403–11, Dec. 2003. 
 
[115] C. Correia-Melo, F. D. Marques, R. Anderson, G. Hewitt, R. Hewitt, J. Cole, B. M. 
Carroll, S. Miwa, J. Birch, A. Merz, M. D. Rushton, M. Charles, D. Jurk, S. W. Tait, R. 
Czapiewski, L. Greaves, G. Nelson, M. Bohlooly-Y, S. Rodriguez-Cuenca, A. Vidal- 
Puig, D. Mann, G. Saretzki, G. Quarato, D. R. Green, P. D. Adams, T. von Zglinicki, V. 
I. Korolchuk, and J. F. Passos, “Mitochondria are required for pro-ageing features of the 
senescent phenotype,” EMBO J., vol. 35, no. 7, pp. 724–742, Feb. 2016. 
 
[116] J. R. Dörr, Y. Yu, M. Milanovic, G. Beuster, C. Zasada, J. H. M. Däbritz, J. Lisec, D. 
Lenze, A. Gerhardt, K. Schleicher, S. Kratzat, B. Purfürst, S. Walenta, W. Mueller- 
Klieser, M. Gräler, M. Hummel, U. Keller, A. K. Buck, B. Dörken, L. Willmitzer, M. 
Reimann, S. Kempa, S. Lee, and C. A. Schmitt, “Synthetic lethal metabolic targeting of 
cellular senescence in cancer therapy.,” Nature, vol. 501, no. 7467, pp. 421–5, Sep. 2013. 
 
[117] C. Quijano, L. Cao, M. M. Fergusson, H. Romero, J. Liu, S. Gutkind, I. I. Rovira, R. P. 
Mohney, E. D. Karoly, and T. Finkel, “Oncogene-induced senescence results in marked 
metabolic and bioenergetic alterations.,” Cell Cycle, vol. 11, no. 7, pp. 1383–92, Apr. 
2012. 
 
[118] J. Campisi, “Cellular senescence: putting the paradoxes in perspective.,” Curr. Opin. 
Genet. Dev., vol. 21, no. 1, pp. 107–12, Feb. 2011. 
 
[119] J. a Martin and J. a Buckwalter, “The role of chondrocyte senescence in the pathogenesis 
of osteoarthritis and in limiting cartilage repair.,” J. Bone Joint Surg. Am., vol. 85–A 
Suppl, pp. 106–110, 2003. 
 
[120] J. Krishnamurthy, M. R. Ramsey, K. L. Ligon, C. Torrice, A. Koh, S. Bonner-Weir, and 
N. E. Sharpless, “p16INK4a induces an age-dependent decline in islet regenerative 
potential.,” Nature, vol. 443, no. 7110, pp. 453–457, 2006. 
 
[121] P. B. Liton, P. Challa, S. Stinnett, C. Luna, D. L. Epstein, and P. Gonzalez, “Cellular 
senescence in the glaucomatous outflow pathway,” Exp. Gerontol., vol. 40, no. 8–9, pp. 
745–748, Aug. 2005. 
 
[122] D. J. Baker, T. Wijshake, T. Tchkonia, N. LeBrasseur, B. Childs, B. van de Sluis, J. 
Kirkland, and J. van Deursen, “Clearance of p16Ink4a-positive senescent cells delays 
ageing-associated disorders,” Nature, vol. 479, pp. 232–236, 2011. 
97  
[123] X. Zhou, F. Perez, K. Han, and D. A. Jurivich, “Clonal senescence alters endothelial 
ICAM-1 function,” Mech. Ageing Dev., vol. 127, no. 10, pp. 779–785, Oct. 2006. 
 
[124] F. Fyhrquist, O. Saijonmaa, and T. Strandberg, “The roles of senescence and telomere 
shortening in cardiovascular disease,” Nat. Rev. Cardiol., vol. 10, no. 5, pp. 274–283, 
May 2013. 
 
[125] G. Nelson, J. Wordsworth, C. Wang, D. Jurk, C. Lawless, C. Martin-Ruiz, and T. von 
Zglinicki, “A senescent cell bystander effect: senescence-induced senescence,” Aging 
Cell, vol. 11, no. 2, pp. 345–349, 2012. 
 
[126] S. Hubackova, K. Krejcikova, J. Bartek, and Z. Hodny, “IL1- and TGFβ-Nox4 signaling, 
oxidative stress and DNA damage response are shared features of replicative, oncogene- 
induced, and drug-induced paracrine ‘bystander senescence’.,” Aging (Albany. NY)., vol. 
4, no. 12, pp. 932–51, Dec. 2012. 
 
[127] S. Parrinello, J.-P. Coppe, A. Krtolica, and J. Campisi, “Stromal-epithelial interactions in 
aging and cancer: senescent fibroblasts alter epithelial cell differentiation.,” J. Cell Sci., 
vol. 118, no. Pt 3, pp. 485–96, Feb. 2005. 
 
[128] A. Krtolica, S. Parrinello, S. Lockett, P. Y. Desprez, and J. Campisi, “Senescent 
fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and 
aging.,” Proc. Natl. Acad. Sci. U. S. A., vol. 98, no. 21, pp. 12072–7, Oct. 2001. 
 
[129] D. Liu and P. J. Hornsby, “Senescent human fibroblasts increase the early growth of 
xenograft tumors via matrix metalloproteinase secretion.,” Cancer Res., vol. 67, no. 7, 
pp. 3117–26, Apr. 2007. 
 
[130] S. Minagawa, J. Araya, T. Numata, S. Nojiri, H. Hara, Y. Yumino, M. Kawaishi, M. 
Odaka, T. Morikawa, S. L. Nishimura, K. Nakayama, and K. Kuwano, “Accelerated 
epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced 
senescence of human bronchial epithelial cells,” Am. J. Physiol. Cell. Mol. Physiol., vol. 
300, no. 3, pp. L391–L401, Mar. 2011. 
 
[131] R. Bhat, E. P. Crowe, A. Bitto, M. Moh, C. D. Katsetos, F. U. Garcia, F. B. Johnson, J. 
Q. Trojanowski, C. Sell, and C. Torres, “Astrocyte Senescence as a Component of 
Alzheimer’s Disease,” PLoS One, vol. 7, no. 9, p. e45069, Sep. 2012. 
 
[132] B. M. Fischer, J. K. Wong, S. Degan, A. B. Kummarapurugu, S. Zheng, P. Haridass, and 
J. A. Voynow, “Increased expression of senescence markers in cystic fibrosis airways,” 
Am. J. Physiol. Cell. Mol. Physiol., vol. 304, no. 6, pp. L394–L400, Mar. 2013. 
 
[133] J. J. Sohn, A. J. Schetter, H. G. Yfantis, L. A. Ridnour, I. Horikawa, M. A. Khan, A. I. 
Robles, S. P. Hussain, A. Goto, E. D. Bowman, L. J. Hofseth, J. Bartkova, J. Bartek, G. 
N. Wogan, D. A. Wink, and C. C. Harris, “Macrophages, Nitric Oxide and microRNAs 
Are Associated with DNA Damage Response Pathway and Senescence in Inflammatory 
Bowel Disease,” PLoS One, vol. 7, no. 9, p. e44156, Sep. 2012. 
98  
[134] D. J. Baker, T. Wijshake, T. Tchkonia, N. K. LeBrasseur, B. G. Childs, B. van de Sluis, J. 
L. Kirkland, and J. M. van Deursen, “Clearance of p16Ink4a-positive senescent cells 
delays ageing-associated disorders.,” Nature, vol. 479, no. 7372, pp. 232–6, Nov. 2011. 
 
[135] M. Demaria, N. Ohtani, S. Youssef, F. Rodier, W. Toussaint, J. Mitchell, R. Laberge, J. 
Vijg, H. Van Steeg, M. Dollé, J. Hoeijmakers, A. Bruin, E. Hara, and J. Campisi, “An 
Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of 
PDGF-AA,” Dev. Cell, vol. 31, no. 6, pp. 722–733, 2014. 
 
[136] R.-M. Laberge, D. Adler, M. DeMaria, N. Mechtouf, R. Teachenor, G. B. Cardin, P.-Y. 
Desprez, J. Campisi, and F. Rodier, “Mitochondrial DNA damage induces apoptosis in 
senescent cells,” Cell Death Dis., vol. 4, no. 7, pp. e727–e727, Jul. 2013. 
 
[137] M. Demaria, M. N. O’Leary, J. Chang, L. Shao, S. Liu, F. Alimirah, K. Koenig, C. Le, N. 
Mitin, A. M. Deal, S. Alston, E. C. Academia, S. Kilmarx, A. Valdovinos, B. Wang, A. 
de Bruin, B. K. Kennedy, S. Melov, D. Zhou, N. E. Sharpless, H. Muss, and J. Campisi, 
“Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.,” 
Cancer Discov., vol. 7, no. 2, pp. 165–176, 2017. 
 
[138] J. Chang, Y. Wang, L. Shao, R. Laberge, M. Demaria, K. Campisi, J Janakiraman, N. 
Sharpless, S. Ding, W. Feng, Y. Luo, X. Wang, N. Aykin-Burns, K. Krager, U. 
Ponnappan, M. Hauer-Jensen, A. Meng, and D. Zhou, “Clearance of senescent cells by 
ABT263 rejuvenates aged hematopoietic stem cells in mice,” Nat. Med., vol. 22, no. 1, 
pp. 78–83, 2016. 
 
[139] Y. Zhu, T. Tchkonia, H. Fuhrmann-Stroissnigg, H. M. Dai, Y. Y. Ling, M. B. Stout, T. 
Pirtskhalava, N. Giorgadze, K. O. Johnson, C. B. Giles, J. D. Wren, L. J. Niedernhofer, P. 
D. Robbins, and J. L. Kirkland, “Identification of a novel senolytic agent, navitoclax, 
targeting the Bcl-2 family of anti-apoptotic factors,” Aging Cell, vol. 15, no. 3, pp. 428– 
435, Jun. 2016. 
 
[140] Y. Zhu, T. Tchkonia, T. Pirtskhalava, A. C. Gower, H. Ding, N. Giorgadze, A. K. 
Palmer, Y. Ikeno, G. B. Hubbard, M. Lenburg, S. P. O’Hara, N. F. LaRusso, J. D. Miller, 
C. M. Roos, G. C. Verzosa, N. K. LeBrasseur, J. D. Wren, J. N. Farr, S. Khosla, M. B. 
Stout, S. J. McGowan, H. Fuhrmann-Stroissnigg, A. U. Gurkar, J. Zhao, D. Colangelo, A. 
Dorronsoro, Y. Y. Ling, A. S. Barghouthy, D. C. Navarro, T. Sano, P. D. Robbins, L. J. 
Niedernhofer, and J. L. Kirkland, “The Achilles’ heel of senescent cells: from 
transcriptome to senolytic drugs,” Aging Cell, vol. 14, no. 4, pp. 644–658, Aug. 2015. 
 
[141] R. Yosef, N. Pilpel, R. Tokarsky-Amiel, A. Biran, Y. Ovadya, S. Cohen, E. Vadai, L. 
Dassa, E. Shahar, R. Condiotti, I. Ben-Porath, and V. Krizhanovsky, “Directed 
elimination of senescent cells by inhibition of BCL-W and BCL-XL,” Nat. Commun., 







[142] O. H. Jeon, C. Kim, R.-M. Laberge, M. Demaria, S. Rathod, A. P. Vasserot, J. W. Chung, 
D. H. Kim, Y. Poon, N. David, D. J. Baker, J. M. van Deursen, J. Campisi, and J. H. 
Elisseeff, “Local clearance of senescent cells attenuates the development of post-traumatic 
osteoarthritis and creates a pro-regenerative environment,” Nat. Med., vol. 23, no. 6, pp. 775–781, 
Apr. 2017. 
 
[143] C. M. Rudin, C. L. Hann, E. B. Garon, M. Ribeiro de Oliveira, P. D. Bonomi, D. R. 
Camidge, Q. Chu, G. Giaccone, D. Khaira, S. S. Ramalingam, M. R. Ranson, C. Dive, E. 
M. McKeegan, B. J. Chyla, B. L. Dowell, A. Chakravartty, C. E. Nolan, N. Rudersdorf, 
T. A. Busman, M. H. Mabry, A. P. Krivoshik, R. A. Humerickhouse, G. I. Shapiro, and 
L. Gandhi, “Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker 
Correlates in Patients with Relapsed Small Cell Lung Cancer,” Clin. Cancer Res., vol. 
18, no. 11, pp. 3163–3169, Jun. 2012. 
 
[144] N. Herranz, S. Gallage, M. Mellone, T. Wuestefeld, S. Klotz, C. J. Hanley, S. Raguz, J. 
C. Acosta, A. J. Innes, A. Banito, A. Georgilis, A. Montoya, K. Wolter, G. 
Dharmalingam, P. Faull, T. Carroll, J. P. Martínez-Barbera, P. Cutillas, F. Reisinger, M. 
Heikenwalder, R. A. Miller, D. Withers, L. Zender, G. J. Thomas, and J. Gil, “mTOR 
regulates MAPKAPK2 translation to control the senescence-associated secretory 
phenotype.,” Nat. Cell Biol., vol. 17, no. 9, pp. 1205–17, Sep. 2015. 
 
[145] F. Prattichizzo, A. Giuliani, R. Recchioni, M. Bonafè, F. Marcheselli, S. De Carolis, A. 
Campanati, K. Giuliodori, M. R. Rippo, F. Brugè, L. Tiano, C. Micucci, A. Ceriello, A. 
Offidani, A. D. Procopio, and F. Olivieri, “Anti-TNF-&amp;#x3B1; treatment modulates 
SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic 
cells,” Oncotarget, vol. 7, no. 11, pp. 11945–58, Mar. 2016. 
 
[146] R. A. Miller, D. E. Harrison, C. M. Astle, E. Fernandez, K. Flurkey, M. Han, M. A. 
Javors, X. Li, N. L. Nadon, J. F. Nelson, S. Pletcher, A. B. Salmon, Z. D. Sharp, S. Van 
Roekel, L. Winkleman, and R. Strong, “Rapamycin-mediated lifespan increase in mice is 
dose and sex dependent and metabolically distinct from dietary restriction,” Aging Cell, 
vol. 13, no. 3, pp. 468–477, Jun. 2014. 
 
[147] D. E. Harrison, R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle, K. Flurkey, N. L. 
Nadon, J. E. Wilkinson, K. Frenkel, C. S. Carter, M. Pahor, M. A. Javors, E. Fernandez, 
and R. A. Miller, “Rapamycin fed late in life extends lifespan in genetically 
heterogeneous mice,” Nature, vol. 460, no. 7253, pp. 392–395, Jul. 2009. 
 
[148] J. Hashimoto, P. Garnero, D. Heijde, N. Miyasaka, K. Yamamoto, S. Kawai, T. 
Takeuchi, H. Yoshikawa, and N. Nishimoto, “Humanized anti-interleukin-6-receptor 
antibody (tocilizumab) monotherapy is more effective in slowing radiographic 
progression in patients with rheumatoid arthritis at high baseline risk for structural 
damage evaluated with levels of biomarkers, radiography, and BMI: data from the 
SAMURAI study,” Mod. Rheumatol., vol. 21, no. 1, pp. 10–15, Feb. 2011. 
 
[149] G. Schett, J.-M. Dayer, and B. Manger, “Interleukin-1 function and role in rheumatic 





[150] J. Acosta, A. O’Loghlen, A. Banito, M. Guijarro, A. Augert, A. Raguz, M. Fumagalli, M. 
Costa, C. Brown, N. Popov, Y. Takatsu, J. Melamed, F. Fagagna, D. Bernard, 
E.Hernando, and J. Gil, “Chemokine signaling via the CXCR2 receptor reinforces senescence,” 
Cell, vol. 133, no. 6, pp. 1006–1018, 2008. 
 
[151] N. V. Vo, R. A. Hartman, P. R. Patil, M. V. Risbud, D. Kletsas, J. C. Iatridis, J. A. 
Hoyland, C. L. Le Maitre, G. A. Sowa, and J. D. Kang, “Molecular mechanisms of 
biological aging in intervertebral discs,” J. Orthop. Res., vol. 34, no. 8, pp. 1289–1306, 
Aug. 2016. 
 
[152] C. Feng, Y. Zhang, M. Yang, M. Lan, H. Liu, B. Huang, and Y. Zhou, “Oxygen-Sensing 
Nox4 Generates Genotoxic ROS to Induce Premature Senescence of Nucleus Pulposus 
Cells through MAPK and NF-κB Pathways.,” Oxid. Med. Cell. Longev., vol. 2017, p. 
7426458, 2017. 
 
[153] J.-S. Park, J.-B. Park, I.-J. Park, and E.-Y. Park, “Accelerated premature stress-induced 
senescence of young annulus fibrosus cells of rats by high glucose-induced oxidative 
stress.,” Int. Orthop., vol. 38, no. 6, pp. 1311–20, Jun. 2014. 
 
[154] S.-M. Dai, Z.-Z. Shan, H. Nakamura, K. Masuko-Hongo, T. Kato, K. Nishioka, and K. 
Yudoh, “Catabolic stress induces features of chondrocyte senescence through 
overexpression of caveolin 1: Possible involvement of caveolin 1–induced down- 
regulation of articular chondrocytes in the pathogenesis of osteoarthritis,” Arthritis 
Rheum., vol. 54, no. 3, pp. 818–831, Mar. 2006. 
 
[155] C. Feng, Y. Zhang, M. Yang, M. Lan, H. Liu, J. Wang, Y. Zhou, and B. Huang, “The 
matrikine N-acetylated proline-glycine-proline induces premature senescence of nucleus 
pulposus cells via CXCR1-dependent ROS accumulation and DNA damage and 
reinforces the destructive effect of these cells on homeostasis of intervertebral discs.,” 
Biochim. Biophys. acta. Mol. basis Dis., vol. 1863, no. 1, pp. 220–230, Jan. 2017. 
 
[156] L. A. Nasto, D. Wang, A. R. Robinson, C. L. Clauson, K. Ngo, Q. Dong, P. Roughley, 
M. Epperly, S. M. Huq, E. Pola, G. Sowa, P. D. Robbins, J. Kang, L. J. Niedernhofer, and 
N. V Vo, “Genotoxic stress accelerates age-associated degenerative changes in 
intervertebral discs.,” Mech. Ageing Dev., vol. 134, no. 1–2, pp. 35–42, Jan. . 
 
[157] W. E. B. Johnson, S. Stephan, and S. Roberts, “The influence of serum, glucose and 
oxygen on intervertebral disc cell growth in vitro: implications for degenerative disc 
disease,” Arthritis Res. Ther., vol. 10, no. 2, p. R46, 2008. 
 
[158] C. L. Le Maitre, A. J. Freemont, and J. A. Hoyland, “Accelerated cellular senescence in 
degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc 
degeneration.,” Arthritis Res. Ther., vol. 9, no. 3, p. R45, Jan. 2007. 
 
[159] H. E. Gruber, J. A. Ingram, D. E. Davis, and E. N. Hanley, “Increased cell senescence is 
associated with decreased cell proliferation in vivo in the degenerating human annulus.,” 
Spine J., vol. 9, no. 3, pp. 210–5, Mar. 2009. 
101  
[160] H. E. Gruber, J. A. Ingram, H. J. Norton, and E. N. Hanley, “Senescence in Cells of the 
Aging and Degenerating Intervertebral Disc,” Spine (Phila. Pa. 1976)., vol. 32, no. 3, pp. 
321–327, Feb. 2007. 
 
[161] J. P. G. Urban and S. Roberts, “Degeneration of the intervertebral disc.,” Arthritis Res. 
Ther., vol. 5, no. 3, pp. 120–30, 2003. 
 
[162] United States Bone and Joint Initiative, “The Burden of MuscThe Burden of 
Musculoskeletal Diseases in the United States: Prevalence, Societal and Economic Costs 
(BMUS),” 2014. 
 
[163] J. M. van Deursen, “The role of senescent cells in ageing.,” Nature, vol. 509, no. 7501, 
pp. 439–46, May 2014. 
 
[164] F. d’Adda di Fagagna, “Living on a break: cellular senescence as a DNA-damage 
response,” Nat. Rev. Cancer, vol. 8, no. 7, pp. 512–522, Jul. 2008. 
 
[165] J.-P. Coppé, C. K. Patil, F. Rodier, Y. Sun, D. P. Muñoz, J. Goldstein, P. S. Nelson, P.-Y. 
Desprez, and J. Campisi, “Senescence-associated secretory phenotypes reveal cell- 
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor.,” PLoS Biol., 
vol. 6, no. 12, pp. 2853–68, Dec. 2008. 
 
[166] M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe, “Oncogenic ras 
provokes premature cell senescence associated with accumulation of p53 and 
p16INK4a.,” Cell, vol. 88, no. 5, pp. 593–602, Mar. 1997. 
 
[167] B. G. Childs, M. Durik, D. J. Baker, and J. M. van Deursen, “Cellular senescence in 
aging and age-related disease: from mechanisms to therapy,” Nat. Med., vol. 21, no. 12, 
pp. 1424–1435, Dec. 2015. 
 
[168] A. Melk, B. M. W. Schmidt, O. Takeuchi, B. Sawitzki, D. C. Rayner, and P. F. Halloran, 
“Expression of p16INK4a and other cell cycle regulator and senescence associated genes 
in aging human kidney.,” Kidney Int., vol. 65, no. 2, pp. 510–20, Feb. 2004. 
 
[169] U. Herbig, “Cellular Senescence in Aging Primates,” Science (80-. )., vol. 311, no. 5765, 
p. 1257, 2006. 
 
[170] C. Wang, D. Jurk, M. Maddick, G. Nelson, C. Martin-Ruiz, and T. von Zglinicki, “DNA 
damage response and cellular senescence in tissues of aging mice,” Aging Cell, vol. 8, no. 
3, pp. 311–323, 2009. 
 
[171] L. Ferrucci, T. B. Harris, J. M. Guralnik, R. P. Tracy, M. C. Corti, H. J. Cohen, B. 
Penninx, M. Pahor, R. Wallace, and R. J. Havlik, “Serum IL-6 level and the development 
of disability in older persons.,” J. Am. Geriatr. Soc., vol. 47, no. 6, pp. 639–46, Jun. 
1999. 
102  
[172] D. E. Alley, E. Crimmins, K. Bandeen-Roche, J. Guralnik, and L. Ferrucci, “Three-year 
change in inflammatory markers in elderly people and mortality: the Invecchiare in 
Chianti study.,” J. Am. Geriatr. Soc., vol. 55, no. 11, pp. 1801–7, Nov. 2007. 
 
[173] O. Moiseeva, V. Bourdeau, A. Roux, X. Deschênes-Simard, and G. Ferbeyre, 
“Mitochondrial dysfunction contributes to oncogene-induced senescence.,” Mol. Cell. 
Biol., vol. 29, no. 16, pp. 4495–4507, 2009. 
 
[174] J. F. Passos, G. Saretzki, S. Ahmed, G. Nelson, T. Richter, H. Peters, I. Wappler, M. J. 
Birket, G. Harold, K. Schaeuble, M. A. Birch-Machin, T. B. L. Kirkwood, and T. von 
Zglinicki, “Mitochondrial Dysfunction Accounts for the Stochastic Heterogeneity in 
Telomere-Dependent Senescence,” PLoS Biol., vol. 5, no. 5, p. e110, May 2007. 
 
[175] J. Kaplon, L. Zheng, K. Meissl, B. Chaneton, V. a Selivanov, G. Mackay, S. H. Van Der, 
S. H. van der Burg, E. M. E. Verdegaal, M. Cascante, T. Shlomi, E. Gottlieb, and D. S. 
Peeper, “A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene- 
induced senescence.,” Nature, vol. 498, no. 7452, pp. 109–12, 2013. 
 
[176] N. V. Vo, R. A. Hartman, T. Yurube, L. J. Jacobs, G. A. Sowa, and J. D. Kang, 
“Expression and regulation of metalloproteinases and their inhibitors in intervertebral 
disc aging and degeneration,” Spine J., vol. 13, no. 3, pp. 331–341, Mar. 2013. 
 
[177] W. Qian and B. Van Houten, “Alterations in bioenergetics due to changes in 
mitochondrial DNA copy number,” Methods, vol. 51, no. 4, pp. 452–457, Aug. 2010. 
 
[178] J. E. Kolesar, C. Y. Wang, Y. V. Taguchi, S.-H. Chou, and B. A. Kaufman, “Two- 
dimensional intact mitochondrial DNA agarose electrophoresis reveals the structural 
complexity of the mammalian mitochondrial genome,” Nucleic Acids Res., vol. 41, no. 4, 
pp. e58–e58, Feb. 2013. 
 
[179] K. J. Livak and T. D. Schmittgen, “Analysis of Relative Gene Expression Data Using 
Real-Time Quantitative PCR and the 2−ΔΔCT Method,” Methods, vol. 25, no. 4, pp. 
402–408, Dec. 2001. 
 
[180] J. F. Passos, G. Nelson, C. Wang, T. Richter, C. Simillion, C. J. Proctor, S. Miwa, S. 
Olijslagers, J. Hallinan, A. Wipat, G. Saretzki, K. L. Rudolph, T. B. L. Kirkwood, and T. 
von Zglinicki, “Feedback between p21 and reactive oxygen production is necessary for 
cell senescence,” Mol. Syst. Biol., vol. 6, p. 347, Feb. 2010. 
 
[181] A. Heddi, P. Lestiennes, D. C. Wallaceq, and G. Stepienll, “THE JOURNAL OF 
BIOLOGICAL CHEMISTRY Mitochondrial DNA Expression in Mitochondrial 
Myopathies and Coordinated Expression of Nuclear Genes Involved in ATP 
Production*,” vol. 268, no. 16, pp. 12156–12163, 1993. 
 
[182] J. Piechota, R. Szczesny, K. Wolanin, A. Chlebowski, and E. Bartnik, “Nuclear and 
mitochondrial genome responses in HeLa cells treated with inhibitors of mitochondrial 
DNA expression.,” Acta Biochim. Pol., vol. 53, no. 3, pp. 485–95, 2006. 
103  
[183] S. Glück, B. Guey, M. F. Gulen, K. Wolter, T.-W. Kang, N. A. Schmacke, A. Bridgeman, 
J. Rehwinkel, L. Zender, and A. Ablasser, “Innate immune sensing of cytosolic  
chromatin fragments through cGAS promotes senescence,” Nat. Cell Biol., vol. 19, no. 9, 
pp. 1061–1070, Jul. 2017. 
 
[184] Z. Dou, K. Ghosh, M. G. Vizioli, J. Zhu, P. Sen, K. J. Wangensteen, J. Simithy, Y. Lan, 
Y. Lin, Z. Zhou, B. C. Capell, C. Xu, M. Xu, J. E. Kieckhaefer, T. Jiang, M. Shoshkes- 
Carmel, K. M. A. Al Tanim, G. N. Barber, J. T. Seykora, S. E. Millar, K. H. Kaestner, B. 
A. Garcia, P. D. Adams, and S. L. Berger, “Cytoplasmic chromatin triggers inflammation 
in senescence and cancer,” Nature, vol. 550, no. 7676, pp. 402–406, Oct. 2017. 
 
[185] H. Yang, H. Wang, J. Ren, Q. Chen, and Z. J. Chen, “cGAS is essential for cellular 
senescence,” Proc. Natl. Acad. Sci., vol. 114, no. 23, pp. E4612–E4620, Jun. 2017. 
 
[186] B. Westermann, “Bioenergetic role of mitochondrial fusion and fission,” Biochim. 
Biophys. Acta - Bioenerg., vol. 1817, no. 10, pp. 1833–1838, Oct. 2012. 
 
[187] S. Lee, S.-Y. Jeong, W.-C. Lim, S. Kim, Y.-Y. Park, X. Sun, R. J. Youle, and H. Cho, 
“Mitochondrial Fission and Fusion Mediators, hFis1 and OPA1, Modulate Cellular 
Senescence,” J. Biol. Chem., vol. 282, no. 31, pp. 22977–22983, Aug. 2007. 
 
[188] Y.-Y. Park, S. Lee, M. Karbowski, A. Neutzner, R. J. Youle, and H. Cho, “Loss of 
MARCH5 mitochondrial E3 ubiquitin ligase induces cellular senescence through 
dynamin-related protein 1 and mitofusin 1,” J. Cell Sci., vol. 123, no. 4, pp. 619–626, 
Feb. 2010. 
 
[189] F. Buttgereit and M. D. Brand, “A hierarchy of ATP-consuming processes in mammalian 
cells.,” Biochem. J., vol. 312 ( Pt 1), no. Pt 1, pp. 163–7, Nov. 1995. 
 
[190] U. Sambamoorthi, X. Tan, and A. Deb, “Multiple Chronic Conditions and Healthcare 
Costs among Adults,” National Center for Chronic Disease Prevention and Health 
Promotion. [Online]. Available: https://www.cdc.gov/chronicdisease/about/multiple- 
chronic.htm. [Accessed: 03-Mar-2018]. 
 
[191] A. Chiodo, D. Alvarez, G. Graziano, H. R. Van Haig, Andrew, P. Park, and C. 
Standiford, “Acute Low Back Pain.” [Online]. Available: 
http://www.med.umich.edu/1info/FHP/practiceguides/back/back. 
 
[192] A. Wong, J. Karppinen, and D. Samartzis, “Low back pain in older adults: risk factors, 
management options and future directions,” Scoliosis Spinal Disord., vol. 12, p. 14, 2017. 
 
[193] M. Hirvensalo, T. Rantanen, and E. Heikkinen, “Mobility difficulties and physical 
activity as predictors of mortality and loss of independence in the community-living older 







[194] C.-Q. Zhao, L.-M. Wang, L.-S. Jiang, and L.-Y. Dai, “The cell biology of intervertebral 
disc aging and degeneration.,” Ageing Res. Rev., vol. 6, no. 3, pp. 247–61, Oct. 2007. 
 
[195] T. Tchkonia, Y. Zhu, J. van Deursen, J. Campisi, and J. L. Kirkland, “Cellular senescence 
and the senescent secretory phenotype: therapeutic opportunities.,” J. Clin. Invest., vol. 
123, no. 3, pp. 966–72, Mar. 2013. 
 
[196] P. A. Pérez-Mancera, A. R. J. Young, and M. Narita, “Inside and out: the activities of 
senescence in cancer.,” Nat. Rev. Cancer, vol. 14, no. 8, pp. 547–58, Aug. 2014. 
 
[197] R. M. Naylor, D. J. Baker, and J. M. van Deursen, “Senescent Cells: A Novel 
Therapeutic Target for Aging and Age-Related Diseases,” Clin. Pharmacol. Ther., vol. 
93, no. 1, pp. 105–116, Dec. 2012. 
 
[198] L. A. Nasto, H.-Y. Seo, A. R. Robinson, J. S. Tilstra, C. L. Clauson, G. A. Sowa, K. Ngo, 
Q. Dong, E. Pola, J. Y. Lee, L. J. Niedernhofer, J. D. Kang, P. D. Robbins, and N. V Vo, 
“ISSLS prize winner: inhibition of NF-κB activity ameliorates age-associated disc 
degeneration in a mouse model of accelerated aging.,” Spine (Phila. Pa. 1976)., vol. 37, 
no. 21, pp. 1819–25, Oct. 2012. 
 
[199] H. Fuhrmann-Stroissnigg, Y. Y. Ling, J. Zhao, S. J. McGowan, Y. Zhu, R. W. Brooks, D. 
Grassi, S. Q. Gregg, J. L. Stripay, A. Dorronsoro, L. Corbo, P. Tang, C. Bukata, N. Ring, 
M. Giacca, X. Li, T. Tchkonia, J. L. Kirkland, L. J. Niedernhofer, and P. D. Robbins, 
“Identification of HSP90 inhibitors as a novel class of senolytics.,” Nat. Commun., vol. 8, 
no. 1, p. 422, Dec. 2017. 
 
[200] A. J. L. Walsh, D. S. Bradford, and J. C. Lotz, “In Vivo Growth Factor Treatment of 
Degenerated Intervertebral Discs,” Spine (Phila. Pa. 1976)., vol. 29, no. 2, pp. 156–163, 
Jan. 2004. 
 
[201] T. Miyamoto, T. Muneta, T. Tabuchi, K. Matsumoto, H. Saito, K. Tsuji, and I. Sekiya, 
“Intradiscal transplantation of synovial mesenchymal stem cells prevents intervertebral 
disc degeneration through suppression of matrix metalloproteinase-related genes in 
nucleus pulposus cells in rabbits,” Arthritis Res. Ther., vol. 12, no. 6, p. R206, 2010. 
 
[202] “11765 - Ham’s F-12 Nutrient Mix - US.” [Online]. Available: 
http://www.thermofisher.com/us/en/home/technical-resources/media- 
formulation.64.html. [Accessed: 14-Oct-2018]. 
 
[203] Lonza Group, “Ham’s F12 Medium.” [Online]. Available: 
file:///C:/Users/prashanti/Downloads/Lonza_BenchGuides_Hams_F12_Medium_28047.p 
df. [Accessed: 14-Oct-2018]. 
 
[204] E. Mavrogonatou and D. Kletsas, “High osmolality activates the G1 and G2 cell cycle 
checkpoints and affects the DNA integrity of nucleus pulposus intervertebral disc cells 
triggering an enhanced DNA repair response,” DNA Repair (Amst)., vol. 8, no. 8, pp. 
930–943, Aug. 2009. 
 
105  
[205] D. M. Soukane, A. Shirazi-Adl, and J. P. G. Urban, “Computation of coupled diffusion of 
oxygen, glucose and lactic acid in an intervertebral disc.,” J. Biomech., vol. 40, no. 12, 
pp. 2645–54, Jan. 2007. 
 
[206] M. Grant, L. Epure, O. Salem, M. Alaqeel, J. Antoniou, and F. Mwale, “Development of 
a Whole Bovine Long-term Organ Culture System that Retains Vertebral Bone for 
Intervertebral Disc Repair and Biomechanical Studies using PrimeGrowth Media,” Glob. 
Spine J., vol. 6, no. 1_suppl, p. s-0036-1582897-s-0036-1582897, Apr. 2016. 
 
[207] A. Freund, R.-M. Laberge, M. Demaria, and J. Campisi, “Lamin B1 loss is a senescence- 
associated biomarker.,” Mol. Biol. Cell, vol. 23, no. 11, pp. 2066–75, Jun. 2012. 
 
[208] J. Bedore, K. Quesnel, D. Quinonez, C. A. Séguin, and A. Leask, “Targeting the annulus 
fibrosus of the intervertebral disc: Col1a2-Cre(ER)T mice show specific activity of Cre 
recombinase in the outer annulus fibrosus.,” J. Cell Commun. Signal., vol. 10, no. 2, pp. 
137–42, Jun. 2016. 
 
[209] K. Wuertz, N. Vo, D. Kletsas, and N. Boos, “Inflammatory and catabolic signalling in 
intervertebral discs: the roles of NF-κB and MAP kinases.,” Eur. Cell. Mater., vol. 23, 
pp. 103-19; discussion 119-20, Jan. 2012. 
 
[210] D. E. Harrison, R. Strong, D. B. Allison, B. N. Ames, C. M. Astle, H. Atamna, E. 
Fernandez, K. Flurkey, M. A. Javors, N. L. Nadon, J. F. Nelson, S. Pletcher, J. W. 
Simpkins, D. Smith, J. E. Wilkinson, and R. A. Miller, “Acarbose, 17-α-estradiol, and 
nordihydroguaiaretic acid extend mouse lifespan preferentially in males,” Aging Cell,  
vol. 13, no. 2, pp. 273–282, Apr. 2014. 
 
[211] M. Ito, T. Yurube, K. Kakutani, K. Maeno, T. Takada, Y. Terashima, Y. Kakiuchi, Y. 
Takeoka, S. Miyazaki, R. Kuroda, and K. Nishida, “Selective interference of 
mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and 
extracellular matrix catabolism with Akt and autophagy induction,” Osteoarthr. Cartil., 
vol. 25, no. 12, pp. 2134–2146, Dec. 2017. 
 
[212] J. C. Newman, S. Milman, S. K. Hashmi, S. N. Austad, J. L. Kirkland, J. B. Halter, and 
N. Barzilai,  “Strategies  and  Challenges  in  Clinical  Trials  Targeting  Human Aging,” 
Journals Gerontol. Ser. A Biol. Sci. Med. Sci., vol. 71, no. 11, pp. 1424–1434, Nov. 2016. 
 
[213] B. Viollet, B. Guigas, N. S. Garcia, J. Leclerc, M. Foretz, and F. Andreelli, “Cellular and 
molecular mechanisms of metformin: an overview,” Clin. Sci., vol. 122, no. 6, pp. 253– 
270, Mar. 2012. 
 
[214] T. Ma, C.-J. Guo, X. Zhao, L. Wu, S.-X. Sun, and Q.-H. Jin, “The effect of curcumin on 
NF-κB expression in rat with lumbar intervertebral disc degeneration.,” Eur. Rev. Med. 
Pharmacol. Sci., vol. 19, no. 7, pp. 1305–14, Apr. 2015. 
 
[215] X. Xia, J. Guo, F. Lu, and J. Jiang, “SIRT1 Plays a Protective Role in Intervertebral Disc 
Degeneration in a Puncture-induced Rodent Model,” Spine (Phila. Pa. 1976)., vol. 40, 
no. 9, pp. E515–E524, May 2015. 
106  
 
[216] D. P. Goldman, D. Cutler, J. W. Rowe, P.-C. Michaud, J. Sullivan, D. Peneva, and S. J. 
Olshansky, “Substantial Health And Economic Returns From Delayed Aging May 
Warrant A New Focus For Medical Research,” Health Aff., vol. 32, no. 10, pp. 1698– 1705, Oct. 
2013. 
[217] L. Gilbertson, S.-H. Ahn, P.-N. Teng, R. K. Studer, C. Niyibizi, and J. D. Kang, “The 
effects of recombinant human bone morphogenetic protein-2, recombinant human bone 
morphogenetic protein-12, and adenoviral bone morphogenetic protein-12 on matrix 
synthesis in human annulus fibrosis and nucleus pulposus cells.,” Spine J., vol. 8, no. 3, 
pp. 449–56, May 2008. 
